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Abstract 
 We are interested in the development of potent and highly selective dynorphin (Dyn) 
analogs targeting kappa opioid receptors (KOR) and studying the pharmacokinetic and 
physicochemical properties of kappa opioid peptides. 
In contrast to the extensive structure-activity relationships (SAR) studies on Dyn A, there 
is minimal SAR information on Dyn B. Therefore we performed an alanine scan of Dyn B 
amide. The results indicated that Tyr
1 
and Phe
4 
residues
 
are critical, while Arg
7
 is important for 
maintaining the KOR affinity of Dyn B amide.  
There is also minimal SAR information for the selective KOR antagonist zyklophin [N
α
-
benzylTyr
1
-cyclo(D-Asp
5
,Dap
8
)]Dyn A(1–11)NH2 which is active in vivo after systemic 
administration. Hence, we synthesized linear and cyclic zyklophin analogs using solid phase 
peptide synthesis. To synthesize cyclic analogs the 5-11 linear fragments were selectively 
deprotected and cyclized, followed by extension of the peptide chain, coupling of the N-terminal 
N-alkyl amino acids and cleavage from the resin. We modified a key synthetic step to avoid 
potential racemization of the N-terminal residue. Pharmacological results suggested that the 
residue in position 5 has a greater influence on the KOR affinity of zyklophin than the residue in 
position 8. While Phe
4
 and Arg
6
 residues in zyklophin were important for maintaining KOR 
affinity, surprisingly Tyr
1
 and Arg
7
 were not important.  
The natural product CJ-15,208 (cyclo[Phe-D-Pro-Phe-Trp]) and its D-Trp isomer 
exhibited KOR activity after oral administration. Therefore, we are investigating the 
pharmacokinetic and physicochemical properties of these lead peptides. In Caco-2 cell 
monolayer permeability studies the D-Trp isomer exhibited 7-fold higher permeability in the 
apical to basolateral direction than CJ-15,208, and the natural product appeared to be an efflux 
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substrate. The permeability of the D-Trp isomer was only 2-fold lower than that of the high 
permeability compound caffeine. We also examined various agents to solubilize these 
hydrophobic peptides that are compatible with in vivo studies. The D-Trp isomer had 5- to 40-
fold higher solubility than the L-Trp isomer irrespective of the type of solubilizing enhancer 
used.  
These studies will help guide the future design of peptidic KOR ligands. 
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Chapter 1 - Overview of the research projects 
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1.1 Introduction 
Most of the peptidic ligands that target kappa opioid receptors (KOR) are analogs of the 
endogenous ligands for KOR the dynorphins (Dyn). Various analogs of dynorphin (Dyn) A have 
been synthesized earlier with activity at KOR.  In addition a few number of linear and 
macrocyclic opioid tetrapeptides have also been synthesized that exhibit activity at KOR. While 
KOR antagonists have been historically used as pharmacological tools, they have potential 
therapeutic uses such as anti-depressant and anxiolytic agents and for the treatment of drug 
abuse. The prototypical non-peptidic KOR antagonists display exceptionally long durations of 
action, while peptidic KOR antagonists are susceptible to metabolism by proteases and hence are 
expected to have a shorter duration of action.
1
  
Our laboratory is interested in studying the structure-activity relationships (SAR) of 
peptides for KOR and develop potent KOR antagonists that can be useful for various therapeutic 
applications, especially for the treatment of drug abuse. We are also interested in studying the 
pharmacokinetic and physicochemical properties of the orally active macrocyclic tetrapeptides. 
The present thesis is divided into three research projects (chapters 3, 4 and 6). Project 1 
(chapter 3) and project 2 (chapter 4) focused on studies of the SAR of the two Dyn related 
peptides, Dyn B amide and the selective KOR antagonist zyklophin ([N
α
-benzylTyr
1
-cyclo(D-
Asp
5
,Dap
8
)]Dyn A(1–11)NH2),
2
 respectively. Project 3 (chapter 6) focused on evaluation of the 
permeability of the opioid macrocyclic tetrapeptide CJ 15,208 and its D-Trp isomer through the 
Caco-2 monolayer intestinal cell model and their solubility analysis in the presence of various 
solubilizing enhancers. 
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Project 1: Synthesis and biological evaluation of alanine substituted analogs of Dyn B 
amide (chapter 3). 
The endogenous opioid peptides Dyn A and Dyn B (Figure 1.1) are obtained from the 
proteolytic cleavage of the precursor protein prodynorphin.
3
 To date studies involving SAR of 
dynorphins have focused almost exclusively on Dyn A with minimal SAR studies related to Dyn 
B. While both Dyn A and Dyn B have identical N-terminal sequences, their C-terminal 
sequences differ. Although Dyn B exhibits lower opioid affinity and potency than Dyn A,
4-7
 it 
appears to be devoid of the cytotoxic non-opioid effects exhibited by Dyn A.
8
 Hence, the 
differences in their C-terminal sequences result in differences in their pharmacological actions.  
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys   
                                                Dyn A(1-13) 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr   
Dyn B 
Figure 1.1 Dyn A(1-13) and Dyn B 
It was hypothesized that unique residue(s) in the C-terminus of Dyn B interact with the 
receptor and contribute to its activity at KOR. To determine which residues are important for 
KOR interaction alanine substituted analogs of Dyn B amide were synthesized. All of the non-
glycine residues up through residue 11 were substituted with Ala in order to explore the role of 
their side chains to the activity of Dyn B. The analogs were synthesized by solid phase peptide 
synthesis using fluorenylmethyloxycarbonyl (Fmoc) protection strategy and evaluated for their 
opioid receptor affinities in radioligand binding assays
9
 and for their efficacy and potency at 
KOR in the GTPS assay.
10
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Project 2:  Structure-activity relationships of the KOR selective antagonist zyklophin 
(chapter 4).  
We are exploring analogs of the endogenous opioid peptide Dyn A as ligands for KOR. 
In our earlier studies of Dyn A analogs, zyklophin (Figure 1.2) was synthesized; this peptide is a 
selective KOR antagonist in vitro
2
 and is active in vivo after systemic administration.
11
 
Zyklophin was the first reported selective KOR antagonist to display finite duration of action 
(less than 12 h) in vivo.
11
 However, there was minimal SAR information available for 
zyklophin.
2, 11, 12
 
 
Figure 1.2 Structure of zyklophin 
The objective of this project was to study the SAR of zyklophin and identify structural 
features responsible for its KOR selectivity and antagonist activity and to enhance its potency.  It 
was hypothesized that the N-terminal alkyl group of zyklophin might affect the interactions of 
the rest of the peptide with KOR, resulting in the ability of zyklophin to bind to the receptor 
without activating it. Hence, to test this hypothesis we synthesized zyklophin analogs with 
different N-alkyl substitutents on the N-terminal Tyr. It was also hypothesized that as the residue 
in position 5 is in proximity to the postulated “message” sequence (see chapter 2, section 2.7.1 
for a discussion of the “message-address” concept),
13
 this residue could play a significant role in 
the antagonist activity of zyklophin. To test this hypothesis the linear analogs [N-benzylTyr
1
,D-
Asn
5
]Dyn A(1-11)NH2 and [N-benzylTyr
1
,Dap(Ac)
8
]Dyn A(1-11)NH2 with substitutions in 
positions 5 and 8, respectively, were also synthesized. In addition, in order to explore the role of 
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ring size and residues involved in the cyclic constraint on the KOR interaction and antagonist 
activity of zyklophin, we synthesized several cyclic analogs containing ring size variants analogs 
and an analog with the opposite configuration of residue 5. We also wanted to investigate the 
importance of different residue side chains to the activity of zyklophin. Hence, we performed an 
Ala scan of the non-glycine residues of zyklophin, excluding residues 5 and 8, up through the 
residue in position 9. In addition, to explore the importance of the phenolic group of Tyr
1
 on the 
activity of zyklophin we also synthesized the Phe
1
 analog of zyklophin.   
The synthesis of zyklophin involved solid phase synthesis of the (2-11) peptide fragment 
on resin using the Fmoc protection strategy followed by coupling of the N-alkyl N-terminal 
amino acid to the peptide fragment on the resin.
2
 The coupling reaction involved dissolution of 
the N-alkyl amino acid in DMF at elevated temperature followed by cooling and coupling to the 
(2-11) peptide fragment. This could lead to potential racemization of the N-terminal residue. An 
HPLC system containing a linear gradient of MeCN over aqueous triethyl ammonium phosphate 
that could resolve the diastereomeric mixture of zyklophin was identified. A modified synthetic 
strategy was used for some of the zyklophin analogs that contained N-terminal residues with 
minimal solubility in DMF or that were prone to racemization.  
The synthesis of the zyklophin analogs and their subsequent evaluation for opioid affinity 
in radioligand assays and efficacy and potency in the GTPS assay are discussed in chapter 4.  
Project 3: Caco-2 cell monolayer permeability and solubility analysis of opioid macrocyclic 
tetrapeptides (chapter 6) 
  The macrocyclic tetrapeptide natural product CJ 15,208 (cyclo[Phe-D-Pro-Phe-Trp]), was 
reported to exhibit KOR antagonism in vitro.
14
 The syntheses of the L- and D-Trp isomers of CJ-
15,208 (Figure 1.3) were performed to establish the stereochemistry of the Trp residue in the 
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natural product  (the L-Trp peptide appears to be the natural product).
15
  The L- and D-Trp 
isomers of this peptide display opioid activity, but exhibit different pharmacological profiles in 
vivo after intracerebroventricular administration to mice;
10
 and both exhibit activity following 
oral administration.
16, 17
 Therefore, both isomers can serve as lead compounds for further 
structural modifications. 
 
Figure 1.3 L- and D-Trp isomers of CJ-15,208 
In order to enhance the oral activity of these macrocyclic peptides, we are exploring the 
pharmacokinetic and physicochemical properties of these two lead compounds. Because of their 
hydrophobicity, we have examined various solubilizing agents, including organic cosolvents, the 
-cyclodextrin derivative Captisol and the surfactants Solutol HS 15 and Tween-80 that are 
compatible with in vivo studies, to solubilize these compounds. We have also evaluated the 
bidirectional permeability of these compounds in the Caco-2 cell monolayer model for intestinal 
absorption using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for 
quantification.  
The results obtained from the Caco-2 permeability assay and solubility analysis of the L- 
and D-Trp isomers of CJ 15,208 are discussed in chapter 6. 
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2.1 Introduction 
While treatment of mild to moderate pain can be accomplished by non-narcotic 
analgesics such as acetaminophen or aspirin, treatment of severe pain requires use of opioid 
analgesics such as morphine. These analgesics, however, suffer from serious side effects 
including addiction liability and respiratory depression which limit their clinical utility.
1  
Beckett and Casy in 1954 proposed that the effects of opioid analgesics were receptor 
mediated,
2
 but it wasn’t until 1970 that the stereospecific binding of opioid ligands to specific 
receptors was shown in mammalian brain tissue preparations.
3-5
 Later, Martin and coworkers in 
the mid-1970’s characterized and classified the opioid receptors into three different types,
6, 7
 
revolutionizing the field of opioid pharmacology. Concurrently, the search for endogenous 
ligands for opioid receptors with opioid-like activity was ongoing. The pentapeptides leucine and 
methionine enkephalin
8
 were the first to be identified, followed by dynorphin (Dyn) A,
9
 β-
endorphin
10
 and more recently the endomorphins
11
 (see Tables 2.1 for the peptide sequences and 
2.2 for opioid receptor affinities and activity). Another major advancement in the field of opioid 
pharmacology came with the cloning of the delta (δ) opioid receptor (DOR)
12, 13
 and the mu (µ) 
opioid receptor (MOR),
14
 and followed by the kappa (κ) opioid receptor (KOR).
15
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Table 2.1 Mammalian opioid peptides and orphanin FQ/nociceptin,
1
 grouped based on their 
precursor proteins 
 
Proenkephalin peptides 
Leu-enkephalin                                  Tyr-Gly-Gly-Phe-Leu 
Met-enkephalin                                  Tyr-Gly-Gly-Phe-Met 
Met-enkephalin-Arg
6
-Phe
7
                Tyr-Gly-Gly-Phe-Met-Arg-Phe 
Met-enkephalin-Arg
6
-Gly
7
-Leu
8
       Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu 
Prodynorphin peptides 
Dynorphin A                                       Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln 
Dynorphin B                                       Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr 
-Neoendorphin                                 Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Arg-Pro-Lys 
-Neoendorphin                                  Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Arg-Pro 
Pro-opiomelanocortin peptides 
-endorphin  (human)                    Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-                                                          
                                                       Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu 
Endomorphins
a
 
Endomorphin-1                                   Tyr-Pro-Trp-Phe-NH2 
Endomorphin-2                                   Tyr-Pro-Phe-Phe-NH2 
Orphanin FQ/nociceptin and related peptides 
Orphanin FQ/ 
Nociceptin                                    Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln 
Orphanin FQ 2                             Phe-Ser-Glu-Phe-Met-Arg-Gln-Tyr-Leu-Val-Leu-Ser-Met-Gln-Ser-Ser-Gln 
Nocistatin (human)                      Pro-Glu-Pro-Gly-Met-Glu-Glu-Ala-Gly-Glu-Met-Glu-Gln-Lys-Gln-Leu-Gln 
a
Precursor protein not know 
2.2 Opioid Receptors 
In the mid 1970’s Martin and coworkers proposed three types of opioid receptors
6, 7
 
MOR, KOR and sigma (σ) receptors, with morphine, ketocyclazocine and SKF-10,047, 
respectively, as the prototypical ligands (Figure 2.1). The discovery of the enkephalins led to the 
proposal of another opioid receptor type, namely DOR.
16
 Sigma receptors, however, are not 
considered to be opioid receptors as the effects associated with these receptors are not reversed 
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by opioid antagonists such as naloxone.
17
 Later Mollereau et al. discovered the opioid-like 
receptor (ORL-1);
18
 orphanin FQ/nociceptin
19, 20
 is the endogenous ligand for this receptor.  
 
Figure 2.1 Prototypical ligands for opioid and sigma receptors 
Table 2.2 Opioid receptor affinities and opioid activity of endogenous opioid peptides in the 
guinea pig ileum (GPI).
1
  
 
 
                             
 
Ki (nM) 
 
Ki Ratio  IC50 (nM) 
Peptide MOR DOR KOR MOR/DOR/KOR GPI 
Proenkephalin peptides 
     Leu-enkephalin 19 1.2 8210 16/1/6840 36 
Met-enkephalin 9.5 0.91 4440 10/1/4880 6.7 
Met-enkephalin-Arg
6
-Phe
7
 3.7 9.4 93 1/2.5/25 10 
Met-enkephalin-Arg
6
-Phe
7
-Leu
8
 6.6 4.8 79 1.4/1/16 35 
Prodynorphin peptides 
     Dynorphin A 0.73 2.4 0.12 6.1/20/1 0.29 
Dynorphin A-(1-8) 3.8 5 1.3 2.9/17/1 4.9 
Dynorphin B 0.68 2.9 0.12 5.7/1.8/1 0.25 
Neoendorphin 6.9 2.1 1.2 5.7/1.8/1 3.3 
Neoendorphin 1.2 0.57 0.2 6/2.8/1 3.0 
POMC peptide 
     -Endorphin 2.1 2.4 96 1/1.1/46 62 
Endomorphins 
     Endomorphins-1 0.36 1510 5430 1/4180/15100 3.6 
Endomorphins-2 0.69 9230 5240 1/13400/7590 4.0 
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2.2.1 Opioid receptor structure 
The opioid receptors belong to the superfamily of G-protein coupled receptors (GPCRs). 
These receptors contain an extracellular N-terminal region, extracellular loops, seven putative 
transmembrane (TM) regions, intracellular loops and an intracellular C-terminus.
1
 The highest 
sequence homology between the three receptors appeared to be in the TM2, TM3 and TM7 
regions (Figure 2.2). The conserved Asp residue in TM3 was proposed to interact with the 
positively charged protonated amine on the opioid ligands.
21
 The third intracellular loop was 
proposed to interact with G-proteins. While the second and third extracellular loops (EL), TM1 
and TM4 to TM6 were less conserved, the largest structural diversity occurred in the 
extracellular N-terminus. Several potential sites for possible post-translational modifications in 
the N-terminal and C-terminal regions of the receptors were also identified.
22
 
 
Figure 2.2 Schematic diagram of the protein structure of the three opioid receptors.
1
 Rectangles 
indicate transmembrane helices and numbers indicate the percentage of identical residues among 
the three opioid receptors in that segment.  
The cloning of all three types of human opioid receptors has been reported.
23-25
 The 
human MOR, KOR and DOR exhibit 90-95% homology to the corresponding type of receptor 
from other species such as rat or mouse.
26
 The ORL-1 receptor also exhibits high sequence 
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homology with the three opioid receptors, with 60-62% identity for the entire transmembrane 
domains and higher homology for TM2, TM3 and TM7.
27
 
Several chimeric receptor studies have attempted to identify the regions of the receptors 
involved in ligand recognition and receptor type selectivity. MOR/KOR chimeric receptors 
suggested that EL3 may be responsible for the low affinity binding of the MOR agonist 
DAMGO ([D-Ala
2
,N-MePhe
4
,Gly-ol]-enkephalin) for KOR.
28, 29
 Subsequent site directed 
mutagenesis studies identified Glu 297, Ser 310, Tyr 312 and Tyr 313 as the responsible residues 
in the KOR.
30
 In contrast the study of MOR/DOR chimeric receptors suggested that the 
exchange of EL1 causes the loss of high affinity binding of DAMGO to DOR,
31, 32
 and further 
site directed mutagenesis studies suggested that Lys 108 in EL1 of DOR was the responsible 
residue.
33
 It was hypothesized that there are acidic residues in EL2 of KOR that could contribute 
directly to the affinity of the opioid peptides Dyn A and Dyn B through ionic interactions with 
the positively charged basic residues in the C-terminus of the peptides. Studies of KOR/MOR
34, 
35
and KOR/DOR
36
 chimeric receptors support the importance of EL2 in KOR for the high 
affinity of Dyn A. However, even after the replacement of half of the acidic residues in EL2 with 
the corresponding neutral amides, Dyn A still displayed high KOR affinity suggesting that the 
charge interactions may not be primarily important for maintaining the binding affinity and 
selectivity of Dyn A.
37
 In contrast the KOR/MOR and KOR/DOR chimeric receptor studies 
indicated that the KOR-selective non-peptide agonists U50,488 and U69,593 appear to require 
the whole KOR except EL2 for binding. These results suggested that different portions of the 
receptors might be involved in interactions with different (peptide and non-peptide) ligands.
34, 35
 
There is also some evidence indicating that agonists and antagonists might differ in their 
interactions with KOR.
38
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 Very recently, the crystal structures of MOR, KOR, DOR and nociception/orphanin FQ 
receptor complexed with -funaltrexamine,
39
 JDTic
40
, naltrindole,
41
 and a peptide mimetic
42
 
respectively, have been reported. All four crystal structures reveal conserved ligand-receptor 
binding interactions in the TM region binding pocket of the receptors.
43
 For example, several 
conserved amino acids (for example Asp 138
3.32
 (the positions of residues in the receptors are 
indicated using Ballesteros-Weinstein numbering
44
 as a superscript) which forms a salt bridge 
and Tyr 139
3.33
 which is involved in hydrogen bonding with the ligand) in TM3, TM6 and TM7 
interact with the “message” region (see section 2.7.1 for discussion of the “message-address” 
concept) of the ligand and are responsible for opioid efficacy. The chemical moieties present in 
the “address” region of ligands can interact with different regions in the binding pocket 
depending on the ligand. For example, the classical morphinan opioids interact with TM6 and/or 
TM7 (for example, the second basic moiety of morphinans (amine in the case of 
norbinaltorphimine (norBNI, Figure 2.8) and guanidine in the case of 5’-guanidinonaltrindole 
(GNTI, Figure 2.8) interact with Glu 297
6.58
) while the phenylpiperidine KOR antagonist JDTic 
interacts with TM2 and TM3 and also with TM7 of KOR. The structure of EL2 appears to be 
very similar in the opioid receptors. The common -hairpin loop structure of EL2 in the opioid 
receptors allows unobstructed access of the ligands to the binding pocket which also might 
explain the reason for the opioid drugs being potent and reversible.
43
  
The crystal structure of KOR
40
 shows that JDTic tightly fits into the binding cleft and 
forms ionic, polar and extensive hydrophobic interactions with the receptor (Figures 2.3 and 2.4) 
and also shows electron density for structured water molecules that mediate polar interactions 
between the receptor and hydroxyl groups. The human KOR consists of a narrow deep binding 
pocket which is partially capped by the EL2 -hairpin.
40
 In the crystal structure JDTic reaches 
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deep in the binding pocket where the protonated amines of the piperidine and isoquionoline 
moieties form salt bridges to the Asp 138
3.32 
side chain, anchoring the ligand in a characteristic 
V-shape. JDTic interacts with four residues, Val 108
2.53
, Val 118
2.63
, Ile 294
6.55 
and Tyr 312
7.35
,
 
in 
the binding pocket that are unique to KOR. The differences in these residues in MOR and DOR 
are thought to contribute to the KOR selectivity of JDTic. The isopropyl group of JDTic reaches 
deep inside the binding pocket to form hydrophobic interactions with the Trp 287
6.48 
side chain, 
which could possibly have a critical role in the activation of the receptor.   
 
Figure 2.3 Interactions of JDTic in the binding pocket of human KOR.
40
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Figure 2.4 Crystal structure of KOR complexed with JDTic. The nitrogen atoms are shown in 
cyan, the oxygen atoms are red and the carbon atoms are green. The water molecules are 
indicated by red dots. TM domains are indicated by roman numbers. 
The opioid receptors are coupled to G proteins and produce effects through these 
proteins. G-proteins are heterotrimers consisting of α, β and γ subunits.
45
 Following binding by 
an agonist, the opioid receptor undergoes a conformational change. This causes the release of 
guanosine 5’-diphosphate (GDP) from the  subunit followed by the binding of guanosine 5’-
diphosphate (GTP). The GTP- subunit then dissociates from the β and γ subunits. 
Subsequently, both the GTP- subunit and the β and γ subunits can interact with a variety of 
downstream signaling pathways including the cyclic adenosine monophosphate (c-AMP) 
pathway and ion channels.
46, 47
 The response is terminated when the GTP bound to the  subunit 
is hydrolyzed to GDP, subsequently leading to reformation of the G-protein heterotrimer. The 
binding of an agonist to opioid receptors results in inhibition of the activity of adenylyl cyclase 
                                                                                                                                                         
19 
 
(AC) and thereby decreases the amount of intracellular c-AMP. Consequently, the activity of c-
AMP-dependent protein kinases is reduced. These events can produce pharmacological effects 
including analgesia.
48
 The opioid receptors also interact with ion channels through Gi or Go type 
G-proteins.
49, 50
 Activation of opioid receptors can result in inactivation of voltage- dependant 
Ca
++ 
channels and activation of K
+
 channels. While inactivation of Ca
++ 
channels causes reduced 
neurotransmitter release, activation of K
+
 channels causes cell hyperpolarization.
49
  
Opioid ligands can also display signal transduction through arrestin-dependent pathways. 
Among the various subtypes of arrestins, -arrestins can act as signal transducers and connect 
the activated receptor to various signaling pathways within the cells.
51
 Recent evidence has 
shown that phosphorylated arrestin-bound GPCRs can elicit responses through mitogen activated 
protein kinase (MAPK) signaling.
51
 The MAPK is a family of genes; and the most characterized 
forms are extracellular signal related kinases 1 and 2 (ERK 1/2), c-Jun-N-terminal kinase (JNK 
1-3) and p38 () stress kinases. While KOR induced activation of p38 requires G-protein 
coupled receptor kinase (GRK) 3/arrestin3 (also called -arrestin2), KOR mediated ERK 1/2 
activation has both -arrestin2 dependent and -arrestin independent components.
52
 
2.3 Opioids with clinical applications 
2.3.1 Clinically used opioids 
Clinically used opioids are mainly MOR agonists such as morphine and its analogs which 
have been used as analgesics for a considerable period of time. Other opioids, especially fentanyl 
and other 4-anilinopiperidines have been extensively used as adjuvants to anesthesia, while 
methadone (Figure 2.5) is used as a maintenance agent for individuals who are addicted to 
narcotics. Other uses of opioid agonists are as antitussive (for example, codeine), and 
antidiarrheal agents (for example, loperamide). Nalfurafine hydrochloride (TRK-820) is a 
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clinically successful KOR agonist that was approved in Japan in 2009 for the treatment of severe 
itching related to hemodialysis.
53, 54
 It was found to be 78-fold selective for KOR over MOR in 
the GPI assay (evaluated using selective opioid receptor antagonists to block specific receptor 
types).
55
 While KOR agonists produce analgesia and generally lack the reinforcing effects, 
however, they have limited utility because of side effects including dysphoria and sedation.
56
 
The mixed agonist/antagonists pentazocine and nalbuphine appear to be KOR agonists 
and MOR antagonists, and butorphanol which exhibits partial MOR agonist and antagonist 
activity and partial KOR agonism are used as analgesics.
1, 57
 Buprenorphine which is a partial 
MOR agonist and KOR antagonist
58, 59
 that also activates ORL-1 receptors,
60
 has been clinically 
approved for the treatment of opioid dependence.
61
 To counteract its potential misuse, 
buprenorphine has been formulated in combination with naloxone for the treatment of opioid 
dependence.
62
 The combination of buprenorphine and naltrexone has been tested in humans as a 
“functional KOR antagonist”
63
 and shown to be effective in the treatment of opioid 
dependence.
63, 64
 (The same combination was recently been shown to decrease compulsive 
cocaine self-administration in rodents with minimal liability to produce opioid dependence 
65
 and 
to attenuate drug primed reinstatement to cocaine and morphine in rats in a conditioned place 
preference paradigm.
66
  
The opioid antagonist naloxone is used in the treatment of opioid overdose and post-
operative sedation, while naltrexone is used for the treatment of opioid dependence and alcohol 
abuse.
1, 57
 Recently, the peripheral MOR antagonist methylnaltrexone bromide
67
 and alvimopan
68
 
(Figure 2.5) have been clinically approved for their use against constipation and recovery of 
normal gastrointestinal function after surgery, respectively.  
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Figure 2.5 Clinically used opioids and opioid antagonists 
2.3.2 Opioids in clinical trials or under clinical development 
A variety of peptidic entities targeting opioid receptors have been tested in clinical trials 
(see Figure 2.6 for opioids under clinical development). Recently, a novel dynorphin A(1-13) 
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derivative CJC-1008 (structure undisclosed) was in Phase II clinical trials for postherpetic 
neuralgia.
69
 It contains a maleimidopropionyl group covalently attaching the peptide to serum 
albumin and thereby extending the peptide’s duration of action. Following intravenous (i.v.) 
infusion it exhibited analgesic activity for at least 8 h, but less than 24 h.
69, 70
 FE200665 (now 
known as CR665), a peripheral KOR agonist,
71
 has completed phase Ia clinical trials and 
exhibited selectivity against visceral pain.
70, 72
 A second generation orally available peptide CR 
845 (structure not disclosed) has been reported to have successfully completed a Phase I trial in 
an oral formulation
73
 and is currently in Phase II clinical trials in an i.v. formulation.
74
 This 
peptide is being clinically developed for the treatment of postoperative pain.  Met
5
-enkephalin 
(referred to as opioid growth factor or OGF)
75
 has been examined in Phase I and II clinical trials 
for the treatment of advanced pancreatic cancer.
75
 It was reported to provide clinical benefit to 
53% of the patients who had failed standard chemotherapy and also to increase survival time by 
three fold.
70, 75
 It is also currently in Phase II clinical trials in head and neck cancers and in Phase 
I clinical trials for hepatocellular cancer.
76
 Recently, a clinical trial of gene therapy with the 
replication defective herpes simplex virus-based NP2 vector that expressed human proenkephalin 
was conducted. The therapy has shown promising results in terms of pain relief and safety.
70, 77
 
Along with peptidic drug candidates, several small molecules targeting opioid receptors 
are also in clinical trials or have the potential for clinical development. The peripherally selective 
KOR agonist asimadoline is currently undergoing clinical trials for the treatment of diarrhea 
predominant irritable bowel syndrome.
78
 Small molecule DOR agonists in clinical trials include 
PF-04856880
79
 (Adolor, Pfizer) for relieving pain related with rheumatoid arthritis and PF-
0465881
80
 (Adolor, Pfizer) for postherpetic neuralgia. A selective DOR antagonist TRK-851 
(Toray) which is an antitussive agent is in clinical development.
81
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Figure 2.6 Structures of opioids in clinical trials or under clinical development 
2.4 Significance of KOR 
KOR agonists, unlike MOR agonists, are devoid of respiratory depression and 
dependence liability. Hence, they have been recently recognized for several potential therapeutic 
applications (see below), sparking renewed interest in ligands for this receptor. The effectiveness 
of KOR agonists in antinociceptive assays varies significantly with the type of noxious stimuli.
82
 
KOR agonists are less effective against thermal antinociception, compared to their effectiveness 
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against mechanical and chemical induced pain.
56
 KOR agonists produce antinociception at both, 
receptors in the CNS and the peripheral KOR that are responsible for mediating inflammatory 
pain.
83, 84
 In addition, KOR agonists have been reported to display anti-arthritic
85
 and anti-
inflammatory activity.
84, 85
 While MOR agonists reinforce the effects of cocaine, KOR agonists 
alone do not produce reinforcing effects and following acute administration have been shown to 
block acute cocaine self-administration.
86-88
 However, it appears that under chronic treatment 
they may paradoxically contribute to cocaine seeking behavior.
89-91
  In addition KOR agonists 
also display other activities that include antipruritic activity,
92
 diuretic effects,
83, 93
 
neuroprotective effects,
94
 suppression of HIV-1 expression
95-97
 and modulation of immune 
responses.
98
 KOR agonists have also been reported to decrease tolerance to morphine,
56
 and 
dynorphins have been reported to inhibit opiate withdrawal symptoms in opiate dependent 
animals.
56, 99, 100
  
 The endogenous KOR system is involved in multiple behavioral responses to stress 
which can impact responses to drugs of abuse and other disease states.
56
 KOR activation also 
contributes to stress induced analgesia.
89, 101, 102
 When exposed to inescapable physical or 
psychological stress, rodents demonstrate stress-induced analgesia that is blocked by disruption 
of the prodynorphin gene
102
 or by KOR antagonists.
56
 Activation of KOR results in decreasing 
dopamine levels, while activation of MOR results in increasing dopamine levels.
103
 Cocaine 
exerts its effects by elevating levels of dopamine. Stressors such as repeated forced swim stress 
dramatically increase the rewarding effects of cocaine
89, 102
 and cause reinstatement of 
extinguished cocaine seeking behavior through a mechanism involving KOR.
104, 105
 This has led 
to the demonstration that KOR selective antagonists can block stress-induced reinstatement of 
cocaine seeking behavior.
106-109
 Further, exposure to forced swim stress also potentiates the 
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immobility response of rodents which appears to be mediated through activation of the 
endogenous KOR system.
110
 The cyclic adenosine monophosphate response element binding 
protein (CREB)-mediated increase in immobility behavior in rodents in forced swim stress was 
blocked by the KOR selective antagonist norBNI, suggesting involvement of KOR.
110
 Increased 
immobility in response to a stressor is also an animal model of depression, and hence KOR 
antagonists may have potential antidepressant activity
111-115
 and anti-anxiety properties.
115-118
  
2.5 Non-Peptidic KOR ligands 
2.5.1 KOR agonists 
A variety of non-peptidic kappa agonists (Figure 2.7) have been developed as potential 
analgesics. Some of the early KOR agonists were benzomorphan derivatives that included 
ligands such as cyclazocine, ethylketocyclazocine and bremazocine. These ligands were used as 
pharmacological tools to study KOR, but they display low selectivity for KOR.
1, 119
 The first 
KOR selective agonist was the benzacetamide U50,488.
120
 Introduction of a spiro ether group on 
the cyclohexane ring of U50,488 resulted U69,593 which had improved selectivity compared 
U50,488.
121
 Replacement of the phenyl ring in U69593 with a benzofuran yielded enandoline 
(CI-977) which is one of the most potent and selective kappa agonists.
122, 123
 Radiolabeled 
derivatives of U69593 and enanadoline have been extensively used as pharmacological tools for 
KOR radioligand binding assays.  
Several novel classes of KOR agonists have emerged recently. Octahydroisoquinoline 
carboxamides, a novel class of KOR agonists that does not contain a basic nitrogen, have been 
disclosed.
124
 The novel KOR agonist, SA14867, was found to be an antinociceptive and 
antipruritic agent in preclinical studies and potently inhibited substance P-induced scratching 
behavior to a similar extent as nalfurafine after oral administration.
125
 Some other structural 
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classes that have been recently described as KOR agonists are the pyrromorphinans
126
 and 6,8-
diazabicyclononane derivatives.
127
 In order to avoid centrally mediated side effects, peripherally 
selective KOR agonists such as asimadoline
128
 were also developed. Asimadoline is currently in 
clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome.
78
 
  
Figure 2.7 Non-peptidic KOR agonists  
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In addition, the non-nitrogenous natural product salvinorin A
129
 displayed potent and 
selectiveKOR agonist activity. Several analogs of salvinorin A have been synthesized to study its 
structure-activity relationships (SAR) and as potentially therapeutically useful analogs for the 
treatment of pain, mood, personality disorder, substance abuse and gastrointestinal disorders.
130, 
131
  
2.5.2 KOR antagonists 
While the early KOR antagonists developed were not very selective for KOR, the 
antagonists developed subsequently displayed much greater selectivity for KOR. The first 
selective non-peptide KOR antagonist described was triethyleneglycolnaltrexamime (TENA, 
Figure 2.8)
132
 which displayed modest selectivity for KOR. Subsequently, the KOR antagonist 
norBNI (Figure 2.8) displayed improved selectivity for KOR.
133, 134
 Later, the delta antagonist 
naltrindole when guanidylated at position 5, produced GNTI
135
 (Figure 2.8) a KOR antagonist 
with increased affinity, selectivity and potency over norBNI. Surprisingly, the guanidylation of 
naltrindole at position 6’ afforded a KOR agonist.
136
 
 Among the various 4-phenylpiperidine N-substituted derivatives, none of them were 
selective KOR antagonists
137, 138
 until the discovery of JDTic
139
 (Figure 2.8).  JDTic and norBNI 
not only displayed selective KOR antagonism in various antinociceptive assays, but also 
suppressed KOR agonist induced diuresis in rats.
140
 JDTic
106
 and norBNI
102
 have been shown to 
inhibit stress induced reinstatement of cocaine and also displayed antidepressant-like activity in 
the forced swim stress,
111
 prompting the examination of these compounds for potential use in the 
treatment of depression
113, 114
 and anxiety.
116, 117
 
These prototypical non-peptide KOR antagonists exhibited delayed onset of activity and 
long durations of action.
140
 The long duration of action extended from weeks to more than a 
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month depending on the species.
140
 Several mechanisms for this unusual long duration of action 
have been proposed including partitioning into the cell membranes, thereby forming a depot 
from which drug is slowly released, and/or due to their resistance to metabolism.
141
  Another 
hypothesis for the slow and persistent antagonism of these selective KOR antagonists may be 
due to an inactive conformation of the receptor which is induced by the compound.
141
 It has been 
proposed that the delay in the onset of norBNI may be due to the large size of the compound 
and/or poor permeability across the blood-brain barrier which in turn causes slow diffusion to the 
site of action.
142
 Recently, it was reported that norBNI, GNTI and JDTic caused activation of  
JNK1 which in turn caused prolonged inhibition of the KOR signaling pathways.
143, 144
 Very 
recently, it was reported that KOR antagonists that exhibit low efficacy for the activation of 
JNK1 pathway have shorter durations of action.
145
  
Recently several analogs of JDTic have been investigated in order to make more potent 
shorter acting derivatives. One of the analogs (compound W, see Figure 2.8), where the -NH- 
group in the tetrahydroisoquinoline ring of JDTic is replaced by a methylene antagonized 
selective kappa agonist-induced diuresis and displayed a duration of action of less than a 
week.
146
 However, it was 9-fold less potent at KOR and 30-fold less selective for KOR over 
MOR than JDTic.
146
 Another analog of JDTic, RTI-194, although not as efficacious as JDTic in 
inhibiting relapse to cocaine due to stress, is one of the very few orally bioavailable KOR 
antagonists
109
 along with JDTic.
147
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Figure 2.8 Non-peptidic KOR antagonists 
Three antagonists, AZ-ECPC, AZ-MTAB and LY-DMPF (Figure 2.8), that belong to 
three different chemical classes lacked the long lasting inhibition (less than 1 week vs. 4 weeks 
exhibited by norBNI) of kappa agonist-induced diuresis.
118
 In the elevated plus maze model for 
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mood disorders, AZ-MTAB and LY-DMPF were able to reverse prenatal stress-induced 
behavioral deficits.
118
 AZ-ECPC, AZ-MTAB and LY-DMPF displayed KOR affinities (Ki ) 
values of 53 nM, 35 nM and 1.8 nM, respectively, in the radioligand binding assays and KOR 
antagonist potencies (IC50 for antagonism of 15 nM Dyn A(1-13)) with values of 83 nM, 19 nM 
and 1.3 nM in the GTPS assay.
118
 AZ-ECPC, AZ-MTAB and LY-DMPF displayed 5-, 37- and 
40-fold selectivity, respectively, for KOR vs MOR in the GTPS assay as compared to 102-fold 
selectivity obtained for norBNI.
118
 In addition, while KOR antagonists such as norBNI,
105
 
JDTic
106
 and zyklophin
108
 must be administered prior to induction of stress to prevent stress-
induced reinstatement of cocaine seeking behaviour, recently developed KOR antagonists such 
as AZ-MTAB and LY-DMPF have been effective post-stress in a model of anxiety.
118
  
PF-04455242 (Figure 2.8) is a selective KOR antagonist developed by Pfizer that has 
been studied extensively in vivo as well as in vitro. Receptor occupancy studies of PF-
04455242
148
 showed that this compound was bound to central KOR for not more than 8 h, 
suggesting that it had a short duration of action
149
 which was later confirmed by the results from 
the warm water tail withdrawal antinociception assay.
145
 PF-04455242 displayed a Ki value of 3 
nM for KOR, and a 20-fold selectivity for KOR over MOR and a KOR antagonist potency of 
1.23 nM in the GTPS assay.
149
 PF-04455242 was also shown to have excellent brain penetration 
and is not a P-glycoprotein substrate.
148
 Although it is highly bound to plasma proteins, its free 
concentrations in the brain strongly correlated with its Ki value for KOR.
148
 PF-04455242 
displayed antidepressant-like behavior, inhibited stress-induced reinstatement of cocaine and also 
inhibited spirolidine-induced increases in rat plasma prolactin levels.
149
  
One of compounds belonging to the class of aminobenzloxyarylamides was an orally 
active selective KOR antagonist (compound X, Figure 2.8)
150
 and another was used as a KOR 
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occupancy tracer (compound Y, Figure 2.8).
150
 Unlike the previously developed tracer that is a 
KOR agonist,
151
 compound Y is a KOR antagonist.
150
 It (compound Y) displays favorable 
specific vs. nonspecific binding, had good brain uptake and could be blocked by pretreatment 
with the orally active KOR antagonist compound X in a dose-dependent manner, demonstrating 
its utility as a tracer for determining the KOR occupancy levels of other KOR ligands. The orally 
active antagonist (compound X), unlike the prototypical KOR antagonists that exhibit a delayed 
onset of action showed potent in vivo antagonism within 30 min of oral dosing and was 63- and 
373-fold selective for KOR over MOR and over DOR, respectively, in radioligand binding 
assays.  
2.6 Overview of peptidic KOR ligands 
 Peptidic ligands targeting KOR include both agonists and antagonists. These ligands 
mainly include analogs of the endogenous KOR ligand the dynorphins, however, peptides 
structurally unrelated to dynorphins such as linear and macrocyclic tetrapeptides also exhibit 
activity at KOR. We are interested in developing Dyn analogs as pharmacological tools to study 
the structure and function of KOR and for therapeutic in vivo applications. Hence, the SAR of 
Dyn A analogs will be discussed extensively in section 2.7.  
2.6.1 Peptide agonists 
Several Dyn A analogs with modifications in the “message” and “address” sequence (The 
“message-address” concept will be discussed below in section 2.7.1) have been reported and 
evaluated in both in vitro and in vivo studies. Dyn A analogs with agonist activity and high 
selectivity at KOR include [D-Pro
10
]Dyn A(1-11) analogs with N-terminal monoalkylation
152
 
and analogs with substitution of either Ala or D-Ala in position 3 of Dyn A(1-11)NH2
153
 (Figure 
2.9 for peptide KOR agonists).  
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Figure 2.9 Peptidic KOR agonists 
A number of modifications have been made to Dyn A to increase its metabolic stability 
so that the peptides can be studied in vivo. Dyn A(1-13) is a potent fragment of Dyn A.
154
 
[NMeTyr
1
]Dyn A(1-13)NH2 was one of the very early Dyn A analogs with KOR agonist activity 
and improved metabolic stability.
154
 This peptide produced antinociception and enhanced 
morphine analgesia in morphine tolerant rats in vivo after intravenous, subcutaneous and 
pulmonary administration.
155, 156
 The Dyn A-(1-8) derivative E-2078 ([NMeTyr
1
,NMeArg
7
,D-
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Leu
8
]Dyn A(1-8)NEt2,
157
 (Figure 2.9), contains several modifications to impart metabolic 
stability. This peptide has been extensively studied in rodents,
158-161
 monkeys
162-165
 and 
humans.
166, 167
 In humans it exhibited analgesic activity comparable to pentazocine.
166
 
Radioiodinated E-2078 was detected in rat brain parenchyma following brain perfusion 
studies,
158
 and E-2078 was also detected in the cerebrospinal fluid of monkeys by mass 
spectrometry.
163
 [I
125
-Tyr]E2078 was shown to cross bovine brain microvessel endothelial cell 
(BBMEC) monolayers, which is a model of blood-brain barrier (BBB), by absorptive-mediated 
endocytosis.
168
 While this peptide has been shown to cross the BBB, the elevation of serum 
prolactin levels by E-2078 suggested that this peptide is a potent peripherally selective KOR 
agonist.
162
 SK-9709 ([D-Ala
2
,Arg
6
ψ(CH2NH)Arg
7
]Dyn A-(1-8) amide, Figure 2.9) is another 
metabolically stable Dyn A(1-8) analog. SK-9709 is 15-fold selective for KOR over MOR which 
is comparable to that of Dyn A(1-13).
169
 It exhibits antinociceptive activity which appears to be 
mediated by both KOR and MOR. Similar to E-2078, SK-9709 exhibited long lasting 
antinociception (maximal effect at 120 min after systemic (s.c.) administration) in the acetic acid 
writhing and the hot plate tests, although it was less potent than E-2078.
169
  
Peptidic KOR agonists unrelated to Dyn includes several all-D tetrapeptides. A 
combinatorial library of these tetrapeptides was screened to identify peptides with affinity for 
each of the opioid receptors.
170
 The tetrapeptides with affinity for KOR included those consisting 
of all D-amino acids include FE20041 (Figure 2.9) which exhibited 30,000- and 68,000-fold 
selectivity for KOR over MOR and DOR, respectively;
171
 this peptide was approximately 10-
fold selective for peripheral over central KOR.
171
 C-terminal modifications of this peptide 
resulted in FE200665 and FE20066 (Figure 2.9) that were 548- and 182-fold selective, 
respectively, for peripheral KOR over the central KOR.
71, 172
 FE200665 has completed phase Ia 
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clinical trial and exhibited peripheral KOR selectivity,
72
 and a second generation peptide CR 845 
(structure undisclosed) has successfully completed Phase I trial in an oral formulation
73
 and is 
currently in Phase II clinical trials as an i.v. formulation.
74
 The candidate is being clinically 
developed for the treatment of postoperative pain.  
2.6.2 Peptide antagonists 
Most of the peptide based KOR antagonists that have been developed are modified Dyn 
A(1-11) derivatives (see Figure 2.10). These include analogs without a basic N-terminus,
173-176
 
[Pro
3
]Dyn A(1-11)NH2 derivatives
177-179
 and also [N,N-diallyl-Tyr
1
,D-Pro
10
]Dyn A(1-11).
152, 180, 
181
  Arodyn (Ac[Phe
1,2,3
,Arg
4
,D-Ala
8
]Dyn A(1-11)NH2), a selective KOR antagonist, synthesized 
in the Aldrich laboratory,
174
 when administered centrally antagonized the antinociceptive effects 
of the centrally administered KOR agonist U50488 in the warm water tail withdrawal assay and 
was able to inhibit stress induced reinstatement of cocaine seeking behavior  in the cocaine 
conditioned place preference assay.
107
 While arodyn was metabolized when tested in whole rat 
blood in vitro, zyklophin ([N
α
-benzylTyr
1
-cyclo(D-Asp
5
,Dap
8
)]Dyn A(1–11)NH2), a cyclic 
selective KOR antagonist, displayed greater metabolic stability than arodyn in vitro
182
 and was 
effective when administered both centrally and peripherally.
108
 The ability of peripherally 
administered zyklophin to antagonize centrally administered U50,488 strongly suggested that 
zyklophin was able to cross the blood brain barrier.
108
 Zyklophin when systemically 
administered (3 mg/kg s.c.) prevented stress- induced reinstatement of cocaine seeking behavior 
in conditioned place preference assay. In the antinociceptive assay, unlike the small molecule 
KOR antagonists, zyklophin inhibited the antinociceptive effect of U50,488 for a shorter 
duration (12-18 h) after s.c administration. 
108
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Figure 2.10 Peptidic KOR antagonists 
Other peptides unrelated to Dyn A have also exhibited KOR antagonism. The natural 
product macrocyclic tetrapeptide CJ-15,208 (cyclo[Phe-D-Pro-Phe-Trp], Figure 2.10) exhibited 
KOR antagonism in a smooth muscle assay in vitro.
183
 In vivo, the parent peptide with L-Trp 
exhibited mixed agonist/antagonist activity.
184
 Orally administered L-Trp isomer displayed dose 
dependent and time dependent inhibition of both cocaine-induced and stress-induced 
reinstatement of cocaine, making it a promising lead for the treatment of drug abuse, especially 
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relapse.
185
 Following intracerebroventricular administration the D-Trp isomer of CJ-15,208 
displayed minimal agonist activity and exhibited KOR selective antagonism that lasted less than 
18 h.
184
 The D-Trp isomer also inhibited stress- but not cocaine-induced reinstatement of 
extinguished cocaine seeking behavior. The relatively short duration of action produced by the 
D-Trp isomer makes it a promising lead compound for maintaining abstinence from substance 
abuse.
184
 Following oral administration the D-Trp isomer exhibited weak KOR agonism, 
displayed KOR antagonism, and prevented stress-, but not cocaine-, induced extinguished 
cocaine seeking behavior in a dose-dependent manner.
186
 
2.7 Dynorphin A analogs 
2.7.1 Introduction 
 Dyn A has the N-terminal tetrapeptide sequence Tyr-Gly-Gly-Phe, common to most other 
endogenous mammalian opioid peptides; however, the C-terminal sequence differs from other 
opioid peptides. Chavkin and Goldstein  proposed the “message-address” hypothesis wherein the 
N-terminal “message” sequence imparts opioid receptor affinity and activity, while the C-
terminal “address” sequence imparts affinity for KOR.
154
 Dyn A(1-13) and Dyn A(1-11) account 
for most of the parent peptide’s opioid activity.
154
 Therefore these two shorter peptides are 
generally used as the parent peptides for incorporating structural modifications.
154
 Most of the 
SAR studies have been focused on Dyn A, and very few Dyn B analogs
187
 have been 
synthesized.  
Several linear and cyclic Dyn A analogs with modifications in the “message” and 
“address” sequences have been synthesized. Some of the early Dyn A analogs include the mono- 
and dialkylated analogs of [D-Pro
10
]Dyn A(1-11).
152, 180, 181, 188
 In addition several cyclic analogs 
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with conformational constraint through a lactam
189-191
 or disulfide bridge
192-194
 have also 
synthesized. Detailed reviews that discuss the early SAR of Dyn A were published earlier.
195, 196
  
2.7.2 Analogs with modifications in the N-terminal “message” sequence 
2.7.2.1 Dyn A analogs with modifications at position 1  
Several analogs containing modifications in position 1 of the “message” sequence have 
been synthesized to explore the SAR of Dyn A (see Table 2.3 for opioid receptor binding 
affinities, and Tables 2.4 and 2.5 for opioid agonist and antagonist potencies, respectively).  
[D-Pro
10
]Dyn A(1-11) was one of the early Dyn A analogs that was synthesized.
197
 N-
Alkylation of Tyr
1
 in this peptide resulted in analogs with increased KOR selectivity, while 
dialkylation resulted in lower KOR affinity and selectivity than the parent peptide.
152, 181, 188
 In 
the earlier studies N,N-diallyl analog was found to be a KOR antagonist.
180
 Subsequent studies of 
the monoalkylated [D-Pro
10
]Dyn A(1-11) showed that the N-benzyl analog has high KOR 
affinity, but, displayed weak agonist activity in the GPI assay
152, 181
 and displayed partial 
agonism (~70% efficacy compared to full agonist Dyn A(1-13)NH2) in the AC assay.
188
 The N-
allyl and the N-cyclopropylmethyl (CPM) analogs also showed high KOR affinity and displayed 
potent agonist activity in GPI assay.
152
 The N-CPM analog also displayed full agonist activity 
(94% efficacy compared to full agonist Dyn A(1-13)NH2) in the AC assay.
188
  
Schiller et al. showed that substitution of the Tyr
1
 residue of opioid agonist peptides with 
residues in which the positively charged N-terminal amino group was replaced with hydrogen or 
methyl group produced opioid antagonists.
175, 198
 The Tyr
1
 residue in Dyn A(1-11)NH2 was 
replaced with Dhp (Dhp = 3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid, Figure 2.11) or 
with Mdp (Mdp = (2S)-2-methyl-3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid, Figure 2.11). 
In the GPI assay the Dhp
1
 analog was a potent KOR antagonist with a Ke value of 17.4 nM, 
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while the Mdp
1
 analog (called dynantin) was found to be even more potent with a Ke value of 
0.63 nM against the agonist Dyn A(1-11)NH2. Dynantin also displayed subnanomolar KOR 
affinity (Ki = 0.82 nM) and high KOR binding selectivity (Ki (KOR/MOR/DOR = 1/259/198)). 
The D-Ala
3 
analogs of [Dhp
1
]Dyn A(1-11)NH2 and [Mdp
1
]Dyn A(1-11)NH2 were prepared, but 
none of them showed  significant improvements in selectivities or antagonist potencies as 
compared to their parent analogs.
175
 The Mdp analog of the KOR agonist E2078 was also 
synthesized, although it was less potent and selective than dynantin.
187
 Schiller and coworkers 
desribed the Mdp
1
 analog of Dyn B, the first Dyn B based KOR antagonist. However, it was less 
potent and less selective than dynantin (see Table 2.3 and 2.5).
187
 
 
Figure 2.11 Tyrosine analogs incorporated into Dyn A analogs 
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Table 2.3 Opioid receptor binding affinities of Dyn A and Dyn B analogs modified at position 1. 
  Ki (nM ± SEM) Ki ratio Ref 
Compound KOR MOR DOR 
KOR/MOR/ 
DOR 
  
[D-Pro
10
]Dyn A(1-11)
a
 0.030 ± 0.001 0.24 ± 0.002 2.1 ± 0.4 1/8/70 152 
[N-Allyl-Tyr
1
,D-Pro
10
]Dyn A(1-11)
a
 0.049 ± 0.001 10.9 ± 0.5 499 ± 15 1/222/9160 152 
[N-CPM-Tyr
1
,D-Pro
10
]Dyn A(1-11)
a
 0.020 ± 0.001 9.6 ± 0.6 558 ± 8.9 1/480/27900    152 
[N-Benzyl-Tyr
1
,D-Pro
10
]Dyn A(1-11)
a
 0.029 ± 0.001 31.1  ±  0.2 176 ± 17 1/1070/6080    152 
[N,N-Diallyl-Tyr
1
,D-Pro
10
]Dyn A(1-11)
a
 3.60 ± 0.50 31.7 ± 3.8 149 ± 58 1/8.8/41 152 
[N,N-DiCPM-Tyr
1
,D-Pro
10
]Dyn A(1-11)
a
 0.19 ± 0.002 3.9 ± 0.1 166 ± 14 1/21/880 152 
[Dhp
1
]Dyn A(1–11)NH2
b
 3.49 ± 0.12 27.9 ± 3.3 122 ± 24 1/8/35 175 
[(2S)-Mdp
1
]Dyn A(1–11)NH2 (Dynantin)
b
 0.823 ± 0.162 213 ± 50 163 ± 15 1/259/198 175 
[Dhp
1
,D-Ala
3
]Dyn A(1–11)NH2
b
 3.84 ± 0.90 73.0 ± 1.1 419 ± 57 1/19/109 175 
[(2S)-Mdp
1
,D-Ala
3
]Dyn A(1–11)NH2
b
 2.47 ± 0.38 167 ± 17 364 ± 101 1/68/147 175 
[(2S)-Mdp
1
,MeArg
7
,D-Leu
8
]Dyn A(1–8)NH2
b,c
 4.07 154 118 1/38/29 187 
[(2S)-Mdp
1
,MeArg
7
,D-Leu
8
]Dyn A(1–8)NHEt2
b,c
 15.2 51.2 13.5 1/3/1 187 
[(2S)-Mdp
1
]Dyn B
b,c
 9.12 21.3 43.6 1/2/5 187 
a 
Affinity for KOR was determined by measuring the inhibition of [3H]bremazocine binding to guinea pig cerebellar 
membranes. Affinities for MOR and DOR were measured in rat forebrain using [3H]DAMGO and [3H]DPDPE, 
respectively. 
b
 Determined by displacement of [
3
H]U69,593 from guinea pig brain membrane binding sites and of [
3
H]DAMGO 
and [
3
H]DSLET from rat brain membrane binding sites. 
c
 SEM not reported 
 
Table 2.4 Opioid agonist potencies of N-terminally modified [D-Pro
10
]Dyn A(1-11) analogs 
Compound IC50 (nM)
a          
Ref 
[D-Pro
10
]Dyn A(1-11) 0.22 (0.11-0.49)          152 
[N-Allyl-Tyr
1
,D-Pro
10
]Dyn A(1-11) 18.3 (13.2-22.4)          152 
[N-CPM-Tyr
1
,D-Pro
10
]Dyn A(1-11) 2.16 (1.6-2.8)              152 
[N-Benzyl-Tyr
1
,D-Pro
10
]Dyn A(1-11) 990 (657-1500)           152 
                                              a IC50 values obtained in the GPI assay. 95% confidence intervals are given in parentheses. 
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Table 2.5 Antagonist potencies of Dyn A and Dyn B analogs modified at position 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Antagonist potency in the GPI assay against [D-Pro
10
]Dyn A(1-11). 
b 
Antagonist potency in the GPI assay against Dyn A(1-13). 
c
 SEM not reported 
 
2.7.2.2 Dyn A analogs modified at position 2 and/or 3 
Schlectingen et al. synthesized Dyn A(1-11)NH2 analogs with Pro-substituted at positions 
2 and 3
177, 179
 (see Table 2.6 for opioid receptor affinities and Table 2.7 for antagonist potencies). 
The Pro
2 
and D-Pro
2
 analogs showed similar KOR affinity and selectivity (~30-fold selective for 
KOR vs. MOR), but their affinities were substantially lower (1000-fold) than Dyn A(1-11)NH2. 
Substitution of Sar (Sar = sarcosine, i.e N-Me Gly) at position 2 yielded an analog that exhibited 
higher KOR affinity (Ki = 1.5 nM) than the Pro
2
 and D-Pro
3
 analogs and was a full agonist (IC50 
= 280 nM)   in the GTPS assay. Although substitution of Pro at position 3 reduced the affinity 
for all three opioid receptors relative to the parent peptide Dyn A(1-11)NH2, it retained 
reasonably high KOR affinity (Ki = 2.7 nM) and is one of the most selective KOR ligands (2200-
fold selective for KOR vs MOR). In contrast, the D-Pro
3
 analog had very low KOR affinity (Ki = 
160 nM) without any gain in selectivity. While the configuration of Pro at position 3 had a 
significant effect on the KOR affinity and selectivity, all of the Pro analogs with substitution in 
positions 2 or 3 were found to be weak KOR antagonists in the [
35
S]GTPS assay, with the Pro
3
 
Compound Ke (nM ± SEM) Ref 
[N,N-Diallyl-Tyr
1
,D-Pro
10
]Dyn A(1-11)
a
 188 ± 32 180 
[Dhp
1
]Dyn A(1–11)-NH2
b
 17.4 ± 2.7 175 
[(2S)-Mdp
1
]Dyn A(1–11)-NH2 (Dynantin)
b
 0.632 ± 0.136 175 
[Dhp
1
,D-Ala
3
]Dyn A(1–11)NH2
b
 11.6 ± 1.4 175 
[(2S)-Mdp
1
,D-Ala
3
]Dyn A(1–11)NH2
b
 3.31 ± 0.24 175 
[(2S)-Mdp
1
,MeArg
7
,D-Leu
8
]Dyn A(1–8)-NH2
 b,c
 8.29 187 
[(2S)-Mdp
1
,MeArg
7
,D-Leu
8
]Dyn A(1–8)-NHEt2
 b,c
 39.1 187 
[(2S)-Mdp
1
]Dyn B
b,c
 114 187 
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analog being the most potent (IC50 = 380 nM), (see Table 2.7).  These analogs were also found to 
be weak antagonists in the GPI assay.
177
 The analog with the larger ring size homolog of Pro, 
piperidinecarboxylic acid (Pip) exhibited decreased KOR affinity (Ki (KOR) = 210 nM) and 
KOR selectivity (60-fold selective for KOR vs MOR) compared to the Pro
3
 analog suggesting 
that increasing the ring size of Pro
3
 residue resulted in decreased KOR affinity and selectivity. 
This suggested that the ϕ dihedral angle and backbone geometry of residue 3 were important for 
maintaining affinity and selectivity for KOR. The disubstituted analog [Sar
2
,Pro
3
]Dyn A(1-
11)NH2 displayed high KOR affinity (Ki = 3.2 nM) and retained selectivity for KOR (see Table 
2.6). While the Sar
2
,Pro
3
 analog displayed comparable KOR affinities to the Pro
3
 analog, it was 
8-fold less potent as an antagonist relative to Pro
3 
analog (see Table 2.7).
178
  
Table 2.6 Opioid receptor binding affinities of Dyn A analogs modified in positions 2 and 3. 
  Ki (nM ± SEM)
a
 Ki ratio Ref 
Compound KOR MOR DOR KOR/MOR/DOR   
[Pro
2
]Dyn A(1-11)NH2 94 ± 18 3200 ± 290 6800 ± 350 1/34/72                   177  
[D-Pro
2
]Dyn A(1-11)NH2 65 ± 8.7 1700 ± 160 3900 ± 300 1/26/1960               177  
[Sar
2
]Dyn A(1-11)NH2 1.5 ± 0.15 390 ± 120 390 ± 62 1/260/260               178  
[Pro
3
]Dyn A(1-11)NH2 2.7 ± 0.33 5700 ± 860 8800 ± 2100 1/2110/3260           177 
[D-Pro
3
]Dyn A(1-11)NH2 160 ± 28 8300 ± 1500 7100 ± 200 1/52/44 177 
[Pip
3
]Dyn A(1-11)NH2 210 ± 19 12600 ± 2400 4700 ± 180 1/60/22 178 
[Sar
2
, Pro
3
]Dyn A(1-11)NH2 3.2 ± 0.3 1490 ± 350 >10,000 1/460/>3000           178 
Dyn A(1-11)NH2 0.059 ± 0.015 5.6 ± 1.6 3.2 ± 0.83 1/95/55                    178 
a
 Ki values were obtained using Chinese hamster ovary (CHO) cell membranes stably expressing opioid receptors 
with [
3
H]diprenorphine as the  radiolabeled ligand 
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Table 2.7 Antagonist potencies of Dyn A analogs substituted at position 2 and 3.  
Compound IC50  (nM ± SEM)
a
 Ref 
[Pro
2
]Dyn A(1-11)NH2 760 ± 220 177 
[D-Pro
2
]Dyn A(1-11)NH2 940 ± 470 177 
[Pro
3
]Dyn A(1-11)NH2
b
 380 ± 54 177 
[D-Pro
3
]Dyn A(1-11)NH2 2200 ± 1300     177 
[Sar
2
, Pro
3
]Dyn A(1-11)NH2 2790 ± 1050 178 
                                                             aAntagonist activity determined against 50 nM U50,488 in GTPS assay.  
                                                         b
Antagonist activity (Ke = 244 ± 51 nM)  determined against U50,488 in GPI assay. 
 
2.7.2.3 Dyn A analogs modified at position 4 
Vig et al. synthesized various Dyn A analogs with substitutions in position 4 of the 
peptide [D-Ala
8
]Dyn A(1-11)NH2
199
 in an effort to understand the spatial orientation of the 
aromatic ring of Phe
4
 required for interaction with KOR (see Table 2.8 for opioid receptor 
binding affinities and Table 2.9 for agonist potencies and efficacies). Substitution of D-Phe at 
position 4 caused a 78-fold decrease in KOR affinity as compared to the parent peptide, 
demonstrating that the backbone stereochemistry at position 4 is important for maintaining KOR 
affinity.
200
 The analog with L-Homophe (homophenylalanine, Figure 2.12)
 
in position 4 showed 
subnanomolar affinity for KOR (Ki = 0.66 nM) and retained selectivity for KOR over MOR 
comparable to the parent peptide. The D-Homophe
4
 substitution, however, resulted in a 3-fold 
decrease in KOR affinity as compared to the L-Homophe
4
 analog.
199
 When the isomers of the 
conformationally constrained residue Atc (Atc = 2-aminotetralin-2-carboxylic acid, Figure 2.12) 
were incorporated in position 4 of [D-Ala
8
]Dyn A(1-11)NH2 the (R)-Atc analog, which 
corresponds to a constrained analog of the D-Phe
4
 peptide, displayed 10-fold higher KOR 
affinity (Ki = 0.89 nM) compared to the (S)-Atc analog. Hence, substitution of Atc at position 4 
of [D-Ala
8
]Dyn A(1-11)NH2 demonstrated a reversal of the preferred stereochemistry for 
KOR.
200
 This also suggested that Atc behaved more as a constrained Homophe rather than as a 
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Phe analog at position 4 in this peptide. Other conformationally constrained Phe analogs i.e. the 
Aic (2-aminoindan-2-carboxylic acid, Figure 2.12, Ki = 26.5 nM) and Tic (1,2,3,4-
tetrahydroisoquinoline 3-carboxylic acid, Figure 2.12, Ki = 4.69 nM) analogs displayed lower 
KOR affinities as compared to the (R)-Atc analog. Therefore among the various 
conformationally constrained residues at position 4, (R)-Atc displayed the most compatible 
spatial orientation for interaction with KOR. These results suggested that the side chain of the 
Phe
4
 residue of Dyn A(1-11)NH2 preferred either the gauche (-), with 

 of approximately -60
o
, 
or trans. These findings are consistent with the computational model of Dyn A interacting with 
KOR that was proposed by Paterlini et al.
201
 Other substitutions at position 4 that could influence 
the backbone conformation of the peptide also affected receptor affinities and selectivities, for 
example, the -MePhe
4
 analog displayed a decrease in KOR affinity while MOR affinity was 
maintained, hence causing a decrease in KOR vs. MOR selectivity compared to the parent 
peptide. The N-MePhe
4
 analog maintained the KOR affinity but displayed an increase in MOR 
affinity causing a decrease in KOR vs. MOR selectivity. While KOR and MOR were able to 
tolerate various substitutions at position 4, these peptides displayed very low affinity for DOR. 
The analogs also differed in their potencies for KOR in the AC assay. While the parent Phe
4
 
analog showed 500-fold higher potency compared to the D-Phe
4
 analog, the (R)-Atc analog 
showed only 8-fold higher potency than the (S)-Atc analog and the Homophe
4
 analog was only 
9-fold more potent at KOR than its D-isomer. These results demonstrated that the affinity, 
potency and selectivity of [D-Ala
8
]Dyn A(1-11)NH2 analogs were influenced by the spatial 
orientation, stereochemistry and backbone conformation of residue 4. However, modifications at 
position 4 had minimal effect on efficacy at KOR, and all of these analogs were KOR 
agonists.
199
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Figure 2.12 Phenylalanine derivatives 
Table 2.8 Opioid receptor binding affinities of Dyn A analogs modified in position 4. 
  Ki (nM ± SEM)
a
 Ki ratio Ref 
Compound KOR MOR DOR KOR/MOR/DOR 
 
[(R)-Atc
4
,D-Ala
8
]Dyn A(1-11)NH2 0.89 ± 0.14 32.9 ± 4.7 >10,000 1/37/>10,000 199 
[(S)-Atc
4
,D-Ala
8
]Dyn A(1-11)NH2 9.54 ± 2.77 88.3 ± 5.9 >10,000 1/9.3/>10,000 199 
[HomoPhe
4
,D-Ala
8
]Dyn A(1-11)NH2 0.66 ± 0.03 13.7 ± 0.3 190 ± 58 1/21/288 199 
[D-HomoPhe
4
,D-Ala
8
]Dyn A(1-11)NH2 1.73 ± 0.51 47.0 ± 3.0 5570 ± 1620 1/27/3220 199 
[D-Phe
4
,D-Ala
8
]Dyn A(1-11)NH2 8.91 ± 0.07 123 ± 37 >10,000 1/14/>1120 200 
[Aic
4
,D-Ala
8
]Dyn A(1-11)NH2 26.5 ± 12.7 364 ± 52 >10,000 1/14/>377 199 
[Tic
4
,D-Ala
8
]Dyn A(1-11)NH2 4.69 ± 0.75 206 ± 36 3590 ± 580 1/44/765 199 
[-MePhe,D-Ala
8
]Dyn A(1-11)NH2 3.20 ± 0.79 3.24 ± 0.87 157 ± 46 1/1/49 199 
[NMePhe
4
,D-Ala
8
]Dyn A(1-11)NH2 0.62 ± 0.19 1.03 ± 0.4 56.1 ± 7.1 1/1.7/90 199 
[D-Ala
8
]Dyn A(1-11)NH2 0.11 ± 0.05 4.20 ± 1.9 6.57 ± 0.23 1/10.4/64.2 200 
a
 Ki values were obtained using CHO cell membranes stably expressing opioid receptors with [
3
H]diprenorphine,  
    [
3
H]DAMGO and [
3
H]DPDPE as the radiolabeled ligands for KOR, MOR and DOR, respectively 
 
 
 
 
 
 
                                                                                                                                                         
45 
 
Table 2.9 Agonist potencies and efficacies at KOR in AC assay of Dyn A analogs modified at 
position 4. 
 
Compound IC 50 (nM ± SEM) 
% max 
inhibition
a
 
Ref 
[(R)-Atc
4
,D-Ala
8
]Dyn A(1-11)NH2 72.4 ± 28.1 96 ± 3 199 
[(S)-Atc
4
,D-Ala
8
]Dyn A(1-11)NH2 573 ± 220 74 ± 1 199 
[HomoPhe
4
,D-Ala
8
]Dyn A(1-11)NH2 5.20 ± 1.99 95 ± 5 199 
[D-HomoPhe
4
,D-Ala
8
]Dyn A(1-11)NH2 46.9 ± 7.1 100 199 
[D-Phe
4
,D-Ala
8
]Dyn A(1-11)NH2 515 ± 330 73 ± 10 199 
[Aic
4
,D-Ala
8
]Dyn A(1-11)NH2       - 39 ± 8  199 
[Tic
4
,D-Ala
8
]Dyn A(1-11)NH2 29.4 ±10.3 91 ± 5 199 
[-MePhe,D-Ala
8
]Dyn A(1-11)NH2 36.5 ± 6.4  100 199 
[NMePhe
4
,D-Ala
8
]Dyn A(1-11)NH2 3.56 ± 0.64 99 ± 1 199 
[D-Ala
8
]Dyn A(1-11)NH2 1.24 ± 0.43 100 199 
a
 Maximum percent inhibition of adenylyl cyclase at a concentration of 10 M relative to the inhibition 
produced by 100 nM Dyn A(1-13)NH2 (100% inhibition). 
 
2.7.2.4 Dyn A analogs modified at multiple positions in the N-terminal “message” sequence 
Several linear analogs of Dyn A with modifications in multiple positions of the N-
terminal tetrapeptide have been synthesized (see Table 2.10 for receptor binding affinities and 
Table 2.11 for efficacies).   
Wan et al. reported the chimeric peptide Ac[Lys
2
,Trp
3,4
,D-Ala
8
]Dyn A-(1-11)NH2 
(initially called JVA901 and more recently called venorphin, see Figure 2.10) which combined 
the N-terminal acetylated derivative of the tetrapeptide Boc-Tyr-Lys-Trp-Trp-NH2,
202
 which 
displayed weak KOR antagonism in the GPI assay,  with the “address” sequence (residues 5-11) 
of [D-Ala
8
]Dyn A-(1-11)NH2.
173
 Venorphin displayed KOR selectivity comparable to [D-
Ala
8
]Dyn A-(1-11)NH2, but had 100-fold lower KOR affinity (Ki = 19.8 nM, see Table 2.10). In 
the AC assay, venorphin was found to be a low efficacy partial agonist at KOR (efficacy = 28% 
of the maximum inhibition of c-AMP formation by Dyn A(1-13)NH2) and was able to 
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completely reverse the agonistic effects of 1 nM Dyn A(1-13)NH2 at KOR in a concentration-
dependent manner.
173
  
In another study, the N-terminal sequence of [D-Ala
8
]Dyn A(1-11)NH2 was replaced by 
[Arg
6
]acetalin (Ac-Arg-Phe-Met-Trp-Met-Arg-NH2), a potent MOR peptide antagonist to yield a 
peptide with a 65-fold increase in affinity for KOR (Ki = 6.6 nM) and retained high MOR 
affinity (Ki = 1.12 nM) which the authors labeled extacet.
203
 Exploration of the SAR of extacet 
through a mixture based combinatorial library
204
 led to the identification of Ac[Phe
1,2,3
,Arg
4
,D-
Ala
8
]Dyn A-(1–11)NH2 (called arodyn, Figure 2.9) that had KOR affinity (Ki = 10 nM) 
comparable to extacet and was 174-fold selective for KOR vs. MOR.
174
   
Initial analogs of arodyn included an alanine scan and other analogs with substitutions in 
position 1. The Ala scan of arodyn suggested that while the basic residues in position 6 and 7 are 
important for maintaining the KOR binding affinity, the basic residues in position 4, 9 and 11 
and residue in position 1 also contributed to the KOR affinity of arodyn.
205
 Replacement of the 
Phe
1
 residue in arodyn with Tyr caused a 7-fold decrease in KOR affinity, suggesting that the 
binding mode of arodyn at KOR differs from that of Dyn A. The Dmt
1
 analog of arodyn 
displayed comparable KOR affinity for arodyn, and hence showed 7-fold higher KOR affinity as 
compared to the Tyr
1
 analog of arodyn.
205
 All of these arodyn analogs exhibited low efficacy at 
KOR in the AC assay (≤ 32% inhibition of AC compared to the full agonist Dyn A(1-13)NH2) 
except for the Tyr
1
 analog of arodyn which was found to be an inverse agonist resulting in a dose 
dependent increase in c-AMP levels over forskolin controls.
205
 
Additional analogs of arodyn involved introducing an NMe group on Phe
1
 and other 
amino acid substitutions in position 3. The NMePhe
1
 analog of arodyn exhibited the highest 
KOR affinity (Ki = 4.56 nM) and 6-fold higher selectivity for KOR vs. MOR as compared to 
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arodyn (see Table 2.10). The NMePhe
1
 analog was also found to completely reverse the agonist 
effects of 10 nM Dyn A(1-13)NH2 in a concentration-dependant manner.
205
 The NMePhe
1
 
analog was unstable, however, and prone to deletion of the Ac-NMe-Phe moiety under acidic 
conditions.
206
 By replacing the acetyl groups with a heteroatom containing group such as 
CH3OCO produced an acid stable analog that had similar KOR affinity and retained KOR 
selectivity (see Table 2.10).
207
 In the AC assay the CH3OCO-NMe-Phe
1
 analog was found to be a 
potent KOR antagonist (KB = 8.5 nM).
207
 The Tyr
3
 and Cha
3 
(Cha = cyclohexylalanine) analogs 
of CH3OCO-NMe-Phe
1 
arodyn retained similar affinity for KOR indicating that replacing Phe
3
 
with a Tyr
3
 or with a non-aromatic residue like Cha
3
 is tolerated by KOR (see Table 2.10).
207
 
These analogs also displayed 4-fold higher efficacy in the AC assay compared to arodyn and 
exhibited partial agonism at KOR (see Table 2.11).
207
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Table 2.10 Opioid receptor binding affinities of Dyn A analogs modified in multiple positions in 
the N-terminus. 
 
  Ki (nM± SEM)
a
 Ki ratio Ref 
Compound KOR MOR DOR 
KOR/MOR/ 
DOR 
  
JVA-901 (Venorphin) 19.8 ± 5.2 251 ± 22 5320 ± 1130 1/12.6/268 173 
Arodyn 10.0 ± 3.0 1740 ± 130 5830 ± 1960 1/174/583 174 
[Ala
1
]arodyn 35.4 ± 3.0 3510 ± 340 >10,000 1/100/>280 205 
[Ala
4
]arodyn 54.2 ± 7.4 1390 ± 70 >10,000 1/30/>185 205 
[Ala
6
]arodyn 71.2 ± 10.8 5370 ± 220 >10,000 1/75/>140 205 
[Ala
7
]arodyn 75.5 ± 2.8 6860 ± 1820 >10,000 1/90/>130 205 
[Ala
11
]arodyn 44.1 ± 13.6 4500 ± 780 >10,000 1/100/>230 205 
[Tyr
1
]arodyn 71.6 ± 10.9 2010 ± 200 >10,000 1/30/>140 205 
[Dmt
1
]arodyn 13.4 ± 0.9 1610 ± 340 >10,000 1/120/>740 205 
[NMePhe
1
]arodyn 4.56 ± 0.45 5060 ± 790 >10,000 1/1100/>2170 205 
[CH3OCO-NMe-Phe
1
]arodyn 4.93 ± 0.15 1750 ± 100 ND 1/355 207 
[C6H5OCH2CO-NMe-Phe
1
]arodyn 7.34 ± 1.37 1450 ± 190 ND 1/198 207 
[CH3OCO-NMe-Phe
1
, Tyr
3
]arodyn 5.8 ± 1.27 1300 ± 340 ND 1/224 207 
[CH3OCO-NMe-Phe
1
, Cha
3
]arodyn 3.60 ± 0.21 818 ± 253 ND 1/227 207 
a
 Ki values were obtained using CHO cell membranes stably expressing opioid receptors with [
3
H] 
diprenorphine, [
3
H] DAMGO and [
3
H] DPDPE  as the radiolabeled ligands for KOR, MOR and DOR, 
respectively 
ND-not determined  
 
 
Table 2.11 KOR efficacies of arodyn analogs in the AC assay 
 
Compound  
AC % inhibition  
at 10 M
a
 
Ref 
 Arodyn 12 ± 8 207 
[NMePhe
1
]  
 
14 ± 1 207 
[CH3OCO-NMe-Phe
1
]  
 
26 ± 13 207 
[C6H5OCH2CO-NMe-Phe
1
]  2 ± 21 207 
[CH3CO-Gly-NMe-Phe
1
]  18 ± 17 207 
[CH3OCO-NMe-Phe
1
, Tyr
3
]  42 ± 10 207 
[CH3OCO-NMe-Phe
1
, Cha
3
]  45 ± 18 207 
                                 a
 relative to the full agonist Dyn A(1-13)NH2 (100% inhibition, 0% control)  
 
2.7.2.5 Dyn A analogs cyclized in the N-terminal “message” sequence 
Several Dyn A analogs with a cyclic constraint in the N-terminal “message” sequence 
including cyclizations from the N-terminus to a side chain and side chain to side chain, have 
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been synthesized (see Table 2.12 for binding affinities and Table 2.13 for potencies and 
efficacies).  
The N-terminal to side chain cyclic analog of venorphin, cyclo
N,5
[Trp
3
,Trp
4
,Glu
5
]Dyn 
A(1-11)NH2 (called cyclodyn, Figure 2.10), displayed KOR affinity and selectivity comparable 
to venorphin, exhibited negligible efficacy (maximum inhibition of 8 ± 8% relative to Dyn A(1-
13)NH2) at KOR in the AC assay and was able to completely reverse the agonist activity of 10 
nM Dyn A(1-13)NH2 in a concentration-dependent manner.
176
  
Table 2.12 Opioid receptor binding affinities of Dyn A analogs cyclized in the N-terminal 
“message” sequence 
 
  Ki (nM ± SEM)
a
 Ki ratio Ref 
Compound KOR MOR DOR 
KOR/MOR/ 
DOR 
 
Cyclodyn 
    
 
(cyclo
N,5
[Trp
3
,Trp
4
,Glu
5
] Dyn A(1-11)NH2)  26.8 ± 2.8 331 ± 29 >8900 1/12>330 176 
Analogs of cyclo [D-Asp
2
, Dap
5
]Dyn A(1-11)NH2  
 
[D-Asp
2
, Dap
5
] 1.59 ± 0.44 0.22 ± 0.04 11.6 ± 2.0 7.2/1/53 208 
cyclo[D-Asp
2
, Dap
5
] 0.46 ± 0.14 0.52 ± 0.06 5.10 ± 0.50 1/1.1/11 208 
cyclo[Ala
3
] 1.10 ± 0.20 2.52 ± 0.13 30.8 ± 3.7 1/2.3/28 208 
cyclo[D-Ala
3
] 0.21 ± 0.05 3.89 ± 0.52 139 ± 11 1/18/662 208 
cyclo[Trp
3
] 1.33 ± 0.26 2.09 ± 0.64 7070 ± 1920 1/1.6/5320 208 
cyclo[D-Trp
3
] 2.25 ± 0.37 7.27 ± 2.01 949 ± 49 1/3.2/422 208 
cyclo[Pro
3
] 9.03 ± 2.26 125 ± 11 >10000 1/14/>1000 208 
RCM analogs of Dyn A(1-11)NH2 
  
 
cyclo[Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2, cis 87.2 ± 6.9 763 ± 35 7670 ± 1030 1/8.8/88 209 
cyclo[Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2, trans 9.46 ± 1.80 180 ± 10 1130 ± 98 1/19/119 209 
cyclo[D-Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2 cis 0.84 ± 0.10 2.33 ± 0.20 9.30 ± 1.00 1/2.8/11 209 
cyclo[D-Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2, trans 1.38 ± 0.31 2.33 ± 0.22 7.17 ± 0.55 1/1.7/5.2 209 
Dyn A(1-11)NH2 0.57 ± 0.01 1.85 ± 0.52 6.81 ± 1.01 1/3/11 210 
a
 Ki values were obtained using CHO cell membranes stably expressing opioid receptors with [
3
H]diprenorphine, 
 [
3
H]DAMGO and [
3
H]DPDPE as the radiolabeled ligands for KOR, MOR and DOR, respectively. 
 
Several analogs of cyclo[D-Asp
2
,Dap
5
]Dyn A(1-11)NH2, a potent high affinity KOR 
agonist,
190
 were synthesized in our laboratory to explore the structure- and conformation-activity 
relationships of the residues within the cyclic region of this peptide.
208
 While the substitutions of 
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Gly
3
 by Ala, D-Ala, Trp and D-Trp in the linear counterpart [D-Asp
2
,Dap
5
]Dyn A(1-11)NH2 and 
in the lead cyclic peptide cyclo[D-Asp
2
,Dap
5
]Dyn A(1-11)NH2 were well tolerated by KOR and 
MOR, these substitutions resulted in large decreases in DOR affinity.
208
 These results suggested 
that there is limited space around residue 3 of Dyn A in the DOR binding pocket compared to 
that of KOR and MOR. In the case of the cyclic analogs, for smaller amino acids such as Ala the 
stereochemistry of residue 3 had a more pronounced effect on the affinity and selectivity as 
compared to the bulkier amino acids such as Trp (see Table 2.12). The effect of bulkier 
substituents on the potency of the cyclic peptides in the AC assay was pronounced (10-30 fold 
decrease in potency) compared to the lead cyclic peptide. All of the cyclic peptides with 
substitutions at position 3 except the Pro
3
 analog were full agonists in AC assay. The Pro
3
 
substitution caused a decrease in efficacy and potency and resulted in a weak partial KOR 
agonist.
208
 
Table 2.13 KOR agonist potencies and efficacies of Dyn A analogs cyclized in the “message” 
sequence. 
 
Compound IC 50 (nM ± SEM) % max inhibition
a
 Ref 
Analogs of cyclo[D-Asp
2
, Dap
5
]Dyn A(1-11)NH2   
 cyclo[D-Asp
2
,Dap
5
] 0.39 ± 0.07 100 208 
cyclo[Ala
3
] 0.65 ± 0.10 100 208 
cyclo[D-Ala
3
] 0.54 ± 0.15 100 208 
cyclo[Trp
3
] 4.19 ± 0.55 100 208 
cyclo[D-Trp
3
] 12.0 ± 2.8 100 208 
cyclo[Pro
3
] 153 ± 86 37 ± 7 208 
RCM analogs of Dyn A(1-11)NH2 
 cyclo[Ala2(-CH=CH-)Ala5]Dyn A(1-11)NH2, cis 190 ± 19 90 ± 2 209 
cyclo[Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2, trans 27 ± 1 104 ± 4 209 
cyclo[D-Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2, cis 0.80 ± 0.34 111 ± 6 209 
cyclo[D-Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2, trans 0.47 ± 0.11 107 ± 4 209 
a
 Maximum percent inhibition of AC at a concentration of 10 M, relative to the full agonist Dyn A(1-13)NH2 
(100% inhibition). 
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Fang et al. synthesized cyclic analogs of Dyn A(1-11)NH2 utilizing ring closing 
metathesis (RCM) of the side chains of allylgylcine residues incorporated in positions 2 and 5.
209
 
Both cis and trans isomers of the peptide were obtained. The isomers with the L-amino acid in 
position 2 showed several fold lower opioid receptor affinities compared to Dyn A(1-11)NH2. 
This indicated that, similar to the earlier reported linear Dyn A analogs,
211
 an L-amino acid in 
position 2 of these cyclic peptides is not well tolerated by opioid receptors. However, MOR and 
DOR were less tolerant to an L-amino acid in position 2 compared to KOR, making these 
peptides more selective for KOR over MOR and DOR.  Both the cis and trans isomers of 
cyclo[D-Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2 exhibited high KOR affinities (Ki = 0.84 nM and 
1.38 nM, respectively, see Table 2.12) that were comparable to that of Dyn A(1-11)NH2. This 
suggested that, as was also observed in the case of earlier reported Dyn A analogs,
190
 a D-amino 
acid in position 2 of these peptides is well tolerated by the opioid receptors. These peptides also 
exhibited high affinity for MOR and DOR, making them less selective for KOR over MOR and 
DOR than Dyn A(1-11)NH2. All of the analogs exhibited concentration-dependent agonist 
activity in the AC assay and efficacies (≥ 90%) comparable to Dyn A(1-13)NH2. The cis and 
trans isomers of cyclo[D-Ala
2
(-CH=CH-)Ala
5
]Dyn A(1-11)NH2 displayed the highest potencies 
(EC50 = 0.80 and 0.47 nM, respectively), while analogs with the L-configuration in position 2 
were less potent than Dyn A(1-11)NH2 (see Table 2.13).
209
 
2.7.3 Analogs with modifications in the C-terminus 
Both linear and cyclic modifications in the C-terminal sequence of Dyn A have been 
reported. 
Based on the Ala scan of [Pro
3
]Dyn A(1-11)NH2 the Ile
8
 and Pro
10
 residues made minor 
contributions to the activity of the parent peptide. Hence, two analogs with Arg substitution in 
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either position 8 or 10 were synthesized.179 [Pro3,Arg8]Dyn A(1-11)NH2 was one of the most 
potent analogs with a subnanomolar KOR affinity (Ki = 0.44 nM) and several thousand-fold 
KOR selectivity (see Table 2.14 for opioid receptor affinities and Table 2.15 for antagonist 
potencies) and both the Arg
8
 and Arg
10
 analogs were found to be KOR antagonists in the GTPS 
assay. The parent Pro
3
 peptide and its Arg
8 
analog were also found to be KOR antagonists in GPI 
assay. At higher doses they were partial agonists in the [
35
S]GTPS assay (16-22% response 
compared to U50,488).
179
  
 
Table 2.14 Opioid receptor binding affinities of [Pro
3
]Dyn A(1-11)NH2 analogs substituted in the 
“address” sequence. 
 
Compound   Ki (nM ± SEM)
a
     Ref 
  KOR MOR DOR KOR/MOR/DOR   
[Pro
3
,Arg
8
]Dyn A(1-11)NH2 0.44 ± 0.10 2750 ± 770 6760 ± 620 1/6300/15000 179 
[Pro
3
,Arg
10
]Dyn A(1-11)NH2 1.20 ± 0.14 1660 ± 76 3230 ± 1460 1/1400/2700 179 
[Pro
3
]Dyn A(1-11)NH2 2.40 ± 0.22 5250 ± 730 8900 ± 2300 1/2200/3700  179 
      aKi values were obtained using CHO cell membranes stably expressing opioid receptors using [
3
H]diprenorphine  
     as radioligand.     
 
Table 2.15 Antagonist potencies of [Pro
3
]Dyn A(1-11)NH2 analogs substituted in the “address” 
sequence. 
 
Compound IC50  (nM ± SEM)
a
 Ke (nM ± SEM)
b
           Ref 
[Pro
3
, Arg
8
]Dyn A(1-11)NH2 340 ± 60 280 ± 53 179 
[Pro
3
, Arg
10
]Dyn A(1-11)NH2 410 ± 200  
179 
[Pro
3
]Dyn A(1-11)NH2 440 ± 60 494 ± 74 179 
                  aAntagonist activity determined against 50 nM U50,488 in the GTPS assay. 
                       
 b
Antagonist activity determined against [D-Ala
3
]Dyn A(1-11)NH2 in the GPI assay.  
 
In order to examine the role of the C-terminus residues in the efficacy of a Dyn A analog, 
Patkar et al. synthesized several analogs of the partial agonist [N-benzyl-Tyr
1
]Dyn A(1-
11)NH2
212
 (see Table 2.16 for receptor binding affinities). Analogs of [N-benzyl-Tyr
1
]Dyn A(1-
11)NH2 (Ki (KOR) = 8.17 nM) containing substitutions in positions 7, 8 and/or 10 were 
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synthesized. In position 7, NMe-Arg was the substituent, while the substitutions in positions 8 
and 10 were D-Ala and D-Pro, respectively. All of the peptides showed 2- to 4-fold higher KOR 
affinities and 2-fold higher KOR selectivities over MOR as compared to [N-benzyl-Tyr
1
]Dyn 
A(1-11)NH2. The selectivity for KOR over DOR was dependent on the individual substitutions, 
with the results indicating that the D-Ala
8
 substitution was important for maintaining high 
selectivity for KOR over DOR.
212
 [N-benzyl-Tyr
1
]Dyn A(1-11)OH was also synthesized and 
interestingly, it displayed 2-fold lower KOR affinity and 3-fold lower KOR selectivity over DOR 
as compared to the C-terminal amide derivative.  
Some of the early examples of Dyn A analogs cyclized in the “address” sequence include 
cyclic disulfide analogs
192-194
 and cyclic lactam analogs.
189, 191
 In the case of cyclic disulfide 
analogs, especially the cyclic (5,11) analogs with an L-amino acid in position 5 displayed high 
binding affinities for KOR (Ki = 0.5-3.1 nM)  in guinea pig brain, but displayed low KOR vs. 
MOR selectivities. However, these analogs displayed relatively low potencies in the GPI assay 
(IC50 > 90 nM), i.e. at peripheral opioid receptors. Those analogs with a D-amino acid in position 
5 displayed low KOR affinities, while either configuration was tolerated for the residue in 
position 11.
194
 Among the cyclic lactam analogs, the cyclic (5,8) (Ki (KOR) = 8-12 nM) and 
cyclic (6,9) Dyn A(1-13)NH2 (Ki  (KOR) = 1.5-2.6 nM)  analogs showed relatively high KOR 
affinities, but low KOR vs. MOR selectivities. While the cyclic (6,9) analogs displayed high 
KOR potency (IC50 = 6-46 nM), the cyclic (5,8) analogs displayed surprisingly low KOR 
potencies (IC50 > 500 nM) in the GPI assay.
191
  
Two cyclic analogs of [N-benzyl-Tyr
1
]Dyn A(1-11)NH2 were also synthesized. The [5,8] 
cyclic analog [N -benzylTyr
1
,cyclo(D-Asp
5
,Dap
8
)]Dyn A(1-11)NH2 (now called zyklophin, 
Figure 2.10)
210
 and [N -benzylTyr
1
,cyclo(D-Asp
6
,Dap
9
)]Dyn A(1-11)NH2
212
 were also 
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synthesized. While zyklophin exhibited 4-fold lower KOR affinity (Ki = 30.3 nM) compared to 
[N-benzyl-Tyr
1
]Dyn A(1-11)NH2, it was 194-fold selective for KOR over MOR (see Table 
2.16). It completely reversed the agonist activity of 10 nM Dyn A-(1-13)NH2 in a concentration-
dependent manner in the AC assay and in Schild analysis for antagonism exhibited a KB value of 
84 nM.
210
 In comparison, the linear counterparts of both cyclic analogs displayed lower affinities 
and selectivities. In the AC assay, the linear analogs with modifications in positions 7, 8 and/or 
10 displayed 70-90% efficacy,
212
 whereas zyklophin and its linear counterpart displayed 
negligible efficacy.
210
 
 
Table 2.16 Opioid binding affinities of C-terminal substituted analogs of [N-benzyl-Tyr
1
]Dyn 
A(1-11)NH2 
 
Compound   Ki (nM± SEM)
a
     Ref 
  KOR MOR DOR KOR/MOR/DOR   
[N

-benzyl-Tyr
1
]Dyn A(1-11)NH2 8.17 ± 2.16 84.9 ± 16.9 474 ± 47 1/10/58 212 
[N
a
-MeArg
7
] 3.99 ± 1.09 49.9 ± 9.7 345 ± 31 1/13/86 212 
[D-Ala
8
] 4.64 ± 0.91 51.2 ± 3.0 372 ± 25 1/11/80 212 
[D-Pro
10
] 4.56 ± 0.42 45.1 ± 4.9 148 ± 5 1/10/32 212 
[N
a
-MeArg
7
, D-Ala
8
] 3.11 ± 0.64 44.8 ± 7.3 458 ± 130 1/14/147 212 
[N
a
-MeArg
7
, D-Pro
10
] 2.17 ± 0.22 36.5 ± 3.6 120 ± 24 1/17/55 212 
[D-Ala
8
, D-Pro
10
] 3.10 ± 0.98 46.1 ± 8.6 337 ± 54 1/15/109 212 
[N
a
-MeArg
7
, D-Ala
8
, D-Pro
10
] 4.40 ± 0.75 69.8 ± 0.7 665 ± 174 1/16/151 212 
cyclo[D-Asp
5
, Dap
8
] (zyklophin) 30.3 ± 1.9 5880 ± 1420 >10,000 1/194/>330 210 
[D-Asn
5
, Dap(Ac)
8
] 66.9 ± 5.9 1660 ± 440 >10,000 1/25/149 210 
a
Ki values were obtained using CHO cell membranes stably expressing opioid receptors with [
3
H]diprenorphine, 
[
3
H]DAMGO and [
3
H]DPDPE as the radiolabeled ligands for KOR, MOR and DOR, respectively.  
 
In vivo zyklophin was devoid of antinociceptive activity and antagonized the 
antinociceptive effects of the KOR selective agonist U50,488 in the mouse warm water tail 
withdrawal assay.
108
 Zyklophin (3 mg/kg, s.c) was also found to be selective for KOR over MOR 
and DOR in vivo. Moreover, peripheral pretreatment with zyklophin (3 mg/kg, s.c.) antagonized 
the antinociceptive effects of centrally administered U50,488 (40 nmol, i.c.v), strongly 
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suggesting that zyklophin crossed the blood-brain barrier (BBB) to act on central KOR. 
Zyklophin (3 mg/kg, s.c.) antagonized the antinociceptive effects of U50,488 for at least 8 h, but 
for less than 12 h. This is in contrast to the prototypical selective KOR antagonists that exhibit 
their antagonist effects ranging from weeks to more than a month depending on the species.
56
 
Zyklophin (3 mg/kg s.c.) inhibited stress- induced reinstatement of cocaine seeking behavior in a 
conditioned place preference assay which was another strong indication that zyklophin was able 
to cross the BBB to exert its effect in the CNS. However, zyklophin did not inhibit cocaine 
induced reinstatement of cocaine seeking in a conditioned place preference assay, consistent with 
results for the other KOR antagonists.
108
  
Fang et al. synthesized Dyn A(1-11)NH2 cyclized by RCM involving allylglycine in 
positions 5 and 8 (see Table 2.17 for receptor binding affinities and Table 2.18 for efficacies).  
The trans isomer of cyclo[Ala
5
(-CH=CH-)Ala
8
]Dyn A(1-11)NH2 exhibited 4-fold lower KOR 
affinity (Ki = 2.46 nM), while the cis isomer exhibited 20-fold lower affinity for KOR, compared 
to Dyn A(1-11)NH2. They both also exhibited several fold lower affinities for MOR and DOR, 
making them more KOR selective than Dyn A(1-11)NH2. While both isomers displayed ≥90% 
efficacies in the AC assay compared to Dyn A(1-13)NH2, they showed several fold lower 
potencies as compared to Dyn A(1-11)NH2 (see Table 2.18 for efficacies) . Consistent with their 
affinities the trans isomer (EC50 = 8.3 nM) was 3-fold more potent than the cis isomer.
209
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Table 2.17 Opioid receptor binding affinities of cyclo(5,8) Dyn A(1-11) NH2 analogs cyclized by 
RCM 
 
Compound   Ki (nM± SEM)
a
   Ref 
  KOR MOR DOR KOR/MOR/DOR   
cyclo[Ala
5
(-CH=CH-)Ala
8
]Dyn A(1-
11)NH2, cis 
10.9 ± 1.8 93.0 ± 6.0 1210 ± 90 1/8.5/111 209 
cyclo[Ala
5
(-CH=CH-)Ala
8
]Dyn A(1-
11)NH2, trans 
2.46 ± 0.57 36.0 ± 2.1 460 ± 51 1/15/187 209 
Dyn A(1-11)NH2 0.57 ± 0.01 1.85 ± 0.52 6.81 ± 1.01 1/3/11 210 
a
Ki values were obtained using CHO cell membranes stably expressing opioid receptors with [
3
H]diprenorphine, 
[
3
H]DAMGO and [
3
H]DPDPE as the radiolabeled ligands for KOR, MOR and DOR, respectively. 
 
Table 2.18 Agonist potencies and efficacies of cyclo(5,8) Dyn A(1-11) NH2 analogs cyclized by 
RCM 
 
Compound IC 50 (nM ± SEM) % max response
a
  Ref 
cyclo[Ala
5
(-CH=CH-)Ala
8
]Dyn A-(1-11)NH2, cis 23 ± 11 110 ± 10 209 
cyclo[Ala
5
(-CH=CH-)Ala
8
]Dyn A-(1-11)NH2, trans 8.3 ± 3.7 106 ± 6 209 
Dyn A(1-11)NH2 0.39 ± 0.02  100 209 
a
 % response  in AC assay  relative to full agonist Dyn A(1-13)NH2 (100%)  
2.7.4 Non-peptide hybrid analogs of Dyn A 
Ronsisvalle et al.  synthesized a series of hybrid analogs in which the heterocyclic 
nucleus MPCB ((-)-cis-N-(2-phenyl-2-carbomethoxy)cyclopropylmethyl-N-normetazocine)  was 
linked to the C-terminal residues Dyn A(6-8)
213
 (Figure 2.13). The MPCB-GRRI and MPCB-
RRI hybrid analogs displayed comparable KOR affinities (Ki = 54.3 ± 8.5 and 78.4 ± 6.4 nM, 
respectively) and 4- and 5-fold higher selectivities for KOR over MOR, respectively, compared 
to Dyn A(1-8) (Ki = 123.8 ± 6.2 nM), suggesting that the heterocyclic moiety mimicked the N-
terminal fragment of dynorphin A.
214
 Various analogs of these hybrid compounds involving non-
peptide replacements of the C-terminal fragment were also described (Figure 2.11). Two analogs 
containing the dipeptide Gly-Leu, a 5-6 carbon atom diamine linker and a butylamidino 
substitution on the C-terminal nitrogen of the diamine linker exhibited high KOR affinities (Ki 
range = 5-7 nM) and KOR over MOR selectivities which were 6- to10-fold higher than those of 
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the parent hybrid analogs MPCB-RRI and MPCB-GRRI. The two butylamidino analogs showed 
potent antinociceptive effects (ED50 = 0.88-1.1 mg/kg, s.c.) in the mouse abdominal constriction 
assay comparable to U50,488 (ED50 =  0.76 mg/kg, s.c.) that was fully prevented by norBNI. 
213
 
 
 
Figure 2.13 Non- peptide analogs of Dyn A 
 
2.8 Conclusions 
Dyn A, the endogenous peptidic ligand for KOR, has been studied extensively and 
various analogs including both agonists and antagonists have been identified. KOR ligands have 
several potential therapeutic applications in addition to pain. Some ligands with mixed activity 
involving KOR are used clinically, and some KOR ligands are in clinical development. While a 
number of non-peptidic KOR antagonists have recently been reported, peptide-based KOR 
antagonists are also being developed and are gaining importance because of their finite duration 
of action. Peptides can have several advantages as potential drugs including their high specificity 
and potency and low toxicity.
215
 However, the delivery of peptides for therapeutic applications 
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still remains a challenge due in part to their metabolism by peptidases. In addition to several Dyn 
A analogs, other metabolically stable peptides including the cyclic tetrapeptides and all D-amino 
acids linear tetrapeptides are gaining importance for therapeutic applications. 
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3.1 Introduction 
3.1.1 Dynorphins and their precursor protein 
Prodynorphin is the precursor peptide for the dynorphins. Prodynorphin is primarily 
cleaved into four larger opioid peptides, dynorphin (Dyn) A, leumorphin, and  and -
neoendorphin.
1
 Dyn A undergoes cleavage to yield dynorphin (1-8) (Figure 3.1). Leumorphin is 
cleaved between the Thr-Arg residues to yield Dyn B. Along with the smaller peptides, larger 
peptides such as Dyn 32 (big Dyn) that contains Dyn A at the N-terminus and Dyn B at the C-
terminus and Dyn 24 are also produced.
1
 These prodynorphin-derived peptides are most 
abundant in the neural lobe of the rat pituitary and in the posterior pituitary. However, they are 
differentially processed in various parts of the brain.
1
 
 Fischli and Goldstein initially isolated the 17-amino acid peptide Dyn A from porcine 
pituitary.
2, 3
 Subsequently, the same group also isolated big Dyn
4, 5
 and Dyn B
4
 from the same 
porcine preparation. The porcine preparation was subjected to a series of purification steps 
involving extraction, gel filtration chromatography, and high performance liquid 
chromatography (HPLC) to obtain Dyn A, big Dyn and Dyn B.  
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Figure 3.1 Dynorphins and related peptides derived from the precursor protein prodynorphin
6
 
3.2 Pharmacological profile of the dynorphins 
Following their isolation, Dyn A, big Dyn and Dyn B were tested for their opioid 
receptor potencies in the rabbit vas deferens (RVD)
7
 and in the guinea pig ileum (GPI) bioassay.
8
 
While the RVD is known to exclusively contain kappa opioid receptors (KOR),
9
 the GPI 
contains multiple opioid receptors.
10
 In the RVD bioassay, Dyn A displayed an IC50 value of 
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0.30 ± 0.07 M while big Dyn and Dyn B displayed values of 3.95 ± 1.91 M and 1.57 ± 0.360 
M, respectively.
7
 Another group also tested Dyn B in the RVD bioassay and obtained a 
relatively potent IC50 value of 41.3 ± 8.8 nM.
11
 In the GPI bioassay, the IC50 values (99% 
confidence intervals) for Dyn A, big Dyn and Dyn B were 0.19 (0.16-0.22) nM, 1.4 (0.77-2.7) 
nM and 3.3 (1.9-5.8) nM, respectively. Another group also tested Dyn B in the GPI assay and 
obtained an IC50 value of 3.23 ± 0.35 nM.
11
 Along with the preparations containing peripheral 
opioid receptors, Dyn A, big Dyn and Dyn B were also evaluated for opioid receptor affinities in 
mouse brain preparations (Table 3.1).
12
  
The three peptides Dyn A, Dyn B and big Dyn were tested at cloned human opioid 
receptors in radioligand binding assays for affinity and in the GTPS assay for potency and 
efficacy
13
 (see Table 3.2 for affinities and Table 3.3 for potencies and efficacies). The peptides 
showed varying selectivity for human kappa opioid receptors (h-KOR) over human mu opioid 
receptors (h-MOR) and human delta opioid receptors (h-DOR). In the binding assays, Dyn A 
showed the highest affinity and selectivity for h-KOR over h-MOR and h-DOR. In the GTPS 
assay, big Dyn was the most potent for h-KOR followed by Dyn A and then by Dyn B. The 
selectivity in the GTPS assay was highest for big Dyn followed by Dyn A and Dyn B.
13
 Species 
differences (rodents vs. human) could contribute to the differences in results from different 
assays.  
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Table 3.1 Binding affinities of dynorphins in mouse brain preparation.
12
 
    Ki (nM ± SEM)
a
     
Peptide KOR MOR DOR KOR/MOR/DOR 
Dyn A 0.3 ± 0.09 2.6 ± 0.9 6.3 ± 0.9 1/9/21 
Dyn B 1.4 ± 0.32 12.6 ± 1.2 20.5 ± 2.5 1/9/15 
a
Ki values were obtained from competition binding experiments performed using mouse brain preparation and 
[
3
H]ethylketocyclazocine, [
3
H]dihydromorphine and [
3
H]DPDPE as the radioligands for KOR, MOR and DOR, 
respectively. 
 
Table 3.2 Binding affinities of dynorphins in radioligand binding assays using human cloned 
receptors.
13
 
 
  
Ki (nM ± SEM)
a
 
  Peptide h-KOR h-MOR h-DOR KOR/MOR/DOR 
 
Dyn A 0.082 ± 0.036 21.4 ± 5.8 111.9 ± 3.8 1/261/1366 
 
Dyn B 3.80 ± 1.58 13.0 ± 2.40 12.8 ± 2.8 1/3/3 
 
Big Dyn 0.198 ± 0.080  14.1 ± 0.5 43.0 ± 14.4 1/71/217 
a
Ki values were obtained from competition binding experiments performed using membranes prepared from 
receptor-expressing cell lines (Chinese hamster ovary (CHO) cells expressing h-KOR and human embryonic kidney 
(HEK) cells expressing h-MOR and h-DOR) and [
3
H]diprenorphine as the radioligand. 
 
Table 3.3 Efficacy and potency of dynorphins in the GTPγS assay.
13
 
Peptide EC50 (nM ± SEM) (%efficacy
a
) EC50 ratio 
  h KOR h MOR h DOR KOR/MOR/DOR 
Dyn A 10.7 ± 4.4 (100%) 150.0 ± 42.1 (100%) 254.0 ± 39.8 (100%) 1/14/24 
     
Dyn B 23.5 ± 10.7 (131%) 105.1 ± 52.6 (88%) 122.7 ± 6.0 (86%) 1/4/5 
 
    Big 
dynorphin 
0.741 ± 0.048 (159%) 87.0 ± 9.9 (115%) 119.2 ± 65.1 (100%) 1/117/161 
a
 Shown as percentage relative to Dyn A (100%). Experiments were performed using membranes prepared from the 
receptor-expressing cell lines as in Table 3.2. 
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3.3 Non-opioid effects of dynorphins 
Although Dyn A is an endogenous ligand for KOR
14
 it not only displays opioid effects 
but also produces non-opioid effects.
15-17
 Dyn A (5 or 20 nmol)
18
 produced hind limb paralysis 
when injected intrathecally (i.t.) into rats
18, 19
 and caused depletion of cell bodies of inter-sensory 
and motor neurons in the lumbosacral cord associated with loss of motor activity.
20
 Lower (1 
nmol) intrathecal doses of Dyn A(1-13) produced no analgesia in rats,
21
 while higher doses (25 
nmol, i.t.) caused irreversible loss of thermally evoked tail flick reflex as a result of hind limb 
paralysis.
22
 This loss of tail flick reflex was resistant to naloxone, but it was blocked by 
preadministration of the N-methyl-D-aspartate (NMDA) antagonist dizoclipine.
22
 Big Dyn (1-10 
fmol, i.t) and Dyn A (0.1-3 pmol, i.t) produced a characteristic nociceptive behavior in rats 
involving hind paw and tail biting. This nociceptive effect was shown to be resistant to naloxone 
but was blocked by dizoclipine, an NMDA antagonist.
23
 Additionally a long lasting state of 
allodynia was caused by single i.t. injections of 3 nmol
24
 and 15 nmol
25
 of Dyn A. Dyn A (5 and 
10 nmol) and Big Dyn (2.5 and 5 nmol) also induced hypothermia in rats after 
intracerebroventricular (i.c.v.) administration. Induction of hypothermia is considered to be a 
mixture of the opioid and non-opioid effects of dynorphins.
26
 The non-opioid effects were also 
displayed by the des Tyr fragment Dyn A(2-17)  which does not bind to opioid receptors.
17
  
Dyn A levels are elevated under certain pathophysiological conditions, for example Dyn 
A levels are increased at sites of spinal cord injury.
27, 28
 It was reported in two studies that the 
increase in concentration of Dyn A was proportional to the severity of trauma.
27, 29
 For example, 
Dyn A levels increased 40% following moderate spinal injury by the end of two weeks, while the 
levels increased 150% following severe spinal injury.
27
  In another study it was shown that the 
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Dyn A levels were elevated approximately 2-fold in rats subjected to nerve injury that 
subsequently caused neuropathic pain.
30
   
The Dyn A fragment Dyn A(1-13) can have dual neurotoxic
31, 32
 and neuroprotective
33, 34
 
actions in spinal cord neurons. At nanomolar concentrations Dyn A(1-13) activates KOR and can 
be neuroprotective, while at micromolar concentrations it exerts excitotoxic effects causing 
neuronal death through NMDA receptors.
33, 34
 In addition, it was also shown subsequently that 
Dyn A and big Dyn caused cytotoxicity in non-neuronal cells as well as neuronal cells through a 
mechanism resistant to naloxone.
31, 32
  
Dyn B has not been studied as extensively for its non-opioid effects as Dyn A. Dyn B at 
higher concentrations (50-100 nmol coinjected with peptidase inhibitors) produced hind limb 
paralysis similar to Dyn A (12.5-25 nmol without peptidase inhibitors) when injected into the 
lumbar space in rats.
35
 In contrast to Dyn A, Dyn B (1000 pmol) administered i.t. did not 
produce characteristic nociceptive behavior in rats involving hind paw and tail biting.
23
 Also Dyn 
B (up to 50 nmol) did not induce hypothermia after i.c.v. administration in rats.
26
 Unlike Dyn A, 
Dyn B did not produce the cytotoxic effects (see above) in neuronal and non-neuronal cells in 
vitro.
31
  
3.4 Membrane interactions of dynorphins 
Membrane interactions of dynorphins have been studied in membrane model systems 
such as phospholipid large unilamellar vesicles (LUVs).
36
 Big Dyn and Dyn A produced 
membrane perturbations of phospholipid LUVs and induced calcein leakage in phospholipid 
LUVs probably by causing a transient pore formation. In contrast, Dyn B did not cause 
membrane perturbation and calcein leakage.
36
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Studies of the membrane interactions of dynorphins were also performed with 
phospholipid bicelles and the results analyzed by NMR and saturation transfer difference (STD) 
experiments.
37
 These studies showed that the N-terminus of Dyn A was inserted in the 
hydrophobic lipid bilayer region while the C-terminal residues were loosely attached to the 
bicelle surface. The N-terminus of Dyn A displayed changes in its NMR due to insertion into the 
phospholipid membrane.
37
 In contrast, Dyn B was bound to the bilayer but did not insert into the 
lipid bilayer, and the NMR of the N-terminus did not change in the presence of the bicelles.
37
  
The above results (sections 3.3 and 3.4) suggest a possible connection between the non-
opioid cytotoxic actions and membrane perturbations of the phospholipid bilayer induced by the 
dynorphins. Although there is a difference in the number of charged residues for the two peptides 
Dyn A and Dyn B, the net charge difference is minimal and the charges do not seem to be the 
driving force for the difference in membrane interactions. Thus, the non-opioid cytotoxic effects 
produced by Dyn A but not by Dyn B (section 3.3) may be due in part to either transient pore 
formation and/or membrane perturbations.  
It is worthwhile to note that although Dyn B exhibits lower affinity, potency and 
selectivity for KOR, it does not exhibit the cytotoxic non-opioid effects exhibited by Dyn A and 
big Dyn. While Dyn A and Dyn B have identical N-terminal sequences, their C-terminal 
sequences differ. Hence, the differences in their interaction with lipid membranes and non-opioid 
cytotoxic effects must be due to their differences in the C-terminal sequences. To date studies 
involving structure-activity relationships (SAR) of dynorphins have focused almost exclusively 
on Dyn A, with minimal SAR studies related to Dyn B. Schiller and coworkers synthesized the 
Mdp
1 
(Mdp = (2S)-2-methyl-3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid) analog of Dyn A 
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(also called dynantin) and Dyn B.
38
 The Dyn A analog was a 180-fold more potent KOR 
antagonist than the Dyn B analog in the GPI assay. 
3.5 Alanine scan of Dyn B amide 
3.5.1 Rationale 
It is hypothesized that unique residue(s) in the C-terminus of Dyn B interact with the 
receptor and contribute to its activity at KOR. To test the above hypothesis, alanine substituted 
analogs of Dyn B were synthesized. All of the non-glycine residues up through residue 11 were 
substituted with Ala in order to explore the roles of their side chains to the activity of Dyn B 
(Figure 3.2).  
 
Figure 3.2 Alanine analogs of Dyn B amide 
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3.6 Results and discussion 
3.6.1 Chemistry 
The peptides were synthesized by the Fmoc (9-fluorenylmethoxycarbonyl) solid phase 
synthetic strategy (Scheme 3.1). The Dyn B amide sequences were assembled on a polyethylene 
glycol-polystyrene (PEG-PS) resin containing the PAL [peptide amide linker, 5-(4-Fmoc-
aminomethyl-3,5-dimethoxyphenoxy)valeric acid] linker using 7-benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and 1-hydroxy-7-benzotriazole 
(HOBt) as the coupling agents and N,N-diisopropylethylamine (DIEA) as the base.  The side 
chains of Lys, Gln, Arg and Tyr were protected with tert-butyloxycarbonyl (Boc), trityl (Trt), 
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) and tert-butyl (tBu) groups, 
respectively. The peptides were assembled using cycles consisting of Fmoc deprotection and 
Fmoc-amino acid coupling. The crude peptides were cleaved from the resin using Reagent B
39
 
(trifluoroacetic acid (TFA) in the presence of scavengers).  
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Scheme 3.1 Synthesis of [Ala
6
]Dyn B amide 
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Table 3.4 Analytical data for the Dyn B amide analogs 
Compound HPLC system tR (min) ESI-MS (m/z) 
 
System 1
a
 
(% Purity ) 
System 2
b  
(%
 
Purity ) 
Calculated Observed 
1 19.1 (100) 29.1 (100) 739.4 (M + 2H)
2+
 739.4 (M + 2H)
2+
 
2 20.7 (100) 24.6 (100) 747.4(M + 2H)
2+
 747.4(M + 2H)
2+
 
3 21.7 (97.9) 23.9 (100)
c
 764.4 (M + 2H)
2+
 764.4 (M + 2H)
2+
 
4 22.2 (99.6) 34.5 (100) 742.9 (M + 2H)
2+
 742.9 (M + 2H)
2+
 
5 23.8 (100) 33.3 (100) 742.9 (M + 2H)
2+
 742.9 (M + 2H)
2+
 
6 29.9 (99.7) 39.8 (100) 756.9 (M + 2H)
2+
 756.9 (M + 2H)
2+
 
7 16.6 (100) 23.2 (100) 747.4 (M + 2H)
2+
 747.4 (M + 2H)
2+
 
8 20.3 (95.5) 31.1 (100) 756.9 (M + 2H)
2+
 756.9 (M + 2H)
2+
 
9 20.1 (99.8) 30.0 (100) 771.4 (M + 2H)
2+
 771.4 (M + 2H)
2+
 
Dyn B amide 18.6 (100) 31.9 (100) 785.4 (M + 2H)
2+
 785.4 (M + 2H)
2+
 
a
Aqueous MeCN containing 0.1% TFA. 
b
Aqueous MeOH containing 0.1% TFA. 
c
Peptide 3 displayed a tR = 18.4 
min and purity of 96.2% on a 25-45% aqueous MeOH containing 0.1% TFA over 40 min. See the Experimental 
Section for gradient details.  
 
The peptides were isolated and purified according to the standard procedures described 
under the Experimental section. Following TFA cleavage of the peptides,
39
 the crude peptide 
residues were diluted with water and lyophilized. The Dyn B amide analogs were hydrophobic 
and required organic solvent for solubilization of the peptide prior to purification by reversed 
phase high performance liquid chromatography (RP-HPLC). MeOH which is a weaker solvent 
for RP-HPLC than MeCN, was used to assist in peptide dissolution while minimizing impact on 
the chromatography.  
3.6.2 Pharmacological activity 
Opioid binding affinities of the alanine substituted analogs of Dyn B amide were 
determined in Chinese hamster ovary (CHO) cell membranes expressing cloned rat MOR and 
KOR and mouse DOR (Table 3.5). The aromatic residues in positions 1 and 4 of the N-terminal 
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sequence of Dyn B amide are critical for its opioid receptor binding affinity. Substitution of Ala 
in position 1 caused a 121-fold decrease while substitution in position 4 caused a 204-fold 
decrease in the KOR binding affinity compared to Dyn B amide. Ala
1
 and Ala
4
 analogs exhibited 
24- and 38-fold decreases, respectively, in MOR binding affinity and showed minimal affinity 
for DOR, suggesting that these two residues are critical for binding to MOR and DOR as well. 
 Table 3.5 Opioid binding affinities of Dyn B amide alanine analogs. 
 
Tyr
1
-Gly-Gly-Phe
4
-Leu
5
-Arg
6
-Arg
7
-Gln
8
-Phe
9
-Lys
10
-Val
11
-Val-Thr-NH2 
 
Compound 
 
Ki (nM ± SEM)
a
 
    KOR MOR DOR KOR/MOR/DOR 
N-Terminal alanine substituted analogs 
  
1 [Ala
1
] 885 ± 219 651 ± 70 >10,000 1/0.7/11 
2 [Ala
4
] 1500 ± 320 1040 ± 100 >10,000 1/0.7/7 
C-Terminal alanine substituted analogs 
  
3 [Ala
5
]    
 
4 [Ala
6
] 43.1 ± 3.8  14.1 ± 3.0  25.5 ± 1.5 1/0.3/0.6 
5 [Ala
7
] 82.4 ± 19.0  16.7 ± 5.1  67.4 ± 8.3 1/0.2/0.8 
6 [Ala
8
] 13.3 ± 1.9  4.31 ± 0.09  53.9 ± 6.8 1/0.3/4 
7 [Ala
9
] 11.3 ± 3.4  3.76 ± 0.22  42.1 ± 2.5 1/0.3/4 
 8 [Ala
10
] 31.6 ± 6.0  40.5 ± 3.9  119 ± 16 1/1/4 
 9 [Ala
11
] 12.4 ± 0.7  7.45 ± 2.7  58.8 ± 3.4 1/0.6/5 
Dyn B amide 7.3 ± 2.0 27.3 ± 14.0 43.2 ± 1.6 1/4/6 
 
a 
values are mean ± SEM for n ≥ 3. 
 
The basic residues in position 6 and 7, i.e. Arg
6
 and Arg
7
, appear to contribute to the 
KOR binding affinity of Dyn B amide. Substitutions of Ala in positions 6 and 7 caused 6- and 
11-fold decreases in KOR binding affinity, respectively. Substitution of the basic Lys residue in 
position 10 by Ala caused a 4-fold decrease, suggesting that Lys
10
 also contributed to KOR 
binding affinity. Substitution of Ala in positions 8, 9 and 11 caused less than a 2-fold decrease in 
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KOR affinity, indicating that these non-charged residues do not contribute significantly to the 
KOR affinity of Dyn B amide. 
None of the residues in the C-terminus appear to be important for MOR binding affinity. 
In contrast it was observed that Ala substitutions in the C-terminus, except for the Ala
10
 analog, 
increased the MOR affinity of most of the analogs while the KOR affinity remained unaltered or 
decreased. Consequently, this shifted the selectivity of these Dyn B analogs from KOR-
preferring to MOR preferring. Similarly, most of the residues did not appear to contribute to 
DOR affinity, with only residue 10 appearing to make minor contributions to the DOR affinity of 
Dyn B(1-13) amide.  
Turcotte et al. performed the Ala scan of Dyn A(1-13)
40
 (Table 3.6). Within the N-
terminal sequence of this peptide Ala
1
 and Ala
4
 substitutions caused dramatic decreases in the 
opioid receptor binding affinity, indicating that the Tyr
1
 and Phe
4
 residues were critical for 
opioid receptor binding.
40
 Outside the N-terminal tetrapeptide sequence the Ala
5
 analog
 
displayed a 15-fold decrease in opioid receptor binding affinity while the Ala
6
 and Ala
7 
analogs 
showed 3- to 7-fold decreases in the opioid receptor binding affinities suggesting that Leu
5
, Arg
6
 
and Arg
7
 also contributed to opioid receptor interactions in the C-terminus. Ala
9
 and Ala
11 
analogs also showed small decreases (2- to 3-fold) in opioid receptor binding affinities, 
suggesting that these residues may be minor contributions to opioid receptor interactions. The 
agonist potencies of the analogs containing Ala substitutions in positions 1 and 4 showed a 
similar trend in the GPI assay as found in the radioligand binding assay. Similarly, among the C-
terminal residues 5, 6 and 7 contributed the most, while residues 9 and 11 also contributed to 
maintaining the agonist potency of Dyn A (1-13) at opioid receptors in the GPI assay.
40
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Table 3.6 Alanine scan of Dyn A(1-13)
40
 
Tyr
1
-Gly
2
-Gly
3
-Phe
4
-Leu
5
-Arg
6
-Arg
7
-Ile
8
-Arg
9
-Pro
10
-Lys
11
-Leu-Lys 
Peptide Agonist potency Affinity 
  IC50 (nM)
a
 Fold decrease
c
 IC50 (nM)
b
 Fold decrease
c
 
[Ala
1
] Dyn A(1-13) 750 ± 30 1070 1400 ± 210 519 
[Ala
2
]-  '' 104 ± 32 149 13.5 ± 0.4 5 
[Ala
3
]-  '' 2.0 ± 0.3 3 21.5 ± 3.7 8 
[Ala
4
]-  '' 700 ± 20 1000 750 ± 35 278 
[Ala
5
]-  '' 14 ± 4 20 45.0 ± 1.1 17 
[Ala
6
]-  '' 23 ± 6 33 19.2 ± 0.8 7 
[Ala
7
]-  '' 19 ± 5 27 10.0 ± 1.2 4 
[Ala
8
]-  '' 1.4 ± 0.1 2 0.3 ± 0.0 - 
[Ala
9
]-  '' 5.5 ± 0.8 8 7.4 ± 0.8 3 
[Ala
10
]- '' 3.3 ± 0.7 5 3.8 ± 0.5 1.5 
[Ala
11
]- '' 7.6 ± 0.4 11 8.7 ± 0.9 3 
Dyn A(1-13) 0.7 ± 0.1 -  2.7 ± 0.3 -  
 a
IC50 obtained from the GPI assay. 
b
IC50 obtained from radioligand binding assays using [
3
H]etorphine in rat brain 
homogenates. 
c
As compared to Dyn A(1-13). 
A comparison of the results obtained from the alanine substituted analogs of Dyn A(1-13) 
and Dyn B amide suggests that the as expected aromatic residues in positions 1 and 4 of both 
Dyn A(1-13) and Dyn B amide are critical for opioid receptor binding. The residues in position 6 
and 7 appear to contribute to the opioid receptor binding of Dyn A(1-13) and KOR binding of 
Dyn B amide. Basic residues 9 and 11 appear to contribute to opioid receptor binding affinity in 
the case of Dyn A(1-13), and Lys
10
 appears to contribute to KOR binding in the case of Dyn 
B(1-13) amide.  Hence, it appears likely that in addition to the basic residues in position 6 and 7, 
a basic residue in the 8-11 sequence of the C-terminus sequences of both peptides contributes to 
the peptides’ receptor binding affinities. Arg
6
 and Arg
7
 residues do not appear to be important for 
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the MOR and DOR affinities of Dyn B amide. While Lys
10
 is not important for MOR affinity, it 
appears to makes minor contributions to DOR affinity. The difference in relative positions of the 
basic residues may be one reason for the differences in the pharmacological profiles exhibited by 
the two peptides. Nonetheless, there could be other reasons for the different pharmacological 
activities exhibited by the two peptides.  
It should be noted that there exists several differences in the radioligand binding assays 
used to evaluate the Ala analogs of the two peptides. In the early studies of Dyn A analogs the 
results represent a weighted average of the affinities at multiple opioid receptors in rat brain 
(which have relatively low expression of KOR)
41
 because a non-selective radiolabeled opioid 
agonist was used. In the case of the Dyn B amide analogs, the opioid affinities were determined 
using cell membranes expressing individual cloned opioid receptors and a radiolabeled 
antagonist that permitted the displayed different effects of substitution of C-terminal residues on 
KOR affinity vs. MOR and DOR affinity to be assessed. Hence, the comparisons of the Ala 
substituted analogs from the two peptides should be made with some caution. 
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Table 3.7 Potencies and efficacies of the Dyn B amide alanine analogs at KOR in GTPS assay 
Peptide EC50
 
(nM ± SEM)a Efficacy (%)b 
C-Terminal alanine substituted analogs 
 
         3 [Ala
5
]                                                             
4 [Ala
6
] 115 ± 17  92 ± 9 
5 [Ala
7
] 300 ± 96  100 
6 [Ala
8
] 51.9 (n=1) 89 
7 [Ala
9
] 17.3 (n=1) 96 
8 [Ala
10
]  
 
9 [Ala
11
]  
 
 Dyn B amide   
 Dyn A(1-13)NH2 30.3 ± 15 (n=4) 100 
a 
Values are for n=2 unless otherwise noted. 
b
As compared to Dyn A(1-13)NH2 (efficacy = 100%). 
The efficacy of peptides 1 and 2 was not determined given their low affinity in the radioligand 
binding assays.  
 
 The potencies and the efficacies of the Ala substituted analogs of Dyn B amide were 
determined using the GTPS assay (see Table 3.7). The analogs with Ala substitutions in 
positions 6 to 9 displayed efficacies from 89 to 100% compared to the reference agonist Dyn 
A(1-13)NH2. The remaining analogs will be evaluated in this assay shortly. 
3.7 Conclusions 
The differences in the C-terminal sequences of Dyn A (1-13) and Dyn B are responsible 
for the differences in their pharmacological profiles. An alanine scan of Dyn B amide and Dyn 
A(1-13) revealed that residues 1 and 4  in the N-terminal regions  of both peptides are critical for 
their opioid receptor binding. The Ala
4
 analog of Dyn B amide displayed 1.5- to 2-fold larger 
decreases in KOR and MOR affinities as compared to the Ala
1
 analog. This suggested that in the 
case of Dyn B amide, Phe
4
 may contribute more to KOR and MOR binding than Tyr
1
. Residues 
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in positions 1 and 4 also contribute to the KOR vs. MOR selectivity of Dyn B amide. While the 
basic residue Arg
7
 appears to be important, Arg
6
 and Lys
10
 also contribute to KOR binding 
affinity of Dyn B amide. While the Arg residues in position 6 and 7 are important for the KOR 
selectivity by both increasing KOR affinity and decreasing MOR affinity, the Lys
10
 residue 
contributes to KOR selectivity primarily by increasing KOR affinity. In the case of Dyn A(1-13), 
along with Arg residues 6 and 7, basic residues 9 and 11 also make minor contributions to opioid 
receptor binding affinity. Thus it is clear that the basic residues in the C-terminus of both 
peptides contribute to their opioid receptor affinities; however, their relative positions in residues 
8-11 in the peptide could be one of the reasons contributing to their different pharmacological 
profiles.  
3.8 Experimental section 
Materials 
The PAL-PEG-PS resin was purchased from Applied Biosystems (Foster City, CA, 
USA). The Fmoc-protected amino acids were purchased from Novabiochem Corp. (San Diego, 
CA, USA) or Peptides International, Inc. (Louisville, KY, USA). PyBOP and HOBt were 
purchased from Novabiochem and Peptide International, Inc., respectively and DIEA was 
obtained from Fischer Scientific (Fair Lawn, NJ). Piperidine was purchased from Sigma Aldrich 
(Milwaukee, WI, USA). All HPLC grade solvents [MeCN, N,N-dimethylformamide (DMF), 
dichloromethane (DCM), and MeOH] used for peptide synthesis or HPLC analysis were 
obtained from Fischer Scientific. TFA for HPLC purification and analysis was purchased from 
Pierce (Rockville, IL, USA). Triisopropylsilane (TIS) were from Acros Organics (Fairlawn, NJ) 
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Peptide synthesis 
 The peptides were prepared by solid phase peptide synthesis performed on an automated 
CS Bio 336 peptide synthesizer. The peptides were assembled on the PAL-PEG-PS resin (0.19 
mmol/g, 200 mg) using standard Fmoc synthetic strategy. The resin was swollen with 5 mL of 
DMF (2 X 10 min). The Fmoc group on the resin was removed using 20% piperidine in DMF (5 
mL, 2 X 10 min), and the resin was washed with DCM/DMF (1:1, 10 X 30 sec).  The desired 
Fmoc-protected amino acids (4 equiv) were coupled to the resin with PyBOP, HOBt (4 equiv 
each) and DIEA (10 equiv) in DMF (2 mL) for 2 h. The side chains of Lys, Gln, Arg and Tyr 
were protected with Boc, trityl (Trt), Pbf and tert-butyl, respectively. The Fmoc deprotection of 
the amino acid on the resin was repeated followed by the next coupling cycle. The deprotection-
coupling cycle was repeated until the desired peptide was assembled on the resin.  
Cleavage of the peptide from the resin 
The peptide resins were treated with Reagent B
39
 (88% TFA, 5% phenol, 5% water, and 
2% TIS, 5 mL) for 2 h with occasional shaking. Subsequently, the resins were filtered and the 
TFA was evaporated in vacuo. Water (20 mL) was added to the residues, and the solutions 
lyophilized to give the crude peptides. 
Purification and analysis of the peptides  
The crude peptides were purified by preparative reversed phase HPLC using an LC-AD 
liquid chromatograph (Shimadzu) equipped with a SPD-10A VP system controller and SPD-10A 
VP UV-Vis detector and a Vydac C18 column (10 μ, 300 Å, 22 mm x 250 mm) equipped with a 
Vydac C18 guard cartridge. For purification, the crude peptides (20-30 mg) were dissolved in 
75-85% MeOH in water (total volume ~1.5 mL). A linear gradient of 15-50% aqueous MeCN 
containing 0.1% TFA over 45 min, at a flow rate of 18 mL/min, was used. The purification was 
                                                                                                                                                         
105 
 
monitored at 214 nm. Peptide 3 was purified using a linear gradient of 30-50% aqueous MeOH 
containing 0.1% TFA over 40 min. Peptide 8 was purified using a linear gradient of 5-40% 
aqueous MeCN containing 0.1% TFA over 70 min with a flow rate of 15 mL/min. The purity of 
the final peptides was verified on a Vydac 218-TP column (5 μ, 300 Å, 4.6 mm x 50 mm) 
equipped with a Vydac guard cartridge on a LC-10AT VP analytical HPLC (Shimadzu) 
equipped with a SCL-10A VP system controller and SPD-10A VP UV-visible detector or on an 
Agilent 1200 series liquid chromatograph system equipped with a multiple wavelength UV-
visible detector. Two systems, a linear gradient of 5-50% solvent B (solvent A = aqueous 0.1% 
TFA and solvent B = MeCN containing 0.1% TFA) over 45 min, at a flow rate of 1 mL/min 
(system 1), and a linear gradient of 15-60% solvent B (solvent A = aqueous 0.1% TFA and 
solvent B = MeOH containing 0.1% TFA) over 45 min, also at a flow rate of 1.0 mL/min 
(system 2), were used for the analyses. The final purity of all peptides by both analytical systems 
was ≥ 98%, except for peptides 3 and 8 that displayed purity of > 95%.  Peptide 3 displayed a 
purity of 96.2% on 25-45% of MeOH with 0.1% TFA in water containing 0.1% TFA over 40 
min, while peptide 8 displayed a purity of 95.5% in system 1.  Molecular weights of the 
compounds were determined by ESI-MS using a Waters-time of flight (TOF) mass spectrometer 
(LCT premier, Waters, Milford, MA). 
Pharmacological assays 
Radioligand binding assays 
Radioligand binding assays were performed as previously described
42
 using cloned rat 
KOR and MOR, and mouse DOR stably expressed separately on CHO cells. [
3
H]Diprenorphine, 
[
3
H]DAMGO ([D-Ala
2
,N-MePhe
4
,Gly-ol]enkephalin) and [
3
H]DPDPE (cyclo[D-Pen
2
,D-
Pen
5
]enkephalin) were used as radioligands in the binding assays for KOR, MOR and DOR, 
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respectively. Incubations were carried out in triplicate with varying concentrations of peptides 
(0.1-10,000 nM) for 90 min at RT in the presence of peptidase inhibitors (10 μM bestatin, 30 μM 
captopril, and 50 μM L-leucyl-L-leucine) and 3 mM Mg
2+
. Nonspecific binding was determined 
in the presence of 10 μM unlabeled Dyn A-(1-13)NH2, DAMGO and DPDPE for KOR, MOR 
and DOR, respectively. IC50 values were determined by nonlinear regression analysis fit to a 
logistic equation for the competition data using Prism software (GraphPad Software Co., San 
Diego, CA). Ki values were calculated from the IC50 values by the Cheng and Prusoff equation
43
 
using KD values of 0.45, 0.49, and 1.76 nM for [
3
H]diprenorphine, [
3
H]DAMGO, and 
[
3
H]DPDPE, respectively.  
GTPS assay 
The binding of the GTP analog [
35
S]GTPS to CHO cell membranes expressing cloned 
KOR was assayed as described previously.
44
 Binding of the test compound was determined in a 
volume of 500 L. The assay mixtures contained 50 mM HEPES, pH 7.4; 1 mM EDTA; 5 mM 
magnesium acetate; 1 M GDP; 1 mM dithiothreitol; 100 mM NaCl, 10 M bestatin, 30 M 
captopril, 50 M Leu-Leu, 1 mg bovine serum albumin per mL; and approximately 100,000 
disintegrations per min (dpm) [
35
S]GTPS (0.08-0.15 nM). Approximately 10 g of KOR 
expressing CHO cell membrane protein was used per tube. Following 90 min incubation at 22 
o
C, the assay was terminated by filtration under vacuum on a Brandel (Gaithersburg, MD) model 
M-48R cell harvester using Schleicher and Schuell Inc. (Keene, NH) number 32 glass fiber 
filters. The filters were rinsed five times (4 mL for each wash) with ice-cold 50 mM Tris HCl, 
pH 7.4, containing 5 mM MgCl, at 5 
o
C to remove unbound [
35
S]GTPS. Filter disks were then 
placed into counting vials to which 8 mL of Biocount scintillation fluid (Research Products 
International Corp., Mount Prospect, IL) was added. Filter-bound radioactivity was determined 
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by liquid scintillation spectrometry (Beckman Instruments, Fullerton, CA) following overnight 
extraction at room temperature. The amount of radioligand bound was less than 10% of the total 
added in all experiments. Specific binding was defined as total binding minus non-specific 
binding occurring in the presence of 3 M unlabeled GTPS. Nonspecific binding was 
approximately 1% of the total binding at 0.1 nM [
35
S]GTPS. 
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Chapter 4 - Structure-activity relationships of Zyklophin – A systemically 
active, selective kappa opioid receptor antagonist. 
 
 
 
 
 
 
 
 
 
 
*Compound numbers in this chapter are applicable only to this chapter 
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4.1 Introduction 
Kappa () opioid receptors (KOR) are one of the three types of opioid receptors.
1
 KOR 
agonists can produce analgesia with less addiction liability and respiratory depression than mu 
() opioid receptor (MOR) agonists,
2, 3
 but they can also produce dysphoria.
4
 KOR antagonists 
were initially used only as pharmacological tools, but recently  their potential therapeutic uses in 
the treatment of depression,
5-8
 anxiety
8-10
 and opiate and cocaine addiction 
6, 8, 11, 12
 have been 
recognized. 
Previously different [N-alkyl-Tyr
1
,D-Pro
10
]Dyn A(1-11)NH2 analogs were explored in our 
laboratory.
13, 14
 The monoalkylated analogs showed comparable affinities and higher KOR 
selectivities vs. MOR and  opioid receptor (DOR) as compared to the parent peptide [D-
Pro
10
]Dyn A(1-11)NH2.  In the guinea pig ileum (GPI) assay the N-benzyl analog displayed lower 
agonist potency than other N-alkyl derivatives, despite its high affinity for KOR. While the 
monosubstituted analogs displayed full agonism in the GPI assay, the N-benzyl analog displayed 
partial agonism in the adenylyl cyclase (AC) assay (>70%).
15
 A series of (5,8) cyclic Dyn A(1-
13)NH2 analogs with varying ring sizes were previously synthesized in our laboratory and all of 
them displayed very low agonist potencies in the GPI assay.
16
 Based on these studies, the 
dynorphin (Dyn) A(1-11)NH2 based KOR selective peptide antagonist zyklophin (Figure 4.1) 
was designed and synthesized in our laboratory.
17
 Zyklophin is a cyclic Dyn A analog with a 
lactam bridge between D-Asp and 2,3-diaminopropionic acid (Dap) in positions 5 and 8, 
respectively, and a benzyl group on the N-terminal Tyr.  
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Figure 4.1 Structures of Dyn A(1-11)NH2 and zyklophin (1) 
Zyklophin displayed negligible efficacy (<10% maximum inhibition relative to Dyn A-
(1-13)NH2) in the AC assay and was found to be an antagonist at KOR in this assay.
17
 It was 
subsequently found to be a selective KOR antagonist in vivo, with a finite duration of activity 
(12-18 h).
18
 Following peripheral subcutaneous administration, zyklophin antagonized the 
antinociceptive activity of the centrally administered KOR agonist U50,488, suggesting that this 
peptide crossed the blood-brain barrier (BBB) to act on KOR in the CNS.
18
 This peptide also 
suppressed stress-induced reinstatement of cocaine seeking behavior in mice following systemic 
administration, suggesting its potential as a lead compound for the development of therapeutics 
for the treatment of cocaine addiction.
18
  
We are interested in exploring the structure-activity relationships (SAR) of zyklophin in 
order to examine its potential interactions with KOR and enhance its antagonist potency. We 
explored the effect of different alkyl substituents at the N-terminus Tyr on the receptor affinity 
and activity of zyklophin (Figure 4.2). We hypothesized that the N-terminal alkyl group might 
affect the interactions of the rest of the peptide with KOR, and therefore the ability of zyklophin 
to bind to the receptor without activating it.  
Initial pharmacological findings from the AC assay suggested that modifications in the C-
terminus, except those in positions 5 and 8, did not affect the efficacy of [N-benzyl]Dyn A(1-
11)NH2
19
 and the modifications in positions 5 and 8 along with the N-terminal alkylation are 
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responsible for the lack of efficacy of zyklophin.
17
 Hence we explored which of these residue(s) 
were responsible for the lack of efficacy of zyklophin (Figure 4.2). Based on the “message-
address” concept
20
 we expected that the residue in position 5 would play a major role in 
contributing to the lack of efficacy of zyklophin. In addition, we explored the role of ring size 
and residues involved in the cyclic constraint on the KOR interactions and the antagonist activity 
of zyklophin. We synthesized several cyclic analogs including ring variants analogs (Figure 4.2). 
We also investigated the role of different residues on the KOR affinity and activity of zyklophin. 
Hence, we performed an Ala scan of the non-glycine residues, excluding residues 5 and 8, up 
through residue 9 of zyklophin. In addition, to explore the importance of the phenolic group of 
Tyr
1
 on the activity of zyklophin we synthesized the Phe
1
 analog of zyklophin (Figure 4.2).   
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4.1.1 Analogs of zyklophin 
 
Figure 4.2 Analogs of zyklophin; changes from zyklophin are bolded. 
4.2 Results and discussion 
The synthesis of the analogs of zyklophin involved synthesis of the N-terminal N-alkyl 
amino acid derivatives in solution and solid phase assembly of the (2-11) peptide fragments. 
Finally the appropriate N-alkyl amino acid derivatives were coupled to the (2-11) peptide 
fragments followed by cleavage of the peptides from the resin. 
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4.2.1 Amino acid syntheses 
The N-alkyl amino acid derivatives were generally synthesized by subjecting the amino 
acid t-butyl ester to reductive amination with the appropriate aldehyde and sodium 
triacetoxyborohydride to yield the N-alkyl amino acid t-butyl ester, which was subsequently 
cleaved with 90% trifluoroacetic acid (TFA) and 10% water to yield the N-alkyl amino acid. 
Almost all of the N-alkyl-Tyr derivatives (Scheme 4.1a) and N-benzyl-Ala (Scheme 4.1d) were 
synthesized according to this procedure. The one exception was N-allyl-Tyr (Scheme 4.1b) 
which was prepared by alkylating H-Tyr-OtBu with 1 equivalent of allyl bromide (to minimize 
diallylation) in the presence of N,N-diisopropylethylamine (DIEA) in N,N-dimethylformamide 
(DMF) followed by subsequent cleavage of the t-butyl ester with 90% TFA and 10% water. For 
the synthesis of N-benzyl,N-methyl-Tyr (Scheme 4.1e), H-Tyr(tBu)-OtBu was subjected to 
reductive amination with benzaldehyde and sodium triacetoxyborohydride to yield N-benzyl-
Tyr(tBu)-OtBu, which was subsequently treated with triphenylphosphine (TPP), iodomethane 
and diisopropyl azodicarboxylate (DIAD) in tetrahydrofuran (THF)
21
 to obtain N-benzyl-N-
methyl-Tyr(tBu)-OtBu. The t-butyl ester and ether of the dialkylated product were cleaved with 
90% TFA and 10% water to obtain N-benzyl-N-methyl-Tyr-OH. 
N-Benzyl-Tyr exhibited low solubility in DMF at RT and required heating to 85
o
C for 
solubilization. While microwave couplings are routinely performed at ≥ 75
o
C, racemization at 
elevated temperatures could be a potential issue during coupling of N-alkyl amino acids to the 
(2-11) peptide. To prevent this potential problem, selected N-alkyl-amino acid derivatives, 
namely N-CPM-Tyr-OtBu and N-benzyl-Phe-OtBu, were treated with allyl chloroformate and 
DIEA in methylene chloride (DCM) to afford the Alloc (allyloxycarbonyl) protected N-alkyl 
amino acid esters (Scheme 1c). In the case of N-CPM-Tyr-OtBu the bis-Alloc derivative was 
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obtained. The ester derivatives were subsequently cleaved with 90% TFA/10% DCM to afford 
the Alloc-protected amino acids (Scheme 4.1c). Unlike the unprotected N-alkyl amino acids, the 
Alloc-protected amino acids were readily soluble in DMF at RT. This avoided heating and 
potential racemization of the amino acids during coupling (see section 4.2.3 below) 
Scheme 4.1 Synthesis of amino acid derivatives: 
a) Synthesis of N-alkyl-Tyr derivatives by reductive amination:  
 
 
b) Synthesis of N-allyl-Tyr: 
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c) Synthesis of Alloc-N-cyclopropylmethyl-Tyr(Alloc)-OH and Alloc-N-benzyl-Phe-OH: 
 
 
d) Synthesis of N-benzyl-Ala: 
 
e) Synthesis of N-benzyl-N-methyl-Tyr: 
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4.2.2 Peptide synthesis 
 The peptides were synthesized using the Fmoc (9-fluorenylmethoxycarbonyl) solid phase 
synthetic strategy. The (2-11) peptide fragments were assembled on a low load poly(ethylene 
glycol)-polystyrene (PEG-PS) resin containing the peptide amide linker [PAL, 5-(4-
aminomethyl-3,5-dimethoxyphenoxy)valeric acid linker] using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 1-hydroxybenzotriazole (HOBt) 
(4 equiv. each) and DIEA (10 equiv.) in DCM:DMF (1:1) to couple the Fmoc-amino acids (4 
equiv) to the growing peptide chain on a manual peptide synthesizer (CHOIR).
22
 The side chain 
protecting groups used were Pbf (2,2,4,6,7-pentamethyl dihydrobenzofurane-5-sufonyl) and Boc 
(tert-butyloxycarbonyl) for Arg and Lys, respectively.  
For the synthesis of selected linear analogs, the (2-11) linear peptide precursors of the 
peptides 2 and 3 were synthesized similar to the above procedure (Scheme 4.2a). The side chains 
of D-Asn in peptide 2 and Dap (Dap = 2,3-diaminopropionic acid) in peptide 3 were protected by 
trityl (Trt) and 4-methyltrityl (Mtt), respectively. For peptide 3, following the synthesis of the (2-
11) linear fragment, the Mtt protecting group on Dap was selectively deprotected by 3% TFA 
and 5% triisopropylsilane (TIS) in DCM, and the resulting amine was acetylated using acetyl 
imidazole in DMF (Scheme 4.2a).  
The (2-11) fragments of the cyclic peptides 4-10 and 15-18 were synthesized by a similar 
approach (see Scheme 4.2b). The D-Asp and Dap residues in positions 5 and 8 were protected 
with the hyperacid labile 2-phenylisopropyl (Pip) and Mtt groups, respectively. Following the 
synthesis of the (5-11) fragments, the Pip and Mtt groups were deprotected by 3% TFA and 5% 
TIPS in DCM. Subsequently, the carboxyl group of D-Asp
5
 and the amine of Dap
8
 were cyclized 
using 6-chloro-benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
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(PyClocK) and 1-hydroxy-7-azabenzotriazole (HOAt) (4 equiv. each) with DIEA (10 equiv) in a 
mixture of DCM:DMF (1:1), generally for 20-24 h.  The cyclizations were monitored using the 
qualitative ninhydrin test. Any remaining unreacted free amine of Dap was acetylated by 
treatment with acetyl imidazole and DIEA in DMF. Further extension of the peptide up to Gly
2 
afforded the (2-11) fragments of the cyclic peptides.  
For the synthesis of peptides 16 and 17, Dab(Mtt) and Orn(Mtt) were incorporated in 
position 8, respectively and for peptide 18 L-Asp(OPip) was incorporated in position 5. In the 
case of these three peptides the cyclizations required longer reaction times (~ 36 h) to go to 
completion. 
Scheme 4.2 Solid phase synthesis of (2-11) peptide fragments: 
a) Synthesis of the 2-11 fragment of peptide 3 : 
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b) Synthesis of the 2-11 fragments of the cyclic peptides 4-10 and 15-18. 
 
 
 
 
 
4.2.3 Coupling of N-alkyl amino acid derivatives to the (2-11) peptide fragment 
The coupling of the N-terminal amino acid derivatives to the resin-bound (2-11) peptide 
sequences was carried out using PyClocK, HOAt and DIEA in DMF. N-Benzyl-Tyr required 
heating to 80-85
o
C to solubilize in DMF prior to coupling. N-Benzyl-Tyr/Ala solutions were 
allowed to cool, followed by addition of the coupling reagents and base, and then the activated 
amino acid was coupled to the (2-11) peptide fragment. The peptides having an N-terminal 
benzyl group, except for peptide 15, were prepared by this procedure.  
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Scheme 4.3 Scheme for coupling of N-alkyl-Tyr to the (2-11) peptide fragment and cleavage 
from the resin 
 
 
 
The N-allyl and N-phenethyl Tyr derivatives required higher temperatures (above 
~100
o
C) to obtain complete dissolution. After allowing the solutions to cool they became turbid 
and hence the coupling agents were added to solutions while they were still hot with subsequent 
cooling and addition of the base, followed by coupling to the (2-11) fragment. In the case of 
peptide 7, N-CPM-Tyr-OH did not couple to the (2-11) fragment, potentially due to its minimal 
solubility in DMF. In the case of peptide 15, following coupling of N-benzyl-Phe-OH to the (2-
11) fragment the final peptide showed a potential epimerization product (Figure 4.6 (a) below), 
suggesting N-benzyl-Phe-OH underwent racemization during heating or subsequent coupling to 
the (2-11) fragment (Figure 4.6 (a)). To avoid this potential side reaction and enhance the 
solubility of these N-alkyl amino acid derivatives, the Alloc-protected derivatives of N-CPM-
Tyr-OH and N-benzyl-Phe-OH were prepared which were soluble in DMF at RT. Following 
coupling of the Alloc derivatives to the (2-11) peptide fragment on the resin, the Alloc group was 
removed by Pd(0) and phenylsilane.
23
 In the case of peptide 6, Fmoc-MeTyr(OtBu)-OH, which 
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is soluble in DMF at RT, was coupled to the (2-11) peptide fragment for 12 h, followed by Fmoc 
deprotection. In the case of peptide 9, Fmoc-Tyr(OtBu)-OH was coupled to the (2-11) peptide 
fragment at RT by the standard coupling procedure, followed by Fmoc deprotection and 
subsequent acylation of the N-terminal of Tyr with benzoic anhydride in the presence of DIEA in 
DMF. 
4.2.4 Investigation of racemization of N-terminal residue of zyklophin and analog 15 by 
HPLC analysis 
Because dissolution of the N-alkyl amino acids required elevated temperature, potential 
racemization was a concern. We identified an HPLC solvent system that could separate the 
diastereomers of zyklophin. N-Benzyl-D-Tyr-OH was then synthesized as described above under 
the general procedure for amino acid synthesis. The N-benzyl-D-Tyr analog of zyklophin was 
synthesized by the procedure described for the zyklophin analogs. While a reversed phase high 
performance liquid chromatography (RP-HPLC) system using a gradient of 10-25% aqueous 
MeCN containing TFA over 30 min did not adequately resolve the diastereomeric mixture of 
zyklophin and [N-benzyl-D-Tyr
1
]zyklophin (Figure 4.3 (a)), a solvent system using a 1-21% 
gradient of aqueous 0.09M triethyammonium phosphate (pH = 2.5)
24
 in MeCN over 40 min did 
successfully resolved the diastereomers of zyklophin (Figure 4.3 (b)). In addition, by increasing 
the concentration of one of the diastereomers in the co-injection mixture, we were able to verify 
the identities of the peaks for the individual diastereomers, with the D-Tyr analog of zyklophin 
eluting before the parent peptide zyklophin (Figure 4.4). Zyklophin synthesized by the above 
procedure that involved solubilization of N-benzyl Tyr at 85
o
C did not show detectable 
racemization when analyzed using the TEAP solvent system (Figure 4.5). This HPLC solvent 
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system served as a tool to detect potential racemization of the N-terminal residue during the 
synthesis of zyklophin and its analogs. 
 
 
  
Figure 4.3 Coinjection of a diastereomeric mixture containing [N-benzyl D-Tyr
1
]zyklophin and 
zyklophin. a) a linear gradient of 10-25% solvent B (solvent A = aqueous 0.1% TFA and solvent 
B = MeCN containing 0.1% TFA) over 30 min. b) a linear gradient of 1-21% solvent B (solvent 
A = aqueous 0.09 M TEAP and solvent B= MeCN) over 40 min.  
  
 
A 
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Figure 4.4 Coinjection of a diastereomeric mixture of [N-benzyl-D-Tyr
1
]zyklophin and 
zyklophin. a) a 1:1 mixture of the diastereomers, b) a mixture with a higher concentration of 
zyklophin. The coinjections were analyzed using a linear gradient of 1-21% solvent B (solvent A 
= aqueous 0.09 M TEAP and solvent B = MeCN) over 40 min. tR for the D-Tyr diastereomer of 
zyklophin = 16.9 min and for parent zyklophin = 17.7 min 
  
The Phe
1
 analog of zyklophin, peptide 15, however, displayed racemization of the N-
terminal residue when synthesized by the general procedure that involved solubilization of N-
                                                                                                                                                         
128 
 
benzyl-Phe in DMF and subsequent coupling to the (2-11) peptide fragment. Figure 4.6 (a) 
shows that a mixture of two peaks A (17.5%) and B (82.5%) was obtained for the peptide 
synthesized by the standard method. However, when synthesized using Alloc-protected N-
benzyl-Phe (Scheme 4.1c), peptide 15 did not show detectable epimerization of the N-terminal 
residue (Figure 6 (b)); only peak B was observed. In order to verify the identity of the peaks in 
Figure 4.6 (a), samples obtained by both the procedures were co-injected. The AUC ratio of peak 
B:peak A was higher in the co-injection chromatogram compared to that in Figure 6 (a), 
verifying that peak B was the desired product.        
           
 
Figure 4.5 Zyklophin synthesized by standard procedure and analyzed using a linear gradient of 
1-21% solvent B (solvent A = aqueous 0.09 M TEAP and solvent B = MeCN) over 40 min. 
None of the peptides analyzed by system 3 (Table 4.1), except for peptide 15 showed 
racemization of the N-terminal residue. All of the peptides were purified by preparative RP-
HPLC and analyzed by electrospray ionization mass spectroscopy (ESI-MS) and analytical RP-
HPLC. The final purity of all of the peptides by all methods was ≥ 98%. 
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Figure 4.6 a) Peptide 15 synthesized by the general procedure. b) Peptide 15 synthesized using 
Alloc(benzyl)Phe. tR for peak A = 18.3 min and peak B = 20.3 min.  
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Table 4.1 Analytical data for the peptides 
 
a
 Aqueous MeCN containing 0.1 % TFA; 
b
 aqueous MeOH containing 0.1 % TFA; 
c
 aqueous MeCN containing 
0.09M triethyl ammonium phosphate (TEAP). See the experimental section for details.  
 
Peptides HPLC tR (min)                                                 ESI-MS(m/z)   
  
System 1
a
   
(% Purity) 
System 2
b
 
(% Purity) 
System 3
c
  
(% Purity) 
Calcd obsd 
2 15.4 (100) 18.0 (100) 
 
[M + 3H]
3+ 
= 484.9 [M + 3H]
3+ 
= 484.9 
    
[M + 2H]
2+ 
= 726.9 [M + 2H]
2+ 
= 726.9 
3 17.7 (99.4) 23.1 (100) 
 
[M + 3H]
3+ 
= 489.6 [M + 3H]
3+ 
= 489.6 
    
[M + 2H]
2+ 
= 733.9 [M + 2H]
2+ 
= 733.9 
4 17.0 (100) 15.3 (100) 21.52 (98.9) [M + 3H]
3+ 
= 474.9 [M + 3H]
3+ 
= 474.9 
5 12.1 (100) 14.2 (100) 11.9 (100) [M + 3H]
3+ 
= 453.5 [M + 3H]
3+ 
= 453.6 
    
[M + 2H]
2+ 
= 679.8 [M + 2H]
2+ 
= 679.9 
6 11.3 (100) 13.1 (99.4)    [M + 3H]
3+ 
= 444.9 [M + 3H]
3+ 
= 444.9 
    
[M + 2H]
2+ 
= 666.8 [M + 2H]
2+ 
= 666.9 
7 13.1 (100) 14.4 (100) 13.5 (99.0) [M + 3H]
3+ 
= 458.2 [M + 3H]
3+ 
= 458.2 
    
[M + 2H]
2+ 
=  686.8 [M + 2H]
2+ 
=  686.8 
8 20.04 (99.6) 17.9 (100) 21.3 (100) [M + 3H]
3+ 
= 474.9 [M + 3H]
3+ 
= 474.9 
    
[M + 2H]
2+ 
= 711.8 [M + 2H]
2+ 
= 711.9 
9 18.1 (100) 23.3 (100) 
 
[M + 3H]
3+ 
= 474.9 [M + 3H]
3+ 
= 474.9 
    
[M + 2H]
2+ 
= 711.8 [M + 2H]
2+ 
= 711.9 
10 13.3 (100) 13.3 (100) 11.58 (100) [M + 3H]
3+ 
= 439.5 [M + 3H]
3+ 
= 439.6 
11 10.1 (100) 8.0 (100) 
 
[M + 3H]
3+ 
= 444.9 [M + 3H]
3+ 
= 444.9 
    
  [M + 2H]
2+ 
= 666.8 [M + 2H]
2+ 
= 666.9 
12 15.1 (100) 18.4 (100) 
 
  [M + 3H]
3+ 
= 441.9 [M + 3H]
3+ 
= 441.9 
    
  [M + 2H]
2+ 
= 662.3 [M + 2H]
2+ 
= 662.4 
13 14.8 (100) 15.2 (98.9) 
 
  [M + 3H]
3+ 
= 441.9 [M + 3H]
3+ 
= 441.9 
    
  [M + 2H]
2+ 
= 662.3 [M + 2H]
2+ 
= 662.4 
14 14.8 (99.7) 14.6 (100) 
 
  [M + 3H]
3+ 
= 441.9 [M + 3H]
3+ 
= 441.9 
   
 
  [M + 2H]
2+ 
= 662.3 [M + 2H]
2+ 
= 662.3 
15 17.0 (98.1)  15.6 (100) 20.1 (98.7)   [M + 3H]3+ = 464.9 [M + 3H]3+ = 464.9 
16 15.3 (100) 18.5 (100)    [M + 3H]
3+ 
= 474.9 [M + 3H]
3+ 
= 474.9 
    [M + 2H]
2+ 
= 711.9 [M + 2H]
2+ 
= 711.9 
17 15.1 (100) 18.1 (100) 
 
[M + 3H]
3+ 
= 479.6 [M + 3H]
3+ 
= 479.6 
    
[M + 2H]
2+ 
= 718.9 [M + 2H]
2+ 
= 718.9 
18 13.2 (99.1) 15.2 (99.0) 
 
[M + 3H]
3+ 
= 470.2 [M + 3H]
3+ 
= 470.2 
    
[M + 2H]
2+ 
= 704.8 [M + 2H]
2+ 
= 704.8 
1 (zyklophin)                    13.32 (99.8) 16.9 (100) 18.3 (100) [M + 3H]
3+ 
= 470.2 [M + 3H]
3+ 
= 470.2 
    [M + 2H]
2+ 
= 704.8 [M + 2H]
2+ 
= 704.8 
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4.3 Pharmacological results 
The peptides were evaluated for affinity in radioligand binding assays using Chinese 
hamster ovary (CHO) cells stably expressing opioid receptors (Table 4.2). While peptide 2 had 
2-fold lower KOR affinity, peptide 3 had 8-fold higher KOR affinity compared to zyklophin. 
This suggested that the residue in position 5 had a much larger influence on the KOR binding 
affinity of zyklophin than position 8. While zyklophin has a D-Asp involved in the lactam 
linkage at position 5, peptide 3 has L-Leu at position 5 as found in the endogenous Dyn A. 
Hence, the side chain of the residue at position 5 and/or changes in the backbone conformation 
of the peptide due to the difference in configuration at residue 5 are likely influencing the KOR 
affinity of the zyklophin analogs. While peptide 2 had low MOR affinity, peptide 3 had 30-fold 
higher MOR affinity compared to zyklophin thereby decreasing its KOR vs. MOR selectivity. 
Both linear analogs 2 and 3 displayed lower selectivity for KOR vs. MOR compared to 
zyklophin.     
Sterically diverse alkyl groups ranging from methyl to phenethyl were incorporated at the 
N-terminus to examine their effect on the affinity, efficacy and potency of the zyklophin analogs. 
Peptides 4-7 had KOR affinities similar to or higher than zyklophin, suggesting that these N-
alkyl modifications are tolerated by KOR. The N-CPM analog 7 had the highest KOR affinity, 
while the N-allyl analog 5 had the lowest KOR affinity among the N-alkylated analogs 
examined. Peptide 9 showed only slightly (<2-fold) lower KOR affinity compared to zyklophin, 
suggesting that a basic secondary amine at the N-terminus is not necessary for maintaining the 
affinity of zyklophin analogs at KOR. All of the analogs displayed low MOR affinity (Ki = 
>1000 nM). Thus while the MOR affinity of all the N-alkyl analogs did not vary much compared 
to zyklophin (except peptide 6 that displayed 4-fold increase in MOR affinity compared to 
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zyklophin) the increased KOR affinity of some analogs (4 and 7) resulted in an increase in their 
KOR vs. MOR selectivity.  
Changes in the ring size of zyklophin were also well tolerated by KOR. Peptides 16 and 
17 showed affinity within 2-fold that of zyklophin. Peptide 18 showed less than a 2-fold change 
in affinity, suggesting that a change in configuration at position 5 was also tolerated by KOR. 
Analogs 16-18 all displayed low affinity for MOR. The KOR vs. MOR selectivity of analogs 16 
and 18 was lower while analog 17 showed slightly higher KOR vs. MOR selectivity compared to 
zyklophin. Hence, the KOR vs. MOR selectivity varied somewhat depending on the analog. 
An alanine scan of zyklophin that included non-glycine residues from position 1 up 
through position 9, excluding residues in position 5 and 8, was also performed to identify 
residues important for the KOR binding of zyklophin. Peptide 10 displayed a 2.5-fold decrease in 
the KOR affinity compared to zyklophin, suggesting that Tyr in position 1 contributes to, but is 
not critical for, zyklophin’s KOR affinity. Alanine substituted analogs 11 (Ala
4
) and 12 (Ala
6
) 
showed the largest decreases, 18- and 8-fold in KOR affinity, respectively, as compared to 
zyklophin, indicating that the residues in positions 4 and 6 are important for maintaining the 
binding affinity of zyklophin at KOR. Peptide 13 (Ala
7
) showed a 3-fold increase in KOR 
affinity, while 14 (Ala
9
) displayed KOR affinity comparable to zyklophin. This suggested that 
the positively charged residues in positions 7 and 9 are not important for the KOR binding 
affinity of zyklophin. The N-benzyl-Phe
1
 analog 15 displayed a 2-fold increase in KOR affinity 
compared to zyklophin, indicating that the phenol of N-terminal Tyr
1
 is not necessary to 
maintain the affinity of zyklophin for KOR.  
Recently obtained KOR affinity values for zyklophin (Ki = 207 ± 12 nM) have been 7-
fold higher compared to those earlier obtained originally (Ki = 30.3 ± 1.9 nM)
17
 in the 
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radioligand binding assay. Similarly, the KOR binding affinity value obtained for Dyn A(1-
11)NH2 (Ki = 2.6 ± 0.3 nM) was 5 fold higher than those earlier obtained(Ki = 0.57 ± 0.01 nM).
19
 
These differences in the Ki values appear to be related to the CHO cells expressing the cloned 
KOR since aliquots of previously prepared peptides showed higher Ki values than those reported 
earlier. 
Table 4.2 Opioid receptor binding affinities of the zyklophin analogs 
 
Peptide Ki (nM ± SEM)
a 
 
 
KOR MOR KOR/MOR 
2 [D-Asn
5
] 424 ± 52  2440 ± 570  1/6 
3 [Dap(Ac)
8
] 28.6 ± 0.6  189 ± 40  1/7 
4 [N-Phenethyl] 118 ± 6  8470 ± 560  1/72 
5 [N-Allyl] 336 ± 69  > 10000  1/26 
6 [N-Me] 159 ± 18  1490 ± 410  1/9 
7 [N-CPM] 88.8 ± 11.0  8570 ± 2220 (n=2) 1/96 
8 [N-Benzyl, N-Me]  3520 ± 370  
9 [N-Benzoyl] 346 ± 21  
 
 
10 [Ala
1
] 515 ± 82  
 
 
11 [Ala
4
] 4010 ± 350  < 10000 (n=2) 1/>2.5 
12 [Ala
6
] 1750 ± 530  
 
 
13 [Ala
7
] 66.5 ± 3.7  
 
 
14 [Ala
9
] 172 ± 80   2550 ± 640  1/15 
15 [Phe
1
] 107 ± 10.0   
16 [Dab
8
] 403 ± 91  3200 ± 850  1/8 
17 [Orn
8
] 222 ± 5  8180 ± 2640  1/37 
18 [L-Asp
5
] 409 ± 16  2610 ± 790  1/6 
1 (zyklophin) 207 ± 12  5880 ± 1420
b
 1/28 
 
    a 
values are mean ± SEM for n ≥3 except where noted, 
b
 ref. 17 
The alanine scan of Dyn A(1-13) performed previously
25
 revealed that within the Leu-
enkephalin core of the peptide Ala
1
 and Ala
4
 substitution caused dramatic decreases in the opioid 
receptor binding affinities, indicating that Tyr
1
 and Phe
4
 residues were critical for opioid receptor 
binding affinity. Kawasaki et al. synthesized [Phe
1
]Dyn A(1-11)NH2 and it displayed  23-fold 
lower KOR affinity compared to Dyn A(1-11)NH2 in guinea pig brain homogenates assay 
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indicating that the phenol of Tyr is critical for the KOR affinity of Dyn A(1-11)NH2.
26
  Outside 
the Leu-Enk core of Dyn A(1-13), the Ala
6
 and Ala
7 
analogs showed the largest decreases (3- to 
7-fold) in binding affinities, suggesting that Arg
6
 and Arg
7
 contributed to the opioid receptor 
binding affinity of Dyn A(1-13). Ala
9
 and Ala
11 
analogs showed small decreases (2- to 3-fold) in 
opioid receptor binding affinity suggesting that these residues had minor contributions to the 
opioid receptor binding affinity of Dyn A(1-13).
25
  
Comparison of the alanine scan data of Dyn A(1-13) and zyklophin reveals that while 
residue 1 was critical in maintaining the opioid receptor binding affinity for Dyn A(1-13), it 
appeared to make a relatively minor contribution to the KOR binding affinity of zyklophin. 
Comparing the data from [Phe
1
] Dyn A(1-11)NH2
26
 to Phe
1
 analog of zyklophin indicated that 
while the phenol of Tyr was important for maintaining the KOR binding affinity of Dyn A(1-
11)NH2, the Tyr phenol of zyklophin was not important. Residue 4 was critical for the opioid 
receptor binding affinity of Dyn A(1-13) and the KOR binding affinity of zyklophin. Residue 6 
contributed to both the opioid binding affinity of Dyn A(1-13) and for the KOR binding affinity 
of zyklophin. In addition, while residue 7 contributed to the opioid receptor binding affinity of 
Dyn A(1-13), it did not in the case of zyklophin. The Arg residue in position 9 did not appear to 
contribute to the binding affinity of either of the peptides. The differences in the alanine scan of 
the two peptides suggest that there could be differences in the binding interactions of the two 
peptides with the receptor. This is not surprising as one of them is a KOR agonist (Dyn A(1-13)) 
while the other is a KOR antagonist (zyklophin). However, in comparing the data obtained from 
the alanine substituted analogs of Dyn A(1-13) and zyklophin, it should be noted that there exists 
several differences in the radioligand binding assays used to evaluate the Ala-substituted analogs 
of the two peptides.  Radioligand binding assays for Dyn A(1-13) analogs were performed in rat 
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brain homogenates as the tissue preparation and using the non-selective radioligand 
[
3
H]etorphine, while Chinese hamster ovary (CHO) cell membranes expressing cloned KOR 
with [
3
H]diprenorphine as the radioligand was used in the case of the zyklophin analogs. While 
the CHO membranes exclusively express KOR, rat brain homogenates contain MOR and DOR 
along with lower levels of KOR.
27
  
The analogs were also screened against cloned DOR at 10 M, and all of them exhibited 
minimal DOR affinity (< 20% inhibition of binding).  
The efficacies of the zyklophin analogs were evaluated in the GTPS assay (Table 4.3). 
All of the peptides displayed negligible efficacy (<15%) in the GTPS assay, except peptide 3 
which showed partial agonist activity (26% efficacy for peptide 3 compared to the full agonist 
Dyn A(1-13)NH2, Table 4.3).  
It was hypothesized that the N-terminal alkyl group might shift the peptide in the binding 
site thereby changing the interactions of the rest of the peptide with the receptor and its ability to 
activate the receptor. Among the N-alkyl analogs, peptide 6 with an N-methyl substitution was 
expected to cause minimal shift of the peptide in its binding site. The negligible efficacy of 
peptides 4-7 and 16-18 suggested that changes in the N-terminal alkyl group, ring size or 
configuration of the residue at position 5 did not alter the negligible efficacy of zyklophin as 
measured in the GTPS assay.  
Although peptides 11 and 12 displayed negligible efficacy, given the low KOR affinity of 
these peptides, it is difficult to evaluate the contributions of residues in position 4 and 6 to the 
lack of efficacy of zyklophin. The GTPS results for peptides 14 suggested that the residue in 
position 9 does not contribute to the lack of efficacy of zyklophin. The GTPS results for peptide 
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15 suggested that removal of the phenol of Tyr
1
 does not contribute to the inability of zyklophin 
to activate the receptor.  
Schild analysis
28
 of selected analogs is being performed at KOR in the GTPS assay 
(Table 4.4), to evaluate the antagonist potency of these analogs. The preliminary results for 
peptide 3 suggested that although it was partial agonist it retained the KOR antagonist potency 
comparable to zyklophin. The results from peptide 7 suggested that the N-CPM modification 
could be the most appropriate N-terminal modification to yield a potent KOR antagonist. In 
addition, preliminary results of peptide 15 suggested that the Tyr phenol may not be required for 
the KOR antagonist potency of zyklophin.  
Table 4.3 Efficacies of the zyklophin analogs at KOR in the GTPS assay 
 
Peptide  % efficacy
a
 
2 [D-Asn
5
] 
 
0  
3 [Dap(Ac)
8
]
b
 
 
26 ± 6 (n=5) 
4 [N-Phenethyl] 
 
6.5 (n=1) 
5 [N-Allyl] 
 
< 10 
6 [N-Me] 
 
<15  
7 [N-CPM] 
 
0  
8 [N-Benzyl, N-Me] 
 
ND 
9 [N-Benzoyl] 
 
0  
10 [Ala
1
] 
 
0 (n=1) 
11 [Ala
4
] 
 
< 10  
12 [Ala
6
] 
 
0  
13 [Ala
7
] 
 
0 (n=1) 
14 [Ala
9
] 
 
0  
15 [Phe
1
] 
 
0  
16 [Dab
8
] 
 
0  
17 [Orn
8
] 
 
< 10  
18 [L-Asp
5
] 
 
0  
1 (zyklophin) 
 
< 10 
a 
Compared to Dyn A(1-13)NH2 (efficacy = 100%);
  
values are for n = 2 except where 
noted.  
                             
b
 EC50 = 39.5 ± 17 nM; ND =  not determined 
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Table 4.4. Preliminary antagonist potencies of selected zyklophin analogs in the GTPS assay at 
KOR 
Peptide KB (nM)
a
 
3 [Dap(Ac)
8
] 791 
7 [N-CPM] 43.7 
15 [Phe
1
] 175 
1(zyklophin)
b
 985 ± 110 (n=2) 
                aObtained from Schild analysis in a GTPS assay. Values obtained from (n = 1) 
          unless otherwise stated.  
b
KB for zyklophin in AC assay previously found to be 83.9 nM      
(8.81-313 nM, 95% confidence interval). 
 
4.4 Conclusions 
Various linear and cyclic analogs of zyklophin were synthesized. In order to detect 
potential racemization of the N-terminal residue, an HPLC solvent system that could resolve the 
diastereomers was also identified. To avoid potential racemization a modified synthetic strategy 
involving preparation of the Alloc derivatives of N-alkyl amino acids was devised. These 
derivatives were readily soluble at RT in the solvents used for the coupling reaction, thereby 
minimizing the potential for racemization.  
The in vitro pharmacological evaluation of the linear and the cyclic zyklophin analogs 
provided initial information about the SAR of the lead peptide zyklophin. The results from 
radioligand binding assay for the linear analogs 2 and 3 suggested that the residue at position 5 
has a greater influence on the affinity of zyklophin as compared to residue 8. The L-
configuration and/or the hydrophobic side chain of Leu in position 5 of peptide 3 likely 
contributes to the higher KOR affinity of this peptide. However, the KOR binding affinity data 
for cyclic analog 18 which has an L-Asp at position 5, suggested that the configuration of residue 
5 might have a minor influence on the KOR affinity of cyclic zyklophin analogs. While all of the 
N-terminal modifications and ring variations were reasonably well tolerated in zyklophin, among 
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the N-alkyl analogs the analog with the N-CPM substitution displayed the highest affinity for 
KOR. It also appears that the basic secondary amine at the N-terminus of zyklophin is not 
necessary for maintaining the KOR affinity of zyklophin, given the similar KOR affinity of 9 and 
zyklophin. The pharmacological results for alanine substituted analogs suggested that the 
residues at positions 4 and 6 are important for zyklophin’s KOR affinity. Substitution of Ala at 
postion 7 surprisingly increased the KOR affinity, while the Ala
9
 analog displayed affinity 
comparable to zyklophin. This suggested that not only are the basic residues 7 and 9 not 
important for the maintaining the KOR affinity of zyklophin, but that Ala substitution in position 
7 could be either causing favorable interactions or eliminating unfavorable interactions with the 
receptor that are responsible for the analog’s increased affinity. In addition, the results suggested 
that the phenolic moiety of Tyr is not important for the KOR affinity of zyklophin. The results 
from the GTPS assay indicated that all of the zyklophin analogs, except peptide 3, synthesized 
in the present study exhibited negligible efficacy (< 15% compared to full agonist Dyn A(1-
11)NH2) similar to zyklophin. The Schild analysis of selected analogs found that the N-CPM 
analog and the Phe
1
 analog were more potent KOR antagonists than zyklophin in this assay. 
These two analogs appear to be promising analogs for in vivo studies towards the development of 
potent peptide KOR antagonists. Further studies of selected zyklophin analogs are underway in 
our laboratory. 
4.5 Experimental section 
Materials 
Fmoc-protected PAL-PEG-PS resin was purchased from Applied Biosystems (Foster 
City, CA). Standard Fmoc-protected amino acids were obtained from EMD Biosciences 
(Gibbstown, NJ) and Peptides International (Louisville, KY), Fmoc-D-Asp(OPip)OH was 
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obtained from Bachem (King of Prussia, PA), and Fmoc-Dap(Mtt)OH, Fmoc-Dab(Mtt)-OH and 
Fmoc-Orn(Mtt)-OH were obtained from EMD Biosciences. Fmoc-NMe-Tyr(OtBu)-OH was 
obtained from APPTec (Louisville, KY), and Tyr-OtBu was obtained from EMD Biosciences. 
PyBOP and PyClocK were purchased from EMD Biosciences. HOBt was purchased from 
Peptides International, and DIEA was from Fisher Scientific (Fair Lawn, NJ).  Piperidine was 
purchased from Sigma-Aldrich (St. Louis, MO). All HPLC-grade solvents (MeCN, DMF, DCM, 
EtOAc, hexane and MeOH) used for amino acid and peptide synthesis or HPLC analysis were 
obtained from Fisher Scientific. TFA for HPLC analysis was purchased from Pierce (Rockford, 
IL); benzaldehyde, sodium cyanoborohydride, iodomethane, DIAD and triphenylphosphine 
(TPP) were from Sigma-Aldrich; and phenylacetaldehyde, allyl bromide, allyl chloroformate and 
TIS were from Acros Organics (Fairlawn, NJ).  
Amino acid synthesis 
General procedure for N-alkyl-Tyr-OH synthesis 
The amino acid t-butyl ester (1 equiv.) and NaBH(OAc)3 (1 equiv.)  were dissolved in anhydrous 
acetonitrile (SureSeal, 5-10 mL/mmol) followed by the addition of the corresponding aldehyde 
(1.5 equiv.) and a catalytic amount of glacial acetic acid (0.2 mL). The reaction was performed 
under N2 for 12-16 h at RT with continuous stirring. The reaction was monitored by TLC (1:2 
EtOAc:hexane  plus 1 drop NEt3). After completion of the reaction the acetonitrile was 
evaporated in vacuo the pH adjusted to 7.0 with saturated NaHCO3 and the aqueous layer 
extracted with EtOAc (3 x 10 mL). The combined EtOAc extracts were washed with water, and 
the organic layer was dried (MgSO4) and evaporated under reduced pressure to obtain crude N-
alkyl-Tyr-OtBu that was purified by flash silica gel column chromatography (20-30% EtOAc in 
hexane). The N-alkyl-Tyr-OtBu was analyzed by HPLC for purity using a gradient of 5-50% 
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aqueous MeCN with 0.1% TFA over 45 min at a flow rate of 1 mL/min. The t-butyl ester on the 
purified N-alkyl-Tyr-OtBu was cleaved by 90% TFA plus 10% water (8-10 mL/mmol) for 12 h. 
The reaction mixture was concentrated in vacuo, and the desired product was obtained by 
precipitation with diethyl ether. 
N-Benzyl-Tyr-OH (22a) 
Tyr-OtBu (0.474 g, 2.0 mmol, 1 equiv.) and NaBH(OAc)3 (0.422 g, 2.0 mmol, 1 equiv.) 
were dissolved in anhydrous acetonitrile (12 mL), followed by the addition of  benzaldehyde 
(0.32 mL, 3.0 mmol, 1.5 equiv.) and 7 drops of glacial acetic acid, and the reaction stirring for 18 
h. The crude product was isolated as described above, and pure N-benzyl-Tyr-OtBu was obtained 
following flash silica gel column chromatography (25% EtOAc/hexane) as an off-white 
amorphous solid: 520 mg (80%); ESI-MS m/z [M+H]
+
 328.1913 (calcd), 328.1784 (observed); 
HPLC: tR 24.3 min ( purity 100%); 
1
H NMR (500 MHz, d6-acetone) δ 8.14 (s, 1H), 7.35 – 7.15 
(m, 5H), 7.04 (d, J = 8.2 Hz, 2H), 6.74 (d, J = 8.7 Hz, 2H), 3.82 (d, J = 13.3 Hz, 1H), 3.64 (d, J = 
13.3 Hz, 1H), 3.30 (t, J = 6.8 Hz, 1H), 2.88 – 2.71 (m, 2H), 1.38 (s, 9H);
 13
C NMR (126 MHz, 
CDCl3) δ 171.90, 153.14, 136.83, 128.38, 126.42, 126.38, 125.96, 125.20, 113.40, 79.60, 60.52, 
49.84, 36.56, 25.98. 
N-Benzyl-Tyr-OtBu (200 mg) was cleaved to the corresponding acid using TFA as 
described above to yield N-benzyl-Tyr-OH as a white amorphous powder: 160 mg (68%); ESI-
MS m/z [M+H]
+ 
272.1287 (calcd), 272.1227 (observed). 
N-Phenethyl-Tyr-OH (23) 
Tyr-OtBu  (0.474 g, 2.0 mmol, 1 equiv.) and NaBH(OAc)3 (0.422 g, 2.0 mmol, 1 equiv.) 
were dissolved in anhydrous acetonitrile (10 mL), followed by the addition of phenyl 
acetaldehyde (0.35 mL, 1.5 mmol, 1.5 equiv.) and 4 drops of glacial acetic acid, and the reaction 
stirred for 16 h. The crude product was isolated as described above under the general procedure. 
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Pure N-phenethyl-Tyr-OtBu was obtained by flash silica gel column chromatography (25% 
EtOAc in hexane) as an off-white oil: 452 mg (66%); ESI-MS m/z [M+H]
+ 
342.2069 (calcd), 
342.2004 (observed); HPLC: tR 27.9 min (purity 100%); 
1
H NMR (500 MHz, d6-acetone) δ 8.13 
(s, 1H), 7.32 – 7.11 (m, 5H), 7.04 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 8.5 Hz, 2H), 3.31 (dd, J = 6.4 
and 7.6 Hz, 1H), 2.83 – 2.68 (m, 6H), 1.34 (s, 9H); 
13
C NMR (126 MHz, d6-acetone) δ 174.49, 
156.89, 141.43, 131.36, 129.64, 129.18, 126.82, 115.77, 80.84, 64.77, 50.22, 39.67, 37.42, 28.25. 
N-Phenethyl-Tyr-OtBu (165 mg) was cleaved to afford the corresponding acid as a 
yellowish-white solid: 125 mg (65%); ESI-MS m/z [M+H]
+
 286.1443 (calcd), 286.1432 
(observed). 
N-Benzyl Ala-OtBu (35) 
Ala-OtBu
 
HCl (0.43 g, 2.4 mmol, 1.2 equiv.) and benzaldehyde (0.2 mL, 2.0 mmol, 1 
equiv.) were dissolved in CHCl3 (10 mL) and a solution of NaBH(OAc)3 (0.63 g, 3 mmol, 1.5 
equiv) in CHCl3 (5 mL) was added to the Ala-OtBu solution. The reaction mixture was allowed 
to stir at RT for 12 h and water (20 mL) was added to the CHCl3 solution. The water layer was 
separated and extracted with CHCl3 (2 x 20 mL). The combined CHCl3 layers were washed with 
water (20 mL), dried over MgSO4 and the solvent evaporated to obtain N-benzyl-Ala-OtBu. The 
product was purified by flash silica gel column chromatography (15% EtOAc /hexane) to give a 
white semisolid: 220 mg (39%); ESI-MS m/z [M+H]
+ 
236.1651 (calcd), 236.1628 (observed); 
HPLC: tR 13.08 min (purity 95.8%) ;
1
H NMR (500 MHz, CDCl3) δ 7.39 – 7.23 (m, 5H), 3.82 (d, 
J = 12.7 Hz, 1H), 3.68 (d, J = 12.7 Hz, 1H), 3.27 (q, J = 7.0 Hz, 1H), 1.86 (s, 1H), 1.51 (s, 9H), 
1.30 (d, J = 7.0 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 175.37, 140.14, 128.59, 128.45, 127.19, 
81.07, 56.86, 52.15, 28.29, 19.35. 
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N-Benzyl-Ala-OtBu (120 mg) was cleaved to afford the corresponding acid as a 
yellowish-white solid: 75 mg (50%); ESI-MS m/z [M+H]
+
 180.1025 (calcd), 180.1009 
(observed). 
N-Benzyl-D-Tyr-OH (22b) 
D-Tyr-OtBu (0.118 g, 0.5 mmol, 1 equiv.) and NaBH(OAc)3 (0.105 g, 0.5 mmol, 1 
equiv.) were dissolved in anhydrous acetonitrile (5 mL), followed by the addition of  
benzaldehyde (0.083 mL, 0.75 mmol, 1.5 equiv.) and 3 drops of glacial acetic acid, and the 
reaction stirred for 18 h. The crude product was isolated as described above, and pure N-benzyl-
D-Tyr-OtBu was obtained following flash silica gel column chromatography (20% 
EtOAc/hexane) as an off-white amorphous solid: 90 mg (55%); ESI-MS m/z [M+H]
+
 328.1913 
(calcd), 328.1890 (observed); 
1
H NMR (500 MHz, CDCl3) δ 7.35 – 7.17 (m, 5H), 6.97 (d, J = 
8.4 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 3.80 (d, J = 12.8 Hz, 1H), 3.66 (d, J = 12.8 Hz, 1H), 3.42 
(t, J = 6.9 Hz, 1H), 2.95 – 2.77 (m, 2H), 1.39 (s, 1H); 
13
C NMR (126 MHz, CDCl3) δ 172.36, 
153.37, 137.44, 128.83, 126.84, 126.74, 126.67, 125.59, 113.75, 79.98, 60.98, 50.29, 37.03, 
26.43.  
N-Benzyl-D-Tyr-OtBu (90 mg) was cleaved to the corresponding acid using TFA as 
described above to yield N-benzyl-D-Tyr-OH as a white amorphous powder: 51 mg (49%); ESI-
MS m/z [M+H]
+  
272.1287 (calcd), 272.1251 (observed). 
N-Cyclopropylmethyl-Tyr-OtBu (27) 
Tyr-OtBu  (0.237 g, 1.0 mmol, 1 equiv.) and NaBH(OAc)3 (0.211 g, 1.0 mmol, 1 equiv.) 
were dissolved in anhydrous acetonitrile (7 mL), followed by addition of 
cyclopropylcarboxaldehyde (0.066 mL, 0.95 mmol, 0.95 equiv.) and 2 drops of glacial acetic 
acid, and the reaction allowed to proceed for 12 h. The crude product was isolated as described 
under the general procedure. The product was purified by flash silica gel column 
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chromatography (30% EtOAc in hexane) to give a white solid powder: 160 mg (55%); ESI-MS 
m/z [M+H]
+ 
292.1913 (calcd), 292.1819 (observed); HPLC: tR 19.10 min (purity 97.4%); 
1
H 
NMR (500 MHz, acetone) 8.05 (s, 1H), 6.97 (dd, J = 6.5, 2.0 Hz, 2H), 6.65 (dd, J = 6.5, 2.1 Hz, 
2H), 3.22 (dd, J = 7.6, 6.3 Hz, 1H), 2.79 – 2.67 (m, 1H), 2.66 – 2.59 (m, 1H), 2.38 (dd, J = 11.7, 
6.1 Hz, 1H), 2.21 (dd, J = 11.7, 7.2 Hz, 1H), 1.26 (s, 9H), 0.82 – 0.72 (m, 1H), 0.35 – 0.27 (m, 
2H), 0.05-0.01 (dd, J = 4.8, 1.8 Hz, 2H);
 13
C NMR (126 MHz, CDCl3) δ 174.11, 155.11, 130.60, 
128.73, 115.55, 81.53, 63.38, 53.28, 38.99, 28.23, 11.10, 3.86, 3.46.  
Alloc-N-cyclopropylmethyl-Tyr(Alloc)-OH (31)  
N-Cyclopropylmethyl-Tyr-OtBu (0.08 g, 0.27 mmol, 1 equiv.) was dissolved in anhydrous 
DCM (2.5 mL), then allyl chloroformate (0.117 mL, 1.08 mmol, 4 equiv.) followed by DIEA 
(0.189 mL, 1.08 mmol, 4 equiv.) were added, and the reaction was allowed to proceed at RT for 
12 h. DCM was evaporated in vacuo, and EtOAc (10 mL) was added, and the solution washed 
with water (10 mL). The water layer was back-extracted with additional EtOAc (10 mL). The 
EtOAc fractions were finally washed with water (10 mL) dried (MgSO4) and evaporated in 
vacuo to afford the product as a yellowish white semisolid: 91 mg (73%); ESI-MS m/z [M+Na]
+ 
482.2155 (calcd), 482.2087 (observed);  HPLC tR 18.51 min (25-95% of aqueous acetonitrile 
with 0.1 %TFA over 35 min, purity 95.4%); 
1
H NMR (500 MHz, CDCl3, 50 
o
C) δ 7.22 – 7.14 
(m, 2H), 7.07 (d, J = 8.5 Hz, 2H), 6.03 – 5.87 (m, 2H), 5.46 – 5.18 (m, 4H), 4.74 – 4.48 (m, 4H), 
4.08 (m, 1H), 3.23 (m, 3H), 2.56 (m, 1H), 1.44 (s, 9H), 0.69 (m, 2H), 0.35 (m, 2H), 0.05 (m, 
1H);
 13
C NMR (126 MHz, CDCl3) δ 169.97, 155.99, 153.61, 150.25, 136.79, 131.57, 130.48, 
121.02, 119.34, 81.73, 69.17, 66.30, 63.35, 53.64, 29.86, 28.24, 10.34, 4.19, 3.83. 
 The ester was cleaved with 90% TFA in DCM for 12 h at RT. TFA was evaporated and 
EtOAc (10 mL) and water (10 mL) was added. The water layer was extracted with EtOAc (10 
mL). The organic extracts were finally washed with water (10 mL), dried with MgSO4 and the 
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solution was evaporated under vacuo to yield the product as a yellowish white semisolid: 75 mg 
(94%); ESI-MS m/z (M+K)
+ 
442.1268. (calcd), 442.1250 (observed); HPLC: tR 12.05 min (25-
95% aqueous acetonitrile with 0.1 % TFA over 35 min, purity 94.5%). 
N-Benzyl Phe-OtBu (28) 
H-Phe-OtBu
 
HCl (0.618 g, 2.4 mmol, 1.2 equiv.) and benzaldehyde (0.2 mL, 2.0 mmol, 1 
equiv.) were dissolved CHCl3 (5 mL). A solution of NaBH(OAc)3 (0.31 g, 3.0 mmol, 1.5 equiv.) 
in CHCl3 (2 mL) was then added to the Phe-OtBu solution, and the reaction mixture allowed to 
stir at RT for 12 h. Water (20 mL) was added to CHCl3 solution. The water layer was separated 
from CHCl3 layer and again extracted with CHCl3 (3 x 20 mL). The combined CHCl3 extracts 
were washed with water (20 mL) and dried over MgSO4, and the crude product was purified by 
flash silica gel column chromatography (5-10% EtOAc in hexane) to obtain a white semisolid: 
335 mg (44%); ESI-MS m/z [M+H]
+
 312.1964 (calcd), 312.1853 (observed); HPLC: tR 28.96 
min (purity 99.1%);
 1
H NMR (500 MHz, CDCl3) δ 7.31 – 7.18 (m, 10H), 3.86 (d, J = 13.0 Hz, 
1H), 3.73 (d, J = 13.0 Hz, 1H), 3.51 (dd, J = 7.6 and 6.6 Hz, 1H), 3.00 (dd, J = 13.6 and 6.5 Hz, 
1H), 2.91 (dd, J = 13.6 and 7.7 Hz, 1H), 1.35 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 172.82, 
138.19, 136.99, 129.47, 128.53, 128.49, 128.31, 127.45, 126.70, 81.65, 62.23, 51.65, 39.21, 
27.97. 
Alloc-N-benzyl-Phe-OH (32) 
N-Benzyl-Phe-OtBu (0.25 g, 0.8 mmol, 1 equiv.) was dissolved in anhydrous DCM (2 
mL), then allyl chloroformate (0.169 mL, 1.6 mmol, 2 equiv.) followed by DIEA (0.278 mL, 1.6 
mmol, 2 equiv.) were added, and the reaction was allowed to proceed for 12 h. DCM was 
evaporated in vacuo, EtOAc (20 mL) was added and the solution washed with water (20 mL). 
The water layer was extracted with additional EtOAc (20 mL), and the combined EtOAc extracts 
were washed with additional water (20 mL). The EtOAc fractions were dried (MgSO4) and 
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evaporated in vacuo to obtain the product as a yellowish semisolid: 208 mg (65%); ESI-MS 
(m/z) [M+Na]
+
 418.1994 (calcd), 418.2047; HPLC: tR 18.68 min (25-95% aqueous acetonitrile 
with 0.1 % TFA over 35 min, purity 96.5%); 
1
H NMR (500 MHz, CDCl3, 50
0
C) δ 7.32 – 7.21 
(m, J = 7.0 Hz, 6H), 7.21 – 7.05 (m, 4H), 6.05 – 5.89 (m, 1H), 5.28  (m, 2H), 4.82 – 4.52 (m, 
3H), 4.16 (m, 1H), 3.99 – 3.82 (m, J = 13.4 Hz, 1H), 3.32 (dd, J = 14.0, 5.8 Hz, 1H), 3.16  (dd, J 
= 14.0, 5.8 Hz, 1H), 1.39 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ 169.47, 156.03, 138.33, 
137.51, 132.81, 129.21, 128.33, 128.13, 127.07, 126.36, 117.50, 81.49, 66.26, 62.40, 51.77, 
36.24, 27.86. 
The ester (120 mg) was cleaved with 90% TFA/10% water for 12 h at RT. The work up 
was done as described under TFA cleavage of 31 to yield the product as a yellowish white 
semisolid: 100 mg (98%); ESI-MS m/z (M+Na)
+
 362.1368 (calcd), 362.1347 (observed); HPLC: 
tR 12.14 min (25-95% aqueous acetonitrile with 0.1 % TFA over 35 min, purity 100%).
  
N-Allyl-Tyr-OH (25) 
Tyr-OtBu (0.237 g, 1.0 mmol, 1 equiv.) was dissolved in DMF (2 mL) and the 
temperature maintained at 0-4 
0
C. DIEA (0.174 mL, 1.0 mmol, 1 equiv.) was added to the 
solution, followed by slow addition of allyl bromide (0.086 mL, 1 mmol, 1 equiv.). The reaction 
mixture was stirred at room temperature under N2 and the progress of the reaction was monitored 
by TLC (1:3 EtOAc:hexane plus 2 drops NEt3). After 45 h, the DMF was removed in vacuo. A 
negligible amount of diallyl product was visible on TLC while a substantial amount of residual 
starting material was present. The crude product was purified by flash silica gel column 
chromatography (22% EtOAc/hexane) as a white solid powder: 80 mg (29%); ESI-MS (m/z) [M-
tBu]
+ 
222.1130 (calcd), 222.1083 (observed); HPLC: tR 15.91 min (purity 100%);
 1
H NMR (500 
MHz, d6-acetone) δ 8.19 (s, 1H), 7.05 (d, J = 8.1 Hz, 2H), 6.75 (d, J = 8.3 Hz, 2H), 5.82 (m, 1H), 
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5.15 (dd, J = 17.2 and 1.3 Hz, 1H), 5.01 (d, J = 10.2 Hz, 1H), 3.31 (t, J = 6.9 Hz, 1H), 3.19 (ddd, 
J = 77.8, 14.2, 5.9 Hz, 2H), 2.79 (ddd, J = 21.1, 13.5, 6.9 Hz, 2H), 1.37 (s, 9H); 
13
C NMR (126 
MHz, d6-acetone) δ 174.52, 156.89, 138.10, 131.35, 129.53, 115.85, 115.76, 80.94, 63.75, 51.09, 
39.67, 28.26.  
Pure N-allyl-Tyr-OtBu (80 mg) was deprotected as described above as to obtain N-allyl-
Tyr-OH as a white solid powder: 43 mg (44%); ESI-MS (m/z) [M+H]
+ 
222.1130 (calcd), 
222.1060 (observed). 
Synthesis of N-benzyl, N-methyl Tyr(tBu)-OtBu 
N-Benzyl-Tyr(tBu)-OtBu (37)  
H-Tyr(tBu)-OtBu
 
HCl (0.79 g, 2.4 mmol, 1.2 equiv.) and benzaldehyde (0.2 mL, 2 mmol, 
1 equiv.) were dissolved in CHCl3 (10 mL), solution of NaBH(OAc)3 (0.63 g, 3 mmol, 1.5 
equiv.) in CHCl3 (3 mL) was added to the Tyr-OtBu solution, and the reaction mixture was 
allowed to stir for 16 h. The crude product was isolated according to the procedure described for 
N-benzyl-Phe-OtBu and purified by flash silica gel column chromatography (25% 
EtOAc/hexane) to obtain a white powder: 550 mg (60%); ESI-MS m/z [M+H]
+ 
384.2539 (calcd), 
384.2461 (observed); HPLC: tR 37.0 min (purity 100%); 
1
H NMR (500 MHz, d6-acetone) 
1
H 
NMR (500 MHz, CDCl3) δ 7.34 – 7.19 (m, 5H), 7.13 – 7.03 (m, 2H), 6.94 – 6.85 (m, 2H), 3.82 
(d, J = 13.1 Hz, 1H), 3.64 (d, J = 13.1 Hz, 1H), 3.39 (t, J = 7.2 Hz, 1H), 2.95 – 2.89 (m, 1H), 
2.86 – 2.80 (m, 1H), 1.35 (s, 9H), 1.32 (s, 9H); 
13
C NMR (126 MHz, d6-acetone) δ 174.51, 
155.02, 141.47, 133.84, 130.83, 129.05, 128.92, 127.62, 124.64, 81.09, 78.40, 63.64, 52.32, 
39.87, 29.19, 28.29. 
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N-Benzyl,N-methyl Tyr(tBu)-OH (39)  
 N-Benzyl-Tyr(tBu)-OtBu (0.550 g, 1.43 mmol, 1 equiv.), DIAD (424 µL, 2.14 mmol, 1.5 
equiv.) and TPP (374 mg, 1.43 mmol, 1 equiv.) were dissolved in dry THF (SureSeal, 6 mL) and 
allowed to stir for 2-3 min at RT. Iodomethane (274 µL, 4.28 mmol, 3 equiv.) was added, and 
the reaction was allowed to proceed for 12 h, at which time TLC system (1:4 EtOAC:hexane 
plus 2 drops TEA) and ESI-MS showed that the reaction was incomplete. As iodomethane is 
volatile, the reaction mixture was evaporated, fresh reagents were added and the reaction was 
continued for an additional 30 h. At the end of a total of 42 h, the reaction appeared to be 
complete by TLC and ESI-MS. The reaction mixture was evaporated, and EtOAc (25 mL) was 
added followed by filtration to remove precipitate. The EtOAc solution was washed twice with 
water (15 mL) and the combined aqueous extracts were again extracted with EtOAc (15 mL). 
The combined EtOAc extracts were dried (MgSO4) and evaporated in vacuo. Along with the 
desired product formation of a quaternary amine product was also observed. The desired product 
was purified by silica flash column chromatography and the product eluted in 5% EtOAc in 
hexane to give N-benzyl,N-methyl Tyr(tBu)-OtBu as a yellowish white semisolid: 180 mg 
(32%); ESI-MS (m/z) [M+H]
+ 
398.2695 (calcd), 398.2490 (observed); HPLC: tR  37.04 min 
(purity 99.1%); 
1
H NMR (500 MHz, CDCl3) 
1
H NMR (500 MHz, CDCl3) δ 7.27 – 7.16 (m, 5H), 
7.07 (dd, J = 6.6, 1.8 Hz, 2H), 6.91 – 6.87 (m, 2H), 3.83 (d, J = 13.6 Hz, 1H), 3.63 (d, J = 13.6 
Hz, 1H), 3.50 – 3.43 (m, 1H), 3.02 (dd, J = 13.7, 8.4 Hz, 1H), 2.94 – 2.86 (m, 1H), 2.33 (s, 1H), 
1.41 (s, 9H), 1.33 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ 170.18, 152.50, 138.47, 132.48, 
128.70, 127.65, 127.09, 125.81, 122.99, 79.92, 77.14, 66.83, 57.67, 36.86, 34.35, 27.79, 27.27. 
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The pure N-benzyl, N-methyl-Tyr-OtBu (105 mg) was deprotected as described above to 
obtain N-benzyl, N-methyl-Tyr-OH as a white powder: 75 mg (71%), ESI-MS (m/z) [M+H]
+
 
286.1443 (calcd), 286.1023 (observed) 
General procedures for solid phase peptide synthesis 
Synthesis of (2-11) peptide fragments  
The peptides were assembled on a low load Fmoc-PAL-PEG-PS resin (0.19 mmol/g). 
Following removal of the Fmoc group from the resin (200 mg, 0.038 mmol) using 20% 
piperidine in DMF (2 x 20 min) the Fmoc-protected amino acids (4 equiv., 0.152 mmol) were 
coupled using PyBOP and HOBt (4 equiv. each, 0.152 mmol) as the coupling reagents and DIEA 
(10 equiv., 0.38 mmol) as the base in DCM:DMF (1:1, 3-4 mL)  for 2 h (unless otherwise noted) 
on a manual peptide synthesizer (CHOIR)
22
 to afford the linear fragments. The side chains of 
Lys and Arg were protected by Boc and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
(Pbf), respectively; those of Dap, Dab and Orn were protected by Mtt, and those of D-Asp and L-
Asp were protected by OPip. 
 The (5-11) linear precursors of the cyclic peptides were synthesized by these standard 
procedures. Selective deprotection of the Pip and Mtt protecting groups on D-Asp and Dap, 
respectively, was performed using 3% TFA and 5% TIS in DCM (3 x 10-15 min). The 
cyclizations were performed using PyClocK and HOAt (4 equiv. each) with DIEA (10 equiv.) as 
the base in DCM:DMF (1:1) (4 mL for 200 mg peptide-resin) for 24 h, with the coupling 
reagents refreshed after every 8-12 h unless otherwise noted. The cyclizations were monitored 
using the qualitative ninhydrin test. Any remaining unreacted free amine of Dap was capped by 
treatment with acetyl imidazole (16 equiv., 0.61 mmol) with DIEA (8 equiv.) as the base in 
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DMF(~ 3 mL) for 30 min. Further extension of the peptide assembly up to Gly
2 
afforded the 
cyclic (2-11) peptide fragments. 
Coupling of the N-terminal amino acid to the (2-11) peptide 
Prior to coupling, complete dissolution of the N-alkyl-Tyr-OH (2 equiv.) was achieved by 
heating to 80-120 
o
C in DMF (1 mL/0.02 mmol of N-alkyl amino acid) followed by cooling to 
RT (unless otherwise indicated), and subsequent addition to PyClock and HOAt (2 equiv. each) 
as the coupling agents plus DIEA (6 equiv). The coupling reactions were generally complete 
after 12 h, as indicated by the qualitative ninhydrin test.  
Final deprotection of the peptides 
The peptides were cleaved from the resin using Reagent B
29
 (88% TFA containing 5% 
water, 5% phenol and 2.5% TIS, 4-5 mL/200 mg resin). The solutions were filtered, diluted with 
10% aqueous acetic acid (10-15 mL), and extracted with diethyl ether (3 x 10 mL). The ether 
extracts were back extracted with 10% acetic acid (10 mL). The combined aqueous solutions 
were pooled and lyophilized to give the crude peptides. 
Synthesis of peptides 2 and 3 
The linear (2-11) fragments were synthesized as described above under the general 
procedure except that Fmoc-DAsn(Trt)OH and Fmoc-Dap(Mtt)OH were used in a 2-fold excess 
for the synthesis of peptides 2 and 3, respectively. In addition, for peptide 3 the coupling of 
Fmoc-Dap(Mtt)-OH to the peptide resin was performed using PyClocK and HOAt (2 equiv each) 
in the presence of DIEA (6 equiv) and DCM:DMF (1:1, 4 mL). For peptide 3, the Mtt on Dap 
was selectively deprotected by 3% TFA and 5% TIPS in DCM (3 x 10 min, 3-4 mL each time) 
followed by acetylating with acetyl imidazole (16 equiv., 0.61 mmol) in the presence of DIEA (8 
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equiv.) in DMF (3 mL) for 1 h. The coupling of N-benzyl-Tyr-OH (2 equiv) to the (2-11) 
fragment was performed according to the general procedure described above. 
Synthesis of peptides 4-10 and 15. 
The (2-11) cyclic peptide fragment was synthesized according to the general procedure 
described above.  
For peptide 4, complete dissolution of N-phenethyl-Tyr-OH (33 mg, 0.114 mmol, 2 
equiv.) was achieved by heating to 115 
o
C in DMF (10 mL). The solution was cooled to ~70 
o
C, 
followed by the addition to PyClocK and HOAt (2 equiv. each). Subsequently, the solution was 
cooled to RT followed by the addition of DIEA (6 equiv.). The amino acid was reacted with the 
(2-11) peptide fragment for 24 h with reagents replaced after 12 h. In the case of peptide 5, N-
allyl-Tyr-OH (20 mg, 0.076 mmol, 2 equiv.) was dissolved in DMF (6 mL) by heating to 105 
o
C. 
When the solution was cooled to ~70 
o
C it became turbid. Therefore, the coupling reagents were 
added to the amino acid solution at 105 
o
C. When the solution was cooled to RT, DIEA (6 
equiv.) was added and the solution was reacted with the (2-11) peptide fragment for 12 h to 
obtain peptide 5. For peptide 6, Fmoc-NMe-Tyr(OtBu)-OH (54 mg, 0.114 mmol, 2 equiv.) was 
dissolved in DMF (5 mL) at RT and coupled to the (2-11) cyclic peptide using PyBOP (60 mg, 
0.114 mmol, 2 equiv.) and HOBt (16 mg, 0.114 mmol, 2 equiv.) in the presence of DIEA (6 
equiv.) followed by subsequent removal of Fmoc to afford peptide 6. For peptide 7, Alloc-N-
cyclopropylmethyl-Tyr(Alloc)-OH (23 mg, 0.057 mmol, 2 equiv.) was dissolved in DMF (3 mL) 
at RT, and the coupling reaction to the (2-11) peptide was performed with PyClocK (31 mg, 
0.057 mmol, 2 equiv.) and HOAt (8 mg, 0.057 mmol, 2 equiv.) in the presence of DIEA (6 
equiv) for 1 h, followed by the subsequent removal of the Alloc group (see below) to afford 
protected peptide 7 on the resin. For peptide 8, N-benzyl,N-methyl-Tyr (21 mg, 0.076 mmol, 2 
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equiv.) in DMF (4 mL) was heated to 65-70 
o
C and then cooled, followed by the addition of 
PyClocK and HOAt (2 equiv. each) and DIEA (6 equiv.). The amino acid solution was then 
reacted with the (2-11) peptide for 4 h to obtain peptide 8. For peptide 9, Fmoc-Tyr(tBu)-OH (52 
mg, 0.114 mmol, 4 equiv.) was coupled to the (2-11) peptide fragment in the presence of PyBOP 
(60 mg, 0.114 mmol, 4 equiv), HOBt (15 mg, 0.114 mmol, 4 equiv. each) and DIEA (10 equiv.) 
in DCM:DMF (1:1, 3mL) for 2 h. Following Fmoc deprotection of Tyr, the N-terminus of the 
Tyr was reacted with benzoic anhydride (0.025 mg, 0.114 mmol, 4 equiv.) and DIEA (8 equiv.) 
in DMF (2-3 mL) overnight. In the case of the synthesis of peptide 10, N-benzyl-Ala (2 equiv.) 
was heated to 85 
o
C in DMF (3.5 mL) followed by cooling the solution to 60 
o
C before adding 
PyClocK and HOAt (2 equiv each) and DIEA (6 equiv.). The coupling was performed for 24 h 
with the amino acid and coupling reagents replaced after 12 h. For peptide 15 Alloc-N-benzyl-
Phe-OH (20 mg, 0.057 mmol, 2 equiv.) was dissolved in DMF (3 mL) at RT with PyClocK and 
HOAt (2 equiv. each) and DIEA (6 equiv.) and coupled to the (2-11) peptide-resin. The coupling 
reaction was performed for 1 h followed by subsequent removal of the Alloc group (see below) 
to afford the peptide 15 on resin. For the D-Tyr derivative of zyklophin, N-benzyl-D-Tyr (5.16 
mg, 0.019 mmol, 2 equiv.) was dissolved in DMF (2 mL) by heating to 85
 o
C. The solution was 
allowed to cool at RT followed by addition of PyClocK and HOAt (2 equiv. each) and DIEA (6 
equiv.) and coupled to the (2-11) peptide for 12 h. 
Alloc deprotection of peptides 7 and 15 
The resin was swollen in DCM (2 x 5 min), phenylsilane (24 equiv./ g of resin) was 
added, and the mixture was bubbled with N2 for 5 min. Tetrakis-(triphenylphosphine) palladium 
(0.3 equiv.) was added, and a septum with a needle was fixed onto the reaction vessel to allow 
the evolved carbon dioxide to escape. The reaction was allowed to proceed on the rocking arm 
                                                                                                                                                         
152 
 
shaker for 12 h. The solution was drained and the resin was subsequently subjected to a series of 
washes as follows: DCM (4 x 1 min), THF (4 x 1 min), DCM (3 x 1 min), DMF (3 x 1 min), 0.5 
% DIEA in DMF (3 x 2 min), 0.2 M sodium diethyldithiocarbamate in DMF (3 x 15 min), DMF 
(3 x 2 min), DCM (3 x 1 min), and MeOH (3 x 1 min), followed by drying of the resin.
23, 30
  
Synthesis of cyclic peptides 11-14 
The synthesis of peptide 11 was performed according to the general procedure described 
above with Ala incorporated in position 4.  
In the case of peptides 12-14 the (5-11) linear peptide fragments with Ala incorporated in 
the indicated position were synthesized as described under the general procedure. Following 
selective deprotection by 3% TFA and 5% TIPS (3 x 10 min) in DCM, the cyclization reactions 
were performed for 24 h using PyClocK and HOAt (4 equiv. each) in the presence of DIEA (6 
equiv) in DCM:DMF (1:1, 4 mL) with the reagents replaced after 12 h. Following capping with 
acetyl imidazole the peptides were extended up through Gly
2 
as described under the general 
procedure. The coupling of N-benzyl-Tyr-OH to the (2-11) fragments followed the general 
procedure as described above to obtain peptides 12-14. 
Synthesis of cyclic peptides 16-18 
For peptide 16 [D-Asp(OPip)
5
,Dab(Mtt)
8
]Dyn A-(5-11)-NH2 was synthesized according 
to the general procedure described above, except that Fmoc-Dab(Mtt)OH (2 equiv.) was 
coupling three times for 2 h each during the initial two couplings and overnight for the third 
coupling. Subsequently, the Pip and Mtt protecting groups on D-Asp and Dab, respectively, were 
selectively deprotected, and the peptide was cyclized for 36 h as described above, with coupling 
agents replaced every 8 h. Any unreacted free amine of Dab was acetylated as described above 
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for Dap.  Further extension of the peptide chain up through Gly
2
 was performed as described 
above under the general procedure. 
 For peptides 17 and 18 the (5-11) linear peptide fragment was synthesized by the general 
procedure as described above. The Pip and Mtt protecting groups on D-Asp and Orn, respectively 
(peptide 17) and L-Asp and Dap, respectively (peptide 18), were selectively deprotected using 
3% TFA and 5% TIS in DCM (3 x 10 min). The peptides were cyclized for 36 h using PyClocK 
and HOAt (4 equiv. each) in the presence of DIEA (6 equiv.) in DCM:DMF (1:1, 4 mL) with the 
reagents replace after every 12 h. Following capping with acetyl imidazole the peptide was 
extended up through Gly
2 
as described under the general procedure. Subsequent coupling of N-
benzyl-Tyr-OH to the corresponding (2-11) fragments was done as described for the general 
procedure to afford peptides 16-18. 
Purification and analysis of the peptides 
 The crude peptides were purified by preparative reversed phased HPLC on an LC-AD 
Shimadzu liquid chromatograph system equipped with an SPD-10A VP system controller and 
SPD-10A VP UV-Vis detector on a Vydac C18 column (10 μ, 300 Å, 22 x 250 mm) equipped 
with a Vydac C18 guard cartridge. For purification, a linear gradient of 5-50% aqueous MeCN 
containing 0.1% TFA over 45 min, at a flow rate of 18 mL/min, was used. The purifications 
were monitored at 214 nm. The purity of the final peptides was verified on a Vydac 218-TP 
column (5 μ, 300 Å, 4.6 mm x 50 mm) equipped with a Vydac guard cartridge on a Shimadzu 
LC-10AT VP analytical HPLC liquid chromatograph (equipped with SCL-10A VP system 
controller and SPD-10A VP UV-Vis detector) or on an Agilent 1200 series liquid chromatograph 
system equipped with a multiple wavelength UV-Vis detector. Two systems, a linear gradient of 
5-50% solvent B (solvent A = aqueous 0.1% TFA and solvent B = MeCN containing 0.1% TFA) 
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over 45 min at a flow rate of 1 mL/min (system 1), and a linear gradient of 15-60% solvent B 
(solvent A = aqueous 0.1% TFA and solvent B = MeOH containing 0.1% TFA) over 45 min at a 
flow rate of 1.0 mL/min (system 2), were used for the analyses. A third system utilized a linear 
gradient of 1-21% solvent B (solvent A = aqueous 0.09 M TEAP, pH = 2.5 and solvent B = 
MeCN) over 40 min. The final purity of all peptides by both analytical systems was ≥ 98% (see 
Table 4.1). Molecular weights of the compounds were determined by ESI-MS using a time of 
flight mass spectrometer analyzer (LCT premier, Waters, Milford, MA).  
Pharmacological assays 
Radioligand binding assays 
Radioligand binding assays were performed as previously described
16
 using cloned rat 
KOR and MOR and mouse DOR stably expressed on CHO cells. [
3
H]Diprenorphine (Kd=0.45 
nM), [
3
H]DAMGO ([D-Ala
2
,NMePhe
4
,glyol]encephalin, Kd = 0.49 nM), and [
3
H]DPDPE 
(cyclo[D-Pen
2
,D-Pen
5
]encephalin, Kd = 1.76 nM) were used as radioligands in assays for KOR, 
MOR, and DOR, respectively. 
GTPS assay 
The binding of the GTP analog [
35
S]GTPS to membranes containing KOR was assayed 
as described previously.
31
 Binding of the test compound was determined in a volume of 500 L. 
The assay mixture contained 50 mM HEPES, pH 7.4, 1 mM EDTA, 5 mM magnesium acetate, 1 
M GDP, 1 mM dithiothreitol, 100 mM NaCl, 10 M bestatin, 30 M captopril, 50 M Leu-
Leu, 1 mg/mL bovine serum albumin, and approximately 100,000 disintegrations per min (dpm) 
[
35
S]GTPS (0.08 - 0.15 nM). Approximately 10 g of KOR expressing CHO cell membrane 
protein was used per tube. Following 90 min incubation at 22 °C, the assay was terminated by 
filtration under vacuum on a Brandel (Gaithersburg, MD) model M-48R cell harvester using 
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Schleicher and Schuell Inc. (Keene, NH) number 32 glass fiber filters. The filters were rinsed 
five times (4 mL for each wash) with ice-cold (5 
o
C) 50 mM Tris HCl, pH 7.4, containing 5 mM 
MgCl to remove unbound [
35
S]GTPS. Filter disks were then placed into counting vials to which 
8 mL of Biocount scintillation fluid (Research Products International Corp., Mount Prospect, IL) 
was added. Filter-bound radioactivity was determined by liquid scintillation spectrometry 
(Beckman Instruments, Fullerton, CA) following overnight extraction at room temperature. The 
amount of radioligand bound was less than 10% of the total added in all experiments. Specific 
binding was defined as total binding minus that occurring in the presence of 3 M unlabeled 
GTPS. Nonspecific binding was approximately 1% of the total binding at 0.1 nM [
35
S]GTPS. 
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5.1 Anatomy and physiology of the intestine 
The human small intestine is 2-6 m in length and is divided into three sections, namely 
the duodenum, jejunum and ileum. The duodenum comprises about 5% of the total length of the 
intestine, whereas the jejunum and ileum comprise about 50 and 45%, respectively.
1
 Out of the 
total absorption of the ingested material in the gastrointestinal tract, approximately 90% occurs 
in the small intestine. The surface of the intestine has numerous surface projections called villi 
that dramatically increase the surface area. While villi increase the surface area by 30-fold, the 
microvilli increase it by a factor of 600.
1
  
The intestinal surface is made up of epithelial cells and is covered by a hydrated gel 
consisting of heavily glycosylated peptides known as mucins. The mucins are secreted by gastric 
faveolar cells and intestinal goblet cells and create a barrier that restricts large particles and 
bacteria from directly coming in contact with the intestinal epithelial cells.
2
 The mucous layer is 
in turn covered by an unstirred water layer that slows down the nutrient absorption by reducing 
the rate at which nutrients reach the microvilli, but also contributes to the absorption by limiting 
the diffusional loss of small nutrients that are released from their larger precursors by the brush 
border digestive enzymes.
3
  
The epithelial cells in the intestine include populations of different cell types including 
enterocytes or absorptive cells, goblet cells, endocrine cells, paneth cells, M cells, tuft cells and 
cup cells.
4, 5
 The epithelial cell layer is sealed by an apical junctional complex which is 
composed of the tight junction and subadjacent adherens junction. Both tight and subadjacent 
adherens junctions are supported by a ring of actin and myosin that regulate barrier function.
3
 
The adherens junctions are composed of cadherins, a family of transmembrane proteins that form 
strong adhesive interactions between the cells. The adherens junctions are required for the 
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assembly of tight junctions which seal the paracellular space. Several transmembrane proteins 
that define tight junctions include claudins, occludins and the peripheral membrane proteins like 
zona occludens 1 and 2.
3
 The tight junction is rate determining in transepithelial transport and a 
major determinant of mucosal permeability.
3
 
5.2 Different routes of intestinal drug absorption 
Drug molecules can cross cellular barriers either by diffusion between the cells 
(paracellular route) or diffusion across the cells (transcellular route, Figure 5.1). Low molecular 
weight hydrophilic molecules are likely to cross the cellular barriers by the paracellular route 
while highly lipophilic molecules generally diffuse through the barrier by the transcellular route.
6
  
5.2.1 Transcellular route 
5.2.1.1 Passive absorption 
Passive absorption occurs through the epithelial cells membranes from a region of high 
concentration to that of low concentration.
7, 8
 Passive absorption is not saturable and usually 
exhibits minimal sensitivity to stereochemical changes in the drug. Passive permeability depends 
on the uncharged fraction of the drug (in other words the pKa of the drug), its octanol partition 
coefficient, hydrogen bonding potential and its molecular size.
8
 The solubility of the drug in the 
aqueous phase of the gut lumen at the site of absorption is also an important requirement for 
passive intestinal drug absorption.
9
  
5.2.1.2 Active transport 
While some hydrophilic compounds are transported through the paracellular route others 
are likely to use a specific transporter system(s) for absorption from the intestine.
8
 Active 
transporters have the capacity to generate concentration gradients across the barriers with the 
help of various energy coupling mechanisms. While some active transporters directly use ATP as 
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a source of energy during the transport cycle, other transporters indirectly couple to ATP through 
the Na
+
 electrochemical gradient generated by the ubiquitous Na
+
/K
+
 ATPase.
7
 Unlike passive 
absorption where increasing the drug dose will cause an increase in the drug absorption, in active 
absorption increasing the drug dose can cause saturation of the carrier resulting in a plateau for 
the amount of drug absorbed.
10
 Absorption of compounds which are substrates of apical active 
efflux transporters such as P-glycoprotein (Pgp) may be limited by active secretion back to the 
apical (luminal) side of the intestinal cells.
10
 
 
Figure 5.1. A schematic representation of different routes of drug permeation through intestinal 
cells.
8 
(Reprinted with permission from Nature Publishing group) 
5.2.1.2.1 Influx transporters in the small intestine 
Various transporters are present in the intestine that transport drug molecules across the 
intestinal wall into blood. The peptide transporter 1 (PEPT-1) oligopeptide transporter that 
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belongs to the family of solute carrier (SLC) family of transporters is present in the small 
intestine.
11
 The PEPT-1 transporter is mainly present on the brush border membranes of 
intestinal cells. PEPT-1 transports di- and tripeptides with different charges, but not free amino 
acids or tetrapeptides.
11
 
 Organic anion transporting polypeptides (OATPs) are another group of SLC transporters 
that possess a wide spectrum of amphipathic transport substrates.
12
 Amongst the various OATPs, 
OATP-B is present in the human small intestine.
12
 In general, OATP substrates are mainly 
anionic or amphipathic molecules with a higher molecular weight (>450) and are mostly albumin 
bound under physiological conditions.
12
 
Ganapathy et al. recently provided evidence of two novel transporters, namely sodium 
dependent oligopeptide transporters (SOPT)-1 and 2, in the human ARPE-19 retinal pigment 
epithelial cell line,
13
 the rabbit CJVE conjunctival cell line,
14
 and the human SK-N-SH neuronal 
cell line cell line.
15
 Subsequently, the same group showed the presence of these transporters in 
the Caco-2 cell line.
16
 Unlike PEPT-1, these transporters do not transport dipeptides and 
tripeptides but transport peptides consisting of 5 or more amino acids. These transporters 
transport various endogenous opioid peptides
14, 17
 and synthetic opioid peptides
13, 14
 including 
deltorphin II, DADLE ([D-Ala
2
, D-Leu
5
]-enkephalin), DAMGO ([D-Ala
2
,N-MePhe
4
,Gly-
ol]enkephalin), DSLET ([D-Ser
2
,Leu
5
,Thr
6
]-enkephalin) and other peptides including Tat47-57.
13
  
Other groups of transporters including the organic cation transporters (OCT); OCT-1, 
OCT-2 and OCT-3 are expressed in Caco-2 cells and the human intestine.
18-21
  This group of 
transporters is involved in the absorption, distribution and elimination of endogenous compounds 
(e.g. amines) as well as drugs and other xenobiotics that are positively charged.
18
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5.2.1.2.2 Efflux transporters in the small intestine 
Three efflux transporters belong to the ATP binding cassette (ABC) superfamily of 
transporters, namely multidrug resistant transporter 1 (MDR1) or P-glycoprotein (Pgp), 
multidrug resistance associated protein (MRP) which includes MRP 1, 2 and 3 and breast cancer 
related protein (BCRP).
22
 These efflux proteins are abundant on the apical side of the cells which 
is exposed to various xenobiotics and function as gatekeepers against foreign substances in the 
gut. However, they are not selective for toxic substances and thereby decrease the bioavailability 
of a number of drugs. The ABC family of transporters consists of a highly conserved ATP-
binding cassette consisting of two nucleotide binding domains.
23, 24
 The general structure consists 
of 12 transmembrane (TM) regions; however, the number of transmembrane segments varies 
with different sub-families.
22
 Expression of MDR1 and MRP3 in the human intestine increases 
from proximal to distal regions, resulting in the highest expression levels in the colon.
25, 26
 
Expression of MRP2 is highest in the duodenum and decreases in the direction of the ileum and 
colon where it is minimal.
27
  
Intestinal Pgp is localized at the villus tip enterocytes.
28, 29
 This is the major site for 
absorption of orally administered drugs, and hence Pgp is ideally positioned to restrict the 
absorption by driving efflux back into the lumen.
22
 A broad range of molecules that are 
lipophilic, basic or uncharged and ranging from 300 to 2000 Da can be substrates for Pgp.
22
 One 
of the modes through which Pgp interacts with substrates includes an induced fit mechanism 
where Pgp is able to accommodate different substrates by altering the packing of its TM 
domains.
30
 For example, while cyclosporine A can be accommodated in the binding site, another 
Pgp substrate such as colchicine can cause rearrangement in the packing of the TM domain to fit 
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into the drug binding site.
30
 The expression of the other transporters in the MDR subfamily, 
namely MDR3, is reported to be low in the small intestine and even lower in Caco-2 cells.
31
  
While Pgp shares some degree of substrate similarity with MRP2, MRP2 transports 
organic anions, especially conjugated compounds. It also transports amphipathic compounds.
22
 
Like Pgp, MRP2 is also localized on the apical side of intestinal cells. There have been reports of 
the efflux of the fluoroquinolone antibiotic grepafloxacin in Caco-2 cells by both Pgp and 
MRP2
32-34
 and of the dietary flavonoids by MRP2.
35
  
BCRP appears to plays a similar role as Pgp and regulates the absorption and disposition 
of drugs along the intestinal border. Anticancer drugs such as topotecan, irinotecan, 
mitoxantrone are substrates for BCRP.
22, 36
 In addition HIV-1 nucleoside reverse transcriptase 
inhibitors including zidovudine also act as substrates for BCRP.
37
 
5.2.1.2.3 Endocytosis 
Endocytosis is characterized by internalization of molecules from the surface of the cell 
into endosomes/vesicles. Bio-macromolecules such as peptide antigens which are not transported 
by other pathways due to their size are transported by endocytosis.
10, 38
 However, the membrane 
vesicles formed during the transport process contain proteolytic enzymes that can cause 
extensive degradation of macromolecular drugs.
10
 Endocytosis can be of two types, the highly 
specific receptor mediated endocytosis or adsorptive mediated endocytosis. Macromolecules 
such as immunoglobulins and growth factors are transported by receptor mediated endocytosis.
39
 
Along with macromolecules; smaller peptides are also transported by endocytosis. Sai et al. 
showed that the basic peptide H-Me-Tyr-Arg-MeArg-D-Leu-NH(CH2)8NH2 was internalized by 
adsorptive mediated endocytosis into Caco-2 cells.
40
 Terasaki et al. have shown that the 
dynorphin (Dyn) analog E-2078 is transported into brain capillaries by adsorptive mediated 
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endocytosis.
41, 42
 Uptake of Big Dyn, Dyn A and Dyn B has been studied across neuronal and 
non-neuronal cells.
43
 Preliminary data suggested that while both energy dependent (caveolar 
endocytosis) and energy independent mechanisms facilitated Big Dyn and Dyn A translocation 
across the plasma membrane into the cells, Dyn B did not translocate.
43
  
5.2.2 Paracellular route   
Low molecular weight hydrophilic molecules generally are transported across the cellular 
barrier by the paracellular route. However, the ability of the drug to cross the cellular barrier by 
this route is limited by the presence of tight junctions between the cells. The main structural 
features that affect the paracellular permeability of drug molecules include the molecular size, 
charge and hydrophilicity. The tight junctions contain narrow pores or gates which open or close 
and hence create a sieving effect which regulates the molecular diffusion of drug molecules.
6
 
The tight junctions are impermeable to molecules with molecular radii larger than 11-15 Å.
44
 In 
terms of molecular weight, molecules lower than 200 Da can be absorbed by the paracellular 
route. Borchardt et al. studied the effect of size and charge of peptides on paracellular transport 
in the Caco-2 intestinal model and observed that as the molecular weight increased (e.g. 
hexapeptides) the size played an important role while the effect of charge became negligible.
45
  
5.3 Intestinal absorption of peptides 
Intestinal absorption of peptides is generally limited because of poor biopharmaceutical 
properties which include metabolic liability and poor cellular permeation. Intestinal permeation 
of peptides can occur via both paracellular and transcellular pathways. Hydrophilic peptides are 
generally restricted to the paracellular pathway
44
 which depends on the size and the charge of the 
peptide.
45, 46
 Hydrophobic peptides that lack charge and exhibit low hydrogen bonding potential 
can traverse through the transcellular route.
6, 47
 While some peptides that permeate through the 
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transcellular route diffusely passively, others cross the intestinal barrier with the aid of various 
transporters located on the apical side of the enterocytes. 
5.3.1 Transporters involved in peptide absorption 
5.3.1.1 PEPT-1 and PEPT-2 transporters  
Both PEPT-1 and PEPT-2 transport di- and tripeptides with different charges, but not free 
amino acids and tetrapeptides.
11
 PEPT-1
48
 is present on the brush border membranes of intestinal 
and renal epithelial cells while the PEPT-2
49
 transporter is located on the brush border 
membranes of renal epithelial cells.  While the presence of peptide bond(s) was considered the 
most important factor in recognition of substrates by these transporters, some studies showed that 
even compounds without peptide bond(s) can be accepted as substrates.
11
 Subsequent studies 
suggested that the  or amino carbonyl structure of substrates is the key determinant of 
substrate affinity for PEPT-2 as opposed to PEPT-1.
50, 51
 After permeating through the apical 
side di- or tripeptides are either hydrolyzed by intracellular peptidases in the cytoplasm to amino 
acids, which then cross the basolateral membrane and are absorbed into the blood, or escape 
hydrolysis and are absorbed as intact peptides into the blood.
52
 Ganapathy et al. showed the 
presence of the PEPT-1 transporter in Caco-2 cells.
53
 Similarly, there are reports about an 
oligopeptide transporter on the basolateral side of Caco-2 cells.
54, 55
 However, the characteristics 
of the apical and basolateral transporters appear to be different in terms of pH requirements of 
the extracellular media for transport of substrates.
55
  
Very recently, Dr. Newstead’s group has determined the crystal structure of PEPT-1 from 
Shewanella oneises
56
 and from the bacterium Streptococcus thermophilus.
57
 While the crystal 
structure obtained from the latter reveals an inward facing conformation, the overall crystal 
structure of the transporters from both organisms is similar.
57  
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5.3.1.2 SOPT-1 and SOPT-2 
Ganapathy et al. showed the existence of SOPT-1 and 2 in Caco-2 cells.
16
 Unlike PEPT-1 
and 2, these transporters do not transport dipeptides and tripeptides but instead transport peptides 
consisting of 5 or more amino acids. SOPT-1 is almost entirely sodium dependent, while SOPT-
2 is partially Na
+
 dependent. H
+
 and Cl
-
 also significantly influence these transport systems. 
SOPT-1 and 2 can be differentiated on the basis of the modulating effects of di- and tripeptides 
on these transporters.
16
 While the di- and tripeptides stimulate SOPT-1, SOPT-2 is inhibited by 
these peptides. This inhibition is not due to competition for the transport site, as these peptides 
do not appear to be substrates for SOPT-2. Instead, they appear to function as allosteric 
modulators of SOPT-1 and 2.
16
 The model peptide substrates used to characterize these 
transporters included the opioid peptide deltorphin II for SOPT-1 and DADLE, a metabolically 
stable analog of enkephalin, for SOPT-2. Although these peptides are known substrates for 
OATP’s, Ganapathy et al. showed that these substrates were transported by SOPT-1 and SOPT-
2, respectively, and not via OATP’s in Caco-2 cells. While the discovery of these transporters is 
encouraging, it is not known whether these systems are expressed in the normal intestinal tract. 
The physiological role of these transporters remains unknown.
16
 
5.3.1.3 Other transporters  
Members of the OATP family of transporters have been shown to be involved in 
transporting opioid peptides across the blood-brain barrier (BBB) and blood cerebrospinal fluid 
barrier in c-RNA injected Xenopus oocytes.
58
 While the human OATP-A, which is expressed at 
the human BBB was shown to transport the linear peptide deltorphin II and to a lesser extent the 
cyclic peptide DPDPE (cyclo[D-Pen2,D-Pen5]enkephalin), rat OAPT1 which is expressed on the 
apical membrane of choroid plexus epithelial cells exhibited high transport activity for both 
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deltorphin II and DPDPE. DPDPE was also transported by rat OATP2 which is expressed at rat 
BBB and the basolateral plasma membrane of choroid plexus epithelial cells. 
58
 Furthermore, 
Pollack et al. demonstrated in vivo in the murine brain perfusion model that DPDPE could be 
transported into the brain by OATP’s, although it was also a Pgp substrate.
59
 Recently, OATP 
4A1 and OATP3A1 have been shown to exist in Caco-2 cell membranes.
60-62
  
The microcystins (MC) (Figure 5.2) are a group of non-ribosomal macrocyclic peptides 
that display hepatotoxicity.
63
 MC variants namely MC-LR and MC-RR display varying levels of 
hepatotoxicity which is partly attributed to their uptake by heaptic OATPs.
64, 65
 In order to 
investigate the intestinal absorption of these peptides uptake studies of variants of microcystins 
were performed in Caco-2 cells. These studies suggested that these molecules have a fast; non-
ATP dependent mechanism of uptake.
62
 The MC variants also displayed a temperature 
dependent mechanism of efflux from the Caco-2 cells. The low lipid permeability of MC’s, the 
presence of OATP transporters and the non-ATP dependent uptake of MCs into Caco-2 cells 
suggested that the uptake of MC variants likely involved OATP transporters. There also existed a 
likely active mechanism of excretion through efflux pumps.
62
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Figure 5.2 Microcystins 
5.3.2 Peptides exhibiting intestinal absorption 
A few orally active non-opioid and opioid peptides have been studied previously. The 
orally active octapeptide analog of somatostatin octreotide (oral bioavalability  ≤ 0.3%), was 
shown to be at least partially absorbed by a membrane transport system.
66-68
 The orally 
administered leutinizing-hormone-releasing hormone (LHRH) analog (D-Ala
6
-desGly
10
-
NH2)LHRH-ethylamide, dose = 10 g in rats) was shown to be orally active.
69, 70 One of the 
early examples of opioid peptides absorbed through the rat intestine is the synthetic pentapeptide 
metkephamid  (Tyr-D-Ala-Gly-Phe-NMe-Met-NH2) which displayed an oral bioavalability of 
0.22%.
71
 A dermorphin analog, ADAMB (N

-amidino-Tyr-D-Arg-Phe-Me-Ala-OH, Figure 5.3) 
that contains N-terminal guanidylation, exhibited oral analgesic activity in mice with an ED50 of 
5.5 mg/kg
72
 and was 4-fold more potent as an analgesic than morphine following oral 
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administration. Another tetrapeptide analog containing D-Arg at position 2, Dmt
1
-DALDA (Dmt 
= 2’, 6’-dimethyltyrosine, DALDA = Tyr-D-Arg-Phe-Lys-NH2), was transported across Caco-2 
monolayers (Papp = 1.24 x 10
-5
 cm/s), suggesting that it could be absorbed orally.
73
 The Dmt-Tic 
(Tic = tetrahydroisoquinoline-3-carboxylic acid) derivative Dmt-Tic-Lys-NH-CH2-Ph (MZ-2, 
Figure 5.3) displayed antagonism at both MOR and DOR and blocked centrally administered 
morphine after oral administration in mice with an AD50 of 1.64 mg/kg.
74
 Oral administration of 
this peptidomimetic caused reduction in weight gain and improvement in obesity related factors 
in obese mice.
75
  
Certain orally active macrocyclic peptides have also been studied. The most significant 
example of an orally active peptide is that of the immunosuppressive undecapeptide cyclosporine 
A (Figure 5.3). The permeability of cyclosporine A (Caco-2 Papp (A-B) = 1 x 10
-6
 cm/s at a 
concentration of 0.5 M) is thought to occur through passive diffusion, but there also exists 
evidence for carrier mediated efflux, presumably by Pgp.
76
 Cyclosporine A has several unusual 
physicochemical properties that affect its absorption. Nine of the eleven peptide bonds in 
cyclosporine are methylated, reducing the number of hydrogen bonding positions. The N-methyl 
groups, lack of charged groups and the partial -sheet conformation result in high lipophilicity 
and low aqueous solubility, and hence the peptide requires emulsifying formulations for drug 
delivery.
77, 78
 The L- and D-Trp isomers of the opioid macrocyclic natural product CJ-15,208 
have been shown to exhibit opioid activity after oral administration
79, 80
 (see chapter 6 for more 
information). Lokey and coworkers have identified a membrane permeating orally bioavailable 
peptide scaffold. The macrocyclic hexapeptide (cyclo[Leu-NMe-D-Leu-NMe-Leu-Leu-D-Pro-
NMe-Tyr]) possessed an impressive oral bioavailability of 28% in rat.
81
 Kessler and coworkers 
synthesized N-methyl analogs of the somatostatin receptor agonist cyclo(-Pro-Phe-D-Trp-Lys-
                                                                                                                                                         
173 
 
Thr-Phe-) (Figure 5.3), also known as the Veber-Hirschmann peptide, and studied their 
permeability in the Caco-2 intestinal model. Among the various N-methyl analogs synthesized, 
an analog with three methyl substituents displayed an absolute oral bioavailability of 9.9% in rats 
and had 8- to 10-fold higher apparent permeability (Papp) as compared to the parent peptide (Papp  
= 0.5 x 10
-6
 cm/sec).
82
 In order to evaluate the effect of multiple methyl groups on the 
bioavalability of peptides, Kessler and coworkers also synthesized a polyalanine cyclic 
hexapeptide library (Figure 5.3) varying in the number and position of the N-methyl groups. The 
peptides were evaluated for intestinal permeability in the Caco-2 model, and selected peptides 
displayed Papp > 1 x 10
-5
 cm/sec. A methyl group placed adjacent to the D-Ala residue was a 
common structural feature in most of the analogs that displayed high Papp values. While the exact 
transport route was not characterized, the peptides did not appear to be transported by passive or 
active transcellular route and were likely transported by facilitated diffusion.
83
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Figure 5.3. Peptides exhibiting intestinal absorption 
Borchardt and coworkers developed the concept of using cyclic peptide prodrugs to 
modify the physicochemical properties of peptides to increase intestinal permeability and thereby 
enhance oral bioavalability.
84
 The acyloxyalkoxy (ACA),
85
 phenylpropionic acid (PPA)
86
 and 
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coumarinic acid (CA)
87
 based cyclic prodrugs of DADLE were synthesized (Figure 5.4)  and 
evaluated for their permeation characteristics in the Caco-2cell monolayer model. As expected 
the Papp of DADLE was very low (7.8 ±  0.7 x 10
-8
 cm/sec). While the CA
87
 and PPA
86
 prodrugs 
showed 31- and 72-fold increased Caco-2 permeability, respectively, the the ACA
85
 prodrugs 
displayed 4-fold lower transport as compared to DADLE. While the CA
87
 and PPA
86
 prodrugs 
did not appear to be substrates for efflux transporters, the low permeability of ACA
85
 prodrug 
suggested that it might be acting as a substrate for at least one of the efflux transporters present 
in Caco-2 cells. However, subsequent studies with the CA prodrugs suggested that it was a 
substrate for P-glycoprotein and MRP-2 efflux transporters present in Caco-2 cells.
88
 In addition, 
a modified CA prodrug (Figure 5.4) was also found to be a substrate for both Pgp and MRP2.
89
 
This difference with the previous results was attributed to the different lots of Caco-2 cells 
used.
88
 Borchardt and coworkers also studied the effects of Pgp inhibitors on the blood-brain 
barrier (BBB) permeation of cyclic prodrugs of DADLE in MDR1-MDCK cells and showed that 
Pgp is the major determinant affecting the permeability of these prodrugs across this model of 
the BBB.
90
 They also performed transport studies of cyclic prodrugs of DADLE in the in situ 
perfused rat ileum model.
91
 In these studies the cyclic prodrugs exhibited low permeation and 
were also found to be substrates for Pgp. In addition, efflux by other transporters and/or drug 
metabolizing enzymes were likely to play a role in their low permeation.  
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Figure 5.4. Bioconversion of peptide cyclic prodrugs to peptides. (a) ACA,
85
 (b) PPA,
86
 (c) CA,
87
 
and (d) modified CA
89
 cyclic prodrugs. 
5.4 Methods for evaluation of intestinal permeability 
5.4.1 Physicochemical methods 
Lipophilicity is one of the most important physicochemical parameters for predicting 
intestinal absorption of drugs. Historically, the octanol-water partition coefficient (log P) was 
used for predicting absorption. While there is generally a correlation between log P and 
absorption that appears to hold true for passively transported drugs that are not subject to efflux, 
the correlation may not hold true for drugs that are transported by active transport.
92
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Immobilized artificial membrane chromatography (IAMC) is a technique which consists 
of phospholipid molecules covalently attached to the silica particles of the column. IAMC is 
efficient, cost effective and can predict permeability of passively permeable compounds.
93
 
However, the permeability of actively transported compounds cannot be predicted by this 
method.
93
 IAMC has also been used to predict solute partitioning into liposomes, brain uptake 
and human skin permeability.
1
 Giralt and coworkers used IAMC to evaluate NMe-Phe rich 
peptides as BBB shuttles for carrying drug cargoes into the CNS.
94, 95
 The permeability of the 
peptides correlated well with the phospholipophilicity (kIAM) obtained by IAMC until the number 
of NMe-Phe residues was increased to four in the peptides. However, with further increase in the 
number of NMe Phe residues, the phospholipophilicity obtained by IAMC was too high for the 
peptide to permeate through the artificial membrane in the parallel artificial membrane 
permeability (PAMPA) assay.
94
  
PAMPA
96
 method consists of a hydrophobic filter material that is impregnated with a 
solution of lecithin in an inert organic solvent such as dodecane or hexadecane. The lecithin 
solution is adsorbed on to a porous frit that mimics a membrane and the permeability of drugs 
through this membrane is studied. The results obtained from this assay show an excellent 
correlation with the extent of absorption of a diverse set of well characterized drugs in humans.
96
 
Although it has high throughput capability, it suffers from similar limitations as the IAMC 
technique. Giralt and coworkers studied NMe-Phe rich peptides as BBB shuttles for carrying 
drug cargoes into the CNS in the PAMPA model. Among the various NMe-Phe rich peptides 
studied, the peptides containing NMe-Phe as the N-terminal amino acid showed high 
permeability in PAMPA and were the best shuttles for carrying drug cargoes into the CNS.
95
 
Kessler and coworkers studied permeability of macrocyclic hexapeptides with multiple N-methyl 
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groups in different positions in the PAMPA model. While N-methylation was shown to increase 
permeability as compared to the non-methylated peptides in the Caco-2 model, none of them 
permeated through the PAMPA artificial membranes, suggesting that N-methylation does not 
facilitate transcellular permeability of the cyclic hexapeptides.
83
 
5.4.2 In vitro methods 
The in vitro techniques used for assessment of intestinal absorption are less laborious and 
cost intensive compared to in vivo analyses. However, the effects of physiological factors during 
absorption such as gastric emptying, gastrointestinal pH, etc. are not taken into account in these 
methods. 
5.4.2.1 Animal tissue based methods 
The everted gut technique
97
 involves incubation of the everted sacs of the rodent 
intestinal region of interest in appropriate media which contains the drug solution. The drug 
transport is monitored by measuring concentration of drug inside the sacs.  It is an ideal model 
for studying intestinal absorption as it can be applied for drugs transported by both active and 
passive transport. However, the gut lacks active blood supply and hence this can lead to rapid 
loss of viability. Additionally, everting the gut can cause morphological changes leading to 
erroneous results.
1
 
The Ussing method
98
 involves isolation of intestinal tissue, which is cut into strips of 
appropriate size and clamped it to a suitable device for measurement of drug transport across the 
tissue. The method is ideal for studying the regional differences on the absorption of drugs by 
mounting tissues from different intestinal areas. However, it also suffers from the same 
limitations as mentioned above for the everted gut technique.
1
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5.4.2.2 Cell based methods 
5.4.2.2.1 Caco-2 model of intestinal permeability 
The Caco-2 cell monolayer model is the most extensively used model for evaluating 
intestinal drug permeability and absorption. Caco-2 cells were obtained from a human colon 
adenocarcinoma.
99-102
 They undergo spontaneous enterocytic differentiation and grow to 
confluency on semipermeable porous filters in 21 days. This model is used for mechanistic 
studies and as an in vitro screening tool for assessing the permeability of drugs. However, there 
remains variability in the absolute permeability coefficients of the individual compounds due to 
differences in the source of Caco-2 cells, differences in the cell culture conditions, the 
composition of cell subpopulations, procedures for transport experiments and calculation 
methods. This model can be used to measure both active and passive transport. The Caco-2 
model can give false negative results as the cell monolayer appears to be exhibit tighter junctions 
than the human small intestine due to its colonic origin.
103
 For example, ranitidine and atenolol 
showed poor permeability in this model despite adequate absorption in humans.
1
 Furthermore, 
there is also a limit to the amount of organic solvent that can be used in the Caco-2 assay. Hence, 
a significant percentage of new lipophilic drug entities cannot be evaluated in this model.
1
  
I. Factors that affect Caco-2 monolayer permeability 
a. Factors related to the Caco-2 cells 
 Caco-2 cells are a heterogeneous cell population with different morphologies
104
 and with 
varying levels of Pgp expression and function.
105, 106
 Differences have been noted in the 
transepithelial electric resistance (TEER) and in the permeability values of low and high 
permeability standards in Caco-2 cells from different sources.
107
 Differences were also noted in 
the cell shape and size, multilayer formation, expression levels of influx and efflux transporters 
and actin staining.
108
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It has been shown that differences in passage number can cause variations in TEER, cell 
growth and mannitol flux.
109
 The passaging procedure affects the biological and the barrier 
properties of Caco-2 monolayers with a selection for faster growing subpopulations.
110
 The 
passage number affects efflux mediated by the Caco-2 cells because of variations in the 
expression of efflux pumps including Pgp.
111
 
The cell seeding density on the semi-porous filters affects the time taken for the cells to 
proliferate and subsequently differentiate. A lower seeding density can cause incomplete 
formation of a monolayer, while higher seeding density can cause formation of multilayers. Also 
the expression levels of Pgp were found to decrease with increasing cell density.
112
 
The age of the monolayer influences the morphology, barrier properties and expression of 
transporters. The cells exhibit different morphologies at different monolayer ages.
101
 On 
polycarbonate (PC) filters initial cell migration occurs on day 2 followed by subconfluency on 
day 4 and apparent confluency on day 6.
113
 Using phalladoin for visualizing cell morphology, it 
was found that a thin monolayer was formed on day 7, a well-established brush border was 
formed on day 21 and multi-layer formation was observed on day 28.
112
 Hence, differences can 
occur in the permeability values depending on the day the transport experiments are performed. 
It was also found that the TEER values are higher and permeability values for mannitol, a low 
permeability standard, were lower with an increase in the age of the monolayers.
114
 There are 
different findings reported concerning whether the expression levels of Pgp are affected by 
monolayer age.
111, 115
 
The cell source also causes significant variations in the levels of transporter expression
106
 
(see the next section for a detailed discussion). 
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b. Factors related to the media 
Different components of the cell culture media and frequency of cell feeding can also 
influence Caco-2 cell monolayer integrity, expression levels of transporters and permeability 
values. The concentrations of both glucose and glutamine in the culture media can affect the tight 
junctions and the barrier properties of Caco-2 monolayers.
116, 117
 The frequency of changing the 
culture media affects the activity of the enzymes present in the cell membranes and the 
expression of various transporters in Caco-2 cells.
118
 Consequently, this can affect the 
permeability of substrates transported by active transport. The presence of serum in the media 
can also influence tight junction formation, and monolayers nourished with serum-containing 
media displayed higher TEER values than those without serum.
119
 Knipp and coworkers showed 
that the source of Caco-2 cells and the media composition caused significant variations in 
transporter expression.
106
 For example, Pgp was expressed approximately 7-fold higher in cells 
obtained from ATCC as compared to cells obtained from Dr. Thomas Cook’s laboratory 
(Rutger’s University) cultured in minimum essential medium alpha (AMEM) and approximately 
3-fold higher in cells obtained from ATCC as compared to cells from Dr Cook’s laboratory 
cultured in Dulbecco’s modified Eagle’s medium (DMEM). Further, the differences in the 
expression levels of Pgp were decreased when cells from both the sources were cultured in 
DMEM as compared to those cultured in AMEM. Similar differences were obtained in the case 
of several other SLC transporter family members.
106
    
The pH of the transport buffer determines the ionization state of drugs which can affect 
drug permeability. While the permeability of acidic drugs was greater in a buffer with pH 5.4, 
the permeability of basic drugs was greater in buffer with pH 7.2.
120 
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c. Factors related to other experimental conditions 
The characteristics of the semi-porous filter, including its composition, diameter, and 
pore size can also affect cell proliferation and differentiation. The type of filter material can 
affect the thickness of the monolayer and the morphology of the cells. It was also found that 
Caco-2 monolayers were more prevalent on PC filters as compared to polyethylene terephthalate 
(PET) filters where multilayers were observed.
121
 Filters with pores greater than 1 M resulted in 
cell migration and subsequent loss of polarity.
113
 The TEER values increased with an increase in 
the filter diameter from 6.5 to 12 to 24 mm.
122
 It was also noted that Pgp expression decreased 
with increased cell culture time if cells were grown in plastic flasks, whereas growing the cells 
on PC filters led to an increase in the expression of Pgp.
111
  
Collagen coating can accelerate cell proliferation and development of cell monolayers 
and also influences drug adsorption.
123
 The presence of a collagen coating was found to increase 
the expression levels of transporters.
112
 
Variation in agitation can result in variability in the transport of drugs by passive 
diffusion. Passive diffusion across the barrier is a combination of diffusion through the unstirred 
water layer (UWL) and the cell monolayer.
114
 It has been shown that the absorption of highly 
permeable lipophilic, poorly water soluble drugs is significantly affected by the UWL.
124
 
Agitation or stirring during the transport experiments reduces the thickness of the UWL.
125
 An 
increase in agitation increases the permeability of poorly water soluble, passively transported 
compounds.
126
  
Variations can arise in the Papp values depending on whether permeability is analyzed 
using a single time point or multiple time points and also whether the calculations are performed 
using a fixed donor compartment concentration for all time points or by adjusting the donor 
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concentration for drug loss over time.  In the case of high permeability drugs, Papp values can be 
higher for multiple time points rather than a single time point.
127
 Varying permeability values 
can also be obtained through calculations depending on whether they take into account cellular 
retention and filter adsorption.
128, 129
 
II. Comparison of the transporter expression levels in the human small intestine and 
the Caco-2 cells 
Seithel et al. determined a general ranking of the mRNA expression levels of the 
transporters in Caco-2 cells and human jejunal tissue (Table 5.1).
21
 In Caco-2 cells it was: MRP2 
> OATPB > PEPT1 >> MDR1 > monocarboxylate transporter (MCT1) ~ MRP3 ~ BCRP ~ 
OCT-N2 ~ OCT3 ~ OCT1 > organic anion transporter (OAT)-2. The general rank order of the 
transporters in human jejunal tissues was found to be PEPT1 >> MRP2 ~ MDR1 ~ BCRP > 
MRP3 > OCTN2 > MCT1 > OATP-B > OCT1 > OAT2 ~ OCT3. Quantitatively, PEPT1 was 10-
fold, MDR1 7-fold and MRP2 2-fold lower in Caco-2 cells compared to human jejunum. 
Similarly, the genes with intermediate expression levels in human jejunum were also expressed 
2- to 7-fold lower in Caco-2 cells. An exception was OATP-B, which was expressed at 13-fold 
higher levels in Caco-2 cells as compared to the human jejunum. However, there is some 
uncertainty in data for OATP-B due to the low amplification efficiency of this transporter. 
However, in contrast to the above finding, Yee and coworkers reported that Pgp is overexpressed 
in the Caco-2 cells as compared to the human intestine.
130
 The significant difference in the 
expression levels of the transporter is an important factor to be considered when analyzing the 
permeability data obtained from the Caco-2 cell based model.  
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Table 5.1 Transporter ranking according to their relative gene expression in Caco-2 cells and 
human jejunum
21
 
Transporter Caco-2 cells
a
 Human Jejunum
a
 
MRP2 1 2 
OATP-B 2 8 
PEPT1 3 1 
MDR1 4 3 
MCT1 5 7 
MRP3 6 5 
BCRP 7 4 
OCTN2 8 6 
OCT3 9 11 
OCT1 10 10 
OAT2 11 9 
 a
 1 corresponds to the transporter with the highest expression and 11 corresponds  
to the transporter with the lowest transporter expression. 
 
TC-7 and 2/4/A1 are alternative cell-based models to the Caco-2 model. However, they 
display certain limitations and hence they have not replaced the Caco-2 model for evaluating 
intestinal permeability. TC-7 is a subclone isolated from the Caco-2 cells that has similar 
morphology as the Caco-2 cells and gives higher TEER values after 21 days as compared to the 
Caco-2 cell line.
131
 However, the TC-7 has been shown to be unsuitable for predicting 
permeability of highly lipophilic drugs, drugs that have low-moderate intestinal absorption and 
drugs that are actively transported.
132
  The 2/4/A1 cells originate from fetal rat intestine.
133
 
However, they do not display the morphological properties of a fully differentiated human 
intestine. This is because the 2/4/A1 cell line is obtained from a fetal rat intestine at 18 day 
gestation, when the rat intestine is not well differentiated. However, the human fetal intestine is 
well differentiated at this time point. While the2/4/A1 cells express intestinal brush border 
enzymes, efflux transporters such as Pgp, MRP and BCRP are not functional in these cells.
133, 134
 
In addition these cells do not express the dipeptide transporter PEPT1.
134
 Hence the 2/4/A1 cells 
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are also considered unsuitable for evaluating actively transported compounds or identifying 
potential Pgp substrates. 
5.4.2.2.2 MDCK cell based model  
The Madin Darby canine kidney (MDCK) cells differentiate into columnar epithelial 
cells and form tight junctions, and hence are used as a model to assess permeability of drug 
molecules.
135
 A good correlation has been obtained between the permeability values obtained 
from MDCK cell and Caco-2 cell monolayers for passively transported drugs;
136
 however, more 
extensive studies are required to confirm this for actively transported drugs. MDCK cells have 
been transfected with various transporter genes to produce MDCK cell lines that express selected 
transporters. For example, the MDCK cells are transfected with the mdr1 gene responsible for 
expressing Pgp to produce MDR1-MDCK cells. The shorter culture time (3 days vs. 3 weeks) 
give the MDCK cells a major advantage over the Caco-2 cell model.
136
 However, the difference 
in species and organ is a disadvantage of the MDCK cell line compared to the Caco-2 cell line 
which was obtained from human colon. The tendencies of transfected MDCK cells to form 
multi-layers and loss of polarization in the lower layers of cells are also disadvantages for 
permeability studies.
137
 Borchardt and coworkers showed that the apparent kinetic constants and 
affinities of substrates determined in MDR1-MDCK and MRP2-MDCK cell monolayers may be 
different from those obtained in Caco-2 cell monolayers.
138, 139
 These differences were suggested 
to result from differences in the relative expression levels of total Pgp and MRP in Caco-2 and 
transfected MDCK cells, different orientations of the Pgp or MRP in the two cell lines and/or the 
different partitioning of substrates into the cell membranes.
138, 139
  
Recently, MDCK cells have been used as an intestinal model to study the transport of 
exedin-4, a 39 amino acid anti-diabetic peptide. To improve patient compliance efforts are being 
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made towards development of its oral administration. It displayed low permeability (0.10 ± 0.06 
× 10
-6
 cm/s) and showed time dependence and, energy independence transport indicative of 
passive transport.
140
 The effect of a self nano-emulsifying drug delivery system (SNEDDS) on 
the transport of insulin phospholipid complex (IPC) was evaluated in the MDCK cell monolayers 
and shown to enhance the transport of IPC.
141
 
5.4.3 In situ method 
This method utilizes in situ perfusion of intestinal segments to study the permeability of 
drugs.
142-145
 The cannulated intestinal segments are perfused with the drug solution prepared in 
physiological buffer, and the absorption of the drug is assessed on the basis of the disappearance 
of the drug from the intestinal lumen. The major advantage of this technique as compared to 
other techniques is the intact blood and nerve supply to the tissue in the experimental animals. 
The method is highly accurate for predicting permeability by passive diffusion.
146
 Although this 
method accurately predicts drug absorption, it is costly as it requires a large number of animals 
to get statistically significant results and also requires large amounts of compound. 
Administration of anesthesia and surgery can also cause significant changes in blood flow to the 
intestine which can affect the rate of compound absorption. Another major disadvantage of this 
method involves its dependence on the disappearance of the compound from the luminal side as 
an indication of absorption, since the decrease in the concentration in the perfusate may not 
always represent the rate of absorption, especially in cases where intestinal or presystemic 
metabolism occurs.
1  
5.4.4 In vivo methods  
Bioavailability studies are performed in laboratory animal models to predict the rate and 
extent of drug absorption in humans. The conventional method of estimating oral bioavailability 
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is through administration of systemic intravenous (IV) and oral doses with a washout period 
between administrations.  The order of IV and oral doses can be randomized. The drug 
concentration is plotted vs. time and the oral bioavailability is defined as the area under the curve 
(AUC) of the drug administered by the oral route divided by the AUC obtained following IV 
administration. The underlying assumption in this setting is that the clearance of the drug from 
one dose to the next remains constant. However, some drugs are able to modify their absorption, 
distribution, metabolism and excretion by induction or inhibition of cytochrome P450s which 
can affect the time course of the subsequent dose.  
5.5 Common challenges pertaining to analysis of poorly water soluble drugs 
Drug transport experiments of poorly water soluble drugs involve various challenges. For 
poorly water soluble compounds the stock solution of the drug, generally in DMSO, when added 
to the aqueous transport buffer can result in immediate precipitation. Filtration of the drug 
solution prior to the experiment removes the insoluble drug particles, but may result in a low 
concentration of drug that is below the limit of analytical detection.
147
 Without filtration, the 
drug solutions may be heterogeneous suspensions which can result in variations in the drug 
concentration and low reproducibility.
124
 Lipophilic drugs can adsorb to plastic and the filter 
support, and accumulation within the barrier can cause loss of compound, poor recovery and low 
mass balance, which in turn can also result in erroneous permeability values. 
124
  
For in vitro models one technique to improve the ability to measure permeability is to 
establish sink conditions throughout the course of the experiment. Passive diffusion is driven by 
a concentration gradient. If sink conditions aren’t maintained passive diffusion may not occur 
because of loss of a concentration gradient. Practically for sink conditions to be maintained the 
concentration of the receiver compartment should not exceed 10% of the concentration in the 
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donor compartment.
124
 Maintaining sink conditions can be problematic in the case of poorly 
soluble drugs
124
 and can have a major impact while studying transport of low solubility and high 
permeability compounds.
148
 Maintaining sink conditions in the case of low solubility compounds 
avoids saturation in the receiver compartment, and in the case of high permeability compounds 
inhibits the back diffusion to the donor compartment.
148
  
5.6 Experimental modifications for poorly water soluble compounds 
5.6.1 Modifications in the media composition 
Several excipients can be used for solubilizing poorly soluble drugs, but the effect of the 
excipient on drug solubility and drug permeability can vary in a compound dependent manner.
149
 
Different excipients also have variable effects on the monolayer integrity of Caco-2 cells. 
Solubilizing agents that have been used in Caco-2 studies include organic cosolvents such as 
dimethylsulfoxide (DMSO), N,N-dimethylacetamide (DMA), N-methylpyrrolidone (NMP), and 
cyclic polysaccharide cyclodextrins.
150, 151
  
Solubilizing agents, especially surfactants such Cremaphor EL and Tween 80, appear to 
diminish the activity of efflux transporters, 
152, 153
 and hence the permeability values obtained for 
drugs differ with changes in the concentration of excipient used.
154
 The use of solubilizing agents 
such as surfactants in transport studies can compromise the free drug concentration due to 
micellization. Hence, to avoid erroneous conclusions the data must be corrected for the free 
concentration of the drug. The data can be corrected by a method called the reciprocal 
permeability approach.
155
 It enables the calculation of true Papp via extrapolation of the Papp 
measured at three surfactant concentrations above the critical micellar concentration.  
Highly lipophilic compounds tend to adsorb to cell membranes. Inclusion of bovine 
serum albumin (BSA) appears to minimize the binding of compounds to cell membranes and 
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also reduces non-specific binding of the drug to experimental apparatus.
156
 Recovery values of 
the compounds can be increased with inclusion of BSA in the medium.
157, 158
 BSA also appears 
to mimic the in vivo sink conditions.
124
 Although inclusion of BSA appears to be beneficial in 
many respects, it increases the cost and the complexity of the study as an additional step of 
sample preparation is often involved.
158
   
Most permeability studies are performed in Hanks balanced salt solution (HBSS) without 
a pH gradient across the monolayers and without physiologically important molecules umsuch as 
phospholipids and bile salts. Utilizing a biologically relevant medium such as fasted state 
intestinal simulated fluid (FaSSIF)
159
 which contains both bile salts and phospholipids helps to 
mimic in vivo conditions and reduces non-specific adsorption of drugs. This biorelevant medium 
can also assist in solubilizing the poorly soluble drugs through micellization.
124
 However, the 
effects of these micelle forming agents on drug permeability studies are controversial and appear 
to be dependent on the transport mechanism of the drug.
124
 In addition, inclusion of biologically 
relevant macromolecules increases the complexity of sample preparation. For example, for non-
radioactive analytical methods, prior to analysis samples containing biologically relevant 
molecules like BSA must be treated with an organic solvent such as MeCN to precipitate 
proteins.
158  
5.7 References 
1. Balimane, P. V.; Chong, S.; Morrison, R. A. Current methodologies used for evaluation 
of intestinal permeability and absorption. J Pharmacol Toxicol Methods 2000, 44, 301-312. 
2. Johansson, M. E.; Phillipson, M.; Petersson, J.; Velcich, A.; Holm, L.; Hansson, G. C. 
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc 
Natl Acad Sci U S A 2008, 105, 15064-15069. 
                                                                                                                                                         
190 
 
3. Turner, J. R. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 
2009, 9, 799-809. 
4. Carr, K., and Toner, P., Morphology of the intestine. In Pharmacology of the intestine, 
Csaky, T., Ed. Springer and Verlag: New York, 1984; pp 1-50. 
5. Madara, J., and Trier, J., Functional morphology of the mucosa of the small intestine. In 
Physiology of the gastrointestinal tract, Johnson, L., Ed. Raven press: New York, 1987; pp 
1209-1249. 
6. Conardi, R. A.; Burton, R. T.; Borchardt, R. T., Physicochemical and biochemical factors 
that influence a drug's cellular permeability by passive diffusion. In Lipophilicity in Drug action 
and Toxicity, Plisaki, V.; Testa, B.; Waterbeend, H. V., Eds. VCH: Weinheim, 1996; pp 233-252. 
7. Sarmento, B.; Andrade, F.; da Silva, S. B.; Rodrigues, F.; das Neves, J.; Ferreira, D. Cell-
based in vitro models for predicting drug permeability. Expert Opin Drug Metab Toxicol 2012, 
8, 607-621. 
8. Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G. F.; 
Faller, B.; Fischer, H.; Gerebtzoff, G.; Lennernaes, H.; Senner, F. Coexistence of passive and 
carrier-mediated processes in drug transport. Nat Rev Drug Discov 2010, 9, 597-614. 
9. Martinez, M. N.; Amidon, G. L. A mechanistic approach to understanding the factors 
affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002, 42, 620-643. 
10. Artursson, P.; Palm, K.; Luthman, K. Caco-2 monolayers in experimental and theoretical 
predictions of drug transport. Adv Drug Deliv Rev 2001, 46, 27-43. 
11. Terada, T.; Inui, K. Recent advances in structural biology of Peptide transporters. Curr 
Top Membr 2012, 70, 257-274. 
                                                                                                                                                         
191 
 
12. Hagenbuch, B.; Meier, P. J. The superfamily of organic anion transporting polypeptides. 
Biochim Biophys Acta 2003, 1609, 1-18. 
13. Chothe, P. P.; Thakkar, S. V.; Gnana-Prakasam, J. P.; Ananth, S.; Hinton, D. R.; Kannan, 
R.; Smith, S. B.; Martin, P. M.; Ganapathy, V. Identification of a novel sodium-coupled 
oligopeptide transporter (SOPT2) in mouse and human retinal pigment epithelial cells. Invest 
Ophthalmol Vis Sci 2010, 51, 413-420. 
14. Ananth, S.; Karunakaran, S.; Martin, P. M.; Nagineni, C. N.; Hooks, J. J.; Smith, S. B.; 
Prasad, P. D.; Ganapathy, V. Functional identification of a novel transport system for 
endogenous and synthetic opioid peptides in the rabbit conjunctival epithelial cell line CJVE. 
Pharm Res 2009, 26, 1226-1235. 
15. Thakkar, S. V.; Miyauchi, S.; Prasad, P. D.; Ganapathy, V. Stimulation of Na+/Cl--
coupled opioid peptide transport system in SK-N-SH cells by L-kyotorphin, an endogenous 
substrate for H+-coupled peptide transporter PEPT2. Drug Metab Pharmacokinet 2008, 23, 254-
262. 
16. Chothe, P.; Singh, N.; Ganapathy, V. Evidence for two different broad-specificity 
oligopeptide transporters in intestinal cell line Caco-2 and colonic cell line CCD841. Am J 
Physiol Cell Physiol 2011, 300, C1260-1269. 
17. Hu, H.; Miyauchi, S.; Bridges, C. C.; Smith, S. B.; Ganapathy, V. Identification of a 
novel Na+- and Cl--coupled transport system for endogenous opioid peptides in retinal pigment 
epithelium and induction of the transport system by HIV-1 Tat. Biochem J 2003, 375, 17-22. 
18. Hayer-Zillgen, M.; Bruss, M.; Bonisch, H. Expression and pharmacological profile of the 
human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 2002, 136, 829-
836. 
                                                                                                                                                         
192 
 
19. Bleasby, K.; Chauhan, S.; Brown, C. D. Characterization of MPP+ secretion across 
human intestinal Caco-2 cell monolayers: role of P-glycoprotein and a novel Na(+)-dependent 
organic cation transport mechanism. Br J Pharmacol 2000, 129, 619-625. 
20. Martel, F.; Grundemann, D.; Calhau, C.; Schomig, E. Apical uptake of organic cations by 
human intestinal Caco-2 cells: putative involvement of ASF transporters. Naunyn Schmiedebergs 
Arch Pharmacol 2001, 363, 40-49. 
21. Seithel, A.; Karlsson, J.; Hilgendorf, C.; Bjorquist, A.; Ungell, A. L. Variability in 
mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between 
human segments and Caco-2 cells. Eur J Pharm Sci 2006, 28, 291-299. 
22. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: 
efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004, 21, 25-51. 
23. Higgins, C. F.; Hiles, I. D.; Salmond, G. P.; Gill, D. R.; Downie, J. A.; Evans, I. J.; 
Holland, I. B.; Gray, L.; Buckel, S. D.; Bell, A. W.; et al. A family of related ATP-binding 
subunits coupled to many distinct biological processes in bacteria. Nature 1986, 323, 448-450. 
24. Hyde, S. C.; Emsley, P.; Hartshorn, M. J.; Mimmack, M. M.; Gileadi, U.; Pearce, S. R.; 
Gallagher, M. P.; Gill, D. R.; Hubbard, R. E.; Higgins, C. F. Structural model of ATP-binding 
proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 
1990, 346, 362-365. 
25. Suzuki, H.; Sugiyama, Y. Role of metabolic enzymes and efflux transporters in the 
absorption of drugs from the small intestine. Eur J Pharm Sci 2000, 12, 3-12. 
26. Fricker, G.; Drewe, J.; Huwyler, J.; Gutmann, H.; Beglinger, C. Relevance of p-
glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J 
Pharmacol 1996, 118, 1841-1847. 
                                                                                                                                                         
193 
 
27. Rost, D.; Mahner, S.; Sugiyama, Y.; Stremmel, W. Expression and localization of the 
multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol 
Gastrointest Liver Physiol 2002, 282, G720-726. 
28. Hunter, J.; Jepson, M. A.; Tsuruo, T.; Simmons, N. L.; Hirst, B. H. Functional expression 
of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine 
secretion and interaction with modulators. J Biol Chem 1993, 268, 14991-14997. 
29. Terao, T.; Hisanaga, E.; Sai, Y.; Tamai, I.; Tsuji, A. Active secretion of drugs from the 
small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J 
Pharm Pharmacol 1996, 48, 1083-1089. 
30. Loo, T. W.; Bartlett, M. C.; Clarke, D. M. Substrate-induced conformational changes in 
the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced 
fit mechanism for drug binding. J Biol Chem 2003, 278, 13603-13606. 
31. Taipalensuu, J.; Tornblom, H.; Lindberg, G.; Einarsson, C.; Sjoqvist, F.; Melhus, H.; 
Garberg, P.; Sjostrom, B.; Lundgren, B.; Artursson, P. Correlation of gene expression of ten drug 
efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in 
human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001, 299, 164-170. 
32. Naruhashi, K.; Tamai, I.; Inoue, N.; Muraoka, H.; Sai, Y.; Suzuki, N.; Tsuji, A. Active 
intestinal secretion of new quinolone antimicrobials and the partial contribution of P-
glycoprotein. J Pharm Pharmacol 2001, 53, 699-709. 
33. Naruhashi, K.; Tamai, I.; Inoue, N.; Muraoka, H.; Sai, Y.; Suzuki, N.; Tsuji, A. 
Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin 
in rats. Antimicrob Agents Chemother 2002, 46, 344-349. 
                                                                                                                                                         
194 
 
34. Lowes, S.; Cavet, M. E.; Simmons, N. L. Evidence for a non-MDR1 component in 
digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 2003, 458, 49-
56. 
35. Walgren, R. A.; Karnaky, K. J., Jr.; Lindenmayer, G. E.; Walle, T. Efflux of dietary 
flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical 
multidrug resistance-associated protein-2. J Pharmacol Exp Ther 2000, 294, 830-836. 
36. Dietrich, C. G.; Geier, A.; Oude Elferink, R. P. ABC of oral bioavailability: transporters 
as gatekeepers in the gut. Gut 2003, 52, 1788-1795. 
37. Wang, X.; Furukawa, T.; Nitanda, T.; Okamoto, M.; Sugimoto, Y.; Akiyama, S.; Baba, 
M. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 
nucleoside reverse transcriptase inhibitors. Mol Pharmacol 2003, 63, 65-72. 
38. de Aizpurua, H. J.; Russell-Jones, G. J. Oral vaccination. Identification of classes of 
proteins that provoke an immune response upon oral feeding. J Exp Med 1988, 167, 440-451. 
39. Sanderson, I. R.; Walker, W. A. Uptake and transport of macromolecules by the intestine: 
possible role in clinical disorders (an update). Gastroenterology 1993, 104, 622-639. 
40. Sai, Y.; Kajita, M.; Tamai, I.; Wakama, J.; Wakamiya, T.; Tsuji, A. Adsorptive-mediated 
endocytosis of a basic peptide in enterocyte-like Caco-2 cells. Am J Physiol 1998, 275, G514-
520. 
41. Terasaki, T.; Hirai, K.; Sato, H.; Kang, Y. S.; Tsuji, A. Absorptive-mediated endocytosis 
of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. J Pharmacol Exp 
Ther 1989, 251, 351-357. 
                                                                                                                                                         
195 
 
42. Terasaki, T.; Deguchi, Y.; Sato, H.; Hirai, K.; Tsuji, A. In vivo transport of a dynorphin-
like analgesic peptide, E-2078, through the blood-brain barrier: an application of brain 
microdialysis. Pharm Res 1991, 8, 815-820. 
43. Marinova, Z.; Vukojevic, V.; Surcheva, S.; Yakovleva, T.; Cebers, G.; Pasikova, N.; 
Usynin, I.; Hugonin, L.; Fang, W.; Hallberg, M.; Hirschberg, D.; Bergman, T.; Langel, U.; 
Hauser, K. F.; Pramanik, A.; Aldrich, J. V.; Graslund, A.; Terenius, L.; Bakalkin, G. 
Translocation of dynorphin neuropeptides across the plasma membrane. A putative mechanism 
of signal transmission. J Biol Chem 2005, 280, 26360-26370. 
44. Pauletti, G. M. G., S.; Knipp, G. T.;  Nerurkar, M. M.; Okumu, F. W.;  Tamura, K.;  
Siahaan, T. J.; Borchardt, R. T. Structural requirements for intestinal absorption of peptide drugs. 
J Control Release 1996, 41, 3-17. 
45. Pauletti, G. M.; Okumu, F. W.; Borchardt, R. T. Effect of size and charge on the passive 
diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm Res 
1997, 14, 164-168. 
46. Borchardt, R. T.; Jeffrey, A.; Siahaan, T. J.; Gangwar, S.; Pauletti, G. M. Improvement of 
oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 1997, 
27, 235-256. 
47. Burton, P. S.; Conradi, R. A.; Ho, N. F.; Hilgers, A. R.; Borchardt, R. T. How structural 
features influence the biomembrane permeability of peptides. J Pharm Sci 1996, 85, 1336-1340. 
48. Ogihara, H.; Saito, H.; Shin, B. C.; Terado, T.; Takenoshita, S.; Nagamachi, Y.; Inui, K.; 
Takata, K. Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem 
Biophys Res Commun 1996, 220, 848-852. 
                                                                                                                                                         
196 
 
49. Shen, H.; Smith, D. E.; Yang, T.; Huang, Y. G.; Schnermann, J. B.; Brosius, F. C., 3rd. 
Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein 
in rat kidney. Am J Physiol 1999, 276, F658-665. 
50. Terada, T.; Sawada, K.; Irie, M.; Saito, H.; Hashimoto, Y.; Inui, K. Structural 
requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. 
Pflugers Arch 2000, 440, 679-684. 
51. Theis, S.; Hartrodt, B.; Kottra, G.; Neubert, K.; Daniel, H. Defining minimal structural 
features in substrates of the H(+)/peptide cotransporter PEPT2 using novel amino acid and 
dipeptide derivatives. Mol Pharmacol 2002, 61, 214-221. 
52. Adibi, S. A. The oligopeptide transporter (Pept-1) in human intestine: biology and 
function. Gastroenterology 1997, 113, 332-340. 
53. Liang, R.; Fei, Y. J.; Prasad, P. D.; Ramamoorthy, S.; Han, H.; Yang-Feng, T. L.; 
Hediger, M. A.; Ganapathy, V.; Leibach, F. H. Human intestinal H+/peptide cotransporter. 
Cloning, functional expression, and chromosomal localization. J Biol Chem 1995, 270, 6456-
6463. 
54. Saito, H.; Inui, K. Dipeptide transporters in apical and basolateral membranes of the 
human intestinal cell line Caco-2. Am J Physiol 1993, 265, G289-294. 
55. Thwaites, D. T.; Brown, C. D.; Hirst, B. H.; Simmons, N. L. H(+)-coupled dipeptide 
(glycylsarcosine) transport across apical and basal borders of human intestinal Caco-2 cell 
monolayers display distinctive characteristics. Biochim Biophys Acta 1993, 1151, 237-245. 
56. Newstead, S.; Drew, D.; Cameron, A. D.; Postis, V. L.; Xia, X.; Fowler, P. W.; Ingram, J. 
C.; Carpenter, E. P.; Sansom, M. S.; McPherson, M. J.; Baldwin, S. A.; Iwata, S. Crystal 
                                                                                                                                                         
197 
 
structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 
and PepT2. EMBO J 2011, 30, 417-426. 
57. Solcan, N.; Kwok, J.; Fowler, P. W.; Cameron, A. D.; Drew, D.; Iwata, S.; Newstead, S. 
Alternating access mechanism in the POT family of oligopeptide transporters. EMBO J 2012, 31, 
3411-3421. 
58. Gao, B.; Hagenbuch, B.; Kullak-Ublick, G. A.; Benke, D.; Aguzzi, A.; Meier, P. J. 
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain 
barrier. J Pharmacol Exp Ther 2000, 294, 73-79. 
59. Dagenais, C.; Ducharme, J.; Pollack, G. M. Uptake and efflux of the peptidic delta-opioid 
receptor agonist. Neurosci Lett 2001, 301, 155-158. 
60. Hayeshi, R.; Hilgendorf, C.; Artursson, P.; Augustijns, P.; Brodin, B.; Dehertogh, P.; 
Fisher, K.; Fossati, L.; Hovenkamp, E.; Korjamo, T.; Masungi, C.; Maubon, N.; Mols, R.; 
Mullertz, A.; Monkkonen, J.; O'Driscoll, C.; Oppers-Tiemissen, H. M.; Ragnarsson, E. G.; 
Rooseboom, M.; Ungell, A. L. Comparison of drug transporter gene expression and functionality 
in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 2008, 35, 383-396. 
61. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A. L.; Karlsson, J. 
Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic 
cell lines. Drug Metab Dispos 2007, 35, 1333-1340. 
62. Zeller, P.; Clement, M.; Fessard, V. Similar uptake profiles of microcystin-LR and -RR 
in an in vitro human intestinal model. Toxicology 2011, 290, 7-13. 
63. Fastner, J.; Erhard, M.; von Dohren, H. Determination of oligopeptide diversity within a 
natural population of Microcystis spp. (cyanobacteria) by typing single colonies by matrix-
                                                                                                                                                         
198 
 
assisted laser desorption ionization-time of flight mass spectrometry. Appl Environ Microbiol 
2001, 67, 5069-5076. 
64. Fischer, W. J.; Altheimer, S.; Cattori, V.; Meier, P. J.; Dietrich, D. R.; Hagenbuch, B. 
Organic anion transporting polypeptides expressed in liver and brain mediate uptake of 
microcystin. Toxicol Appl Pharmacol 2005, 203, 257-263. 
65. Hermansky, S. J.; Markin, R. S.; Fowler, E. H.; Stohs, S. J. Hepatic ultrastructural 
changes induced by the toxin microcystin-LR (MCLR) in mice. J Environ Pathol Toxicol Oncol 
1993, 12, 101-106. 
66. Fricker, G.; Drewe, J.; Vonderscher, J.; Kissel, T.; Beglinger, C. Enteral absorption of 
octreotide. Br J Pharmacol 1992, 105, 783-786. 
67. Kohler, E.; Duberow-Drewe, M.; Drewe, J.; Ribes, G.; Loubatieres-Mariani, M. M.; 
Mazer, N.; Gyr, K.; Beglinger, C. Absorption of an aqueous solution of a new synthetic 
somatostatin analogue administered to man by gavage. Eur J Clin Pharmacol 1987, 33, 167-171. 
68. Fricker, G.; Bruns, C.; Munzer, J.; Briner, U.; Albert, R.; Kissel, T.; Vonderscher, J. 
Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization. 
Gastroenterology 1991, 100, 1544-1552. 
69. Amoss, M.; Rivier, J.; Guillemin, R. Release of gonadotropins by oral administration of 
synthetic LRF or a tripeptide fragment of LRF. J Clin Endocrinol Metab 1972, 35, 175-177. 
70. Nishi, N.; Arimura, A.; Coy, D.; Vilchez-Martinez, J. A.; Schally, A. V. The effect of 
oral and vaginal administration of synthetic LH-RH and [D-ALA-6, DES GLY-10-NH2]-LH-RH 
ethylamide on serum LH levels in ovariectomized, steroid blocked rats. Proc Soc Exp Biol Med 
1975, 148, 1009-1012. 
                                                                                                                                                         
199 
 
71. Langguth, P.; Bohner, V.; Biber, J.; Merkle, H. P. Metabolism and transport of the 
pentapeptide metkephamid by brush-border membrane vesicles of rat intestine. J Pharm 
Pharmacol 1994, 46, 34-40. 
72. Ogawa, T.; Miyamae, T.; Murayama, K.; Okuyama, K.; Okayama, T.; Hagiwara, M.; 
Sakurada, S.; Morikawa, T. Synthesis and structure-activity relationships of an orally available 
and long-acting analgesic peptide, N(alpha)-amidino-Tyr-D-Arg-Phe-MebetaAla-OH 
(ADAMB). J Med Chem 2002, 45, 5081-5089. 
73. Zhao, K.; Luo, G.; Zhao, G. M.; Schiller, P. W.; Szeto, H. H. Transcellular transport of a 
highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther 2003, 304, 425-432. 
74. Jinsmaa, Y.; Marczak, E. D.; Balboni, G.; Salvadori, S.; Lazarus, L. H. Inhibition of the 
development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-
Lys-NH-CH2-Ph. Pharmacol Biochem Behav 2008, 90, 651-657. 
75. Marczak, E. D.; Jinsmaa, Y.; Myers, P. H.; Blankenship, T.; Wilson, R.; Balboni, G.; 
Salvadori, S.; Lazarus, L. H. Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent 
mu/delta-opioid receptor antagonist, regulates obese-related factors in mice. Eur J Pharmacol 
2009, 616, 115-121. 
76. Augustijns, P. F.; Bradshaw, T. P.; Gan, L. S.; Hendren, R. W.; Thakker, D. R. Evidence 
for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. 
Biochem Biophys Res Commun 1993, 197, 360-365. 
77. Tarr, B. D.; Yalkowsky, S. H. Enhanced intestinal absorption of cyclosporine in rats 
through the reduction of emulsion droplet size. Pharm Res 1989, 6, 40-43. 
78. Fahr, A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993, 24, 472-495. 
                                                                                                                                                         
200 
 
79. Aldrich, J. V.; Senadheera, S. N.; Ross, N. C.; Ganno, M. L.; Eans, S. O.; McLaughlin, J. 
P. The Macrocyclic Peptide Natural Product CJ-15,208 Is Orally Active and Prevents 
Reinstatement of Extinguished Cocaine-Seeking Behavior. J Nat Prod 2013, 76, 433-438. 
80. Eans, S. O.; Ganno, M. L.; Reilley, K. J.; Patkar, K. A.; Senadheera, S. N.; Aldrich, J. V.; 
McLaughlin, J. P. The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting kappa 
opioid receptor antagonism in the CNS after oral administration. Br J Pharmacol 2013, 169, 
426-436. 
81. White, T. R.; Renzelman, C. M.; Rand, A. C.; Rezai, T.; McEwen, C. M.; Gelev, V. M.; 
Turner, R. A.; Linington, R. G.; Leung, S. S.; Kalgutkar, A. S.; Bauman, J. N.; Zhang, Y.; Liras, 
S.; Price, D. A.; Mathiowetz, A. M.; Jacobson, M. P.; Lokey, R. S. On-resin N-methylation of 
cyclic peptides for discovery of orally bioavailable scaffolds. Nat Chem Biol 2011, 7, 810-817. 
82. Chatterjee, J.; Gilon, C.; Hoffman, A.; Kessler, H. N-methylation of peptides: a new 
perspective in medicinal chemistry. Acc Chem Res 2008, 41, 1331-1342. 
83. Ovadia, O.; Greenberg, S.; Chatterjee, J.; Laufer, B.; Opperer, F.; Kessler, H.; Gilon, C.; 
Hoffman, A. The effect of multiple N-methylation on intestinal permeability of cyclic 
hexapeptides. Mol Pharm 2011, 8, 479-487. 
84. Borchardt, R. T. Optimizing oral absorption of peptides using prodrug strategies. J 
Control Release 1999, 62, 231-238. 
85. Bak, A.; Gudmundsson, O. S.; Friis, G. J.; Siahaan, T. J.; Borchardt, R. T. 
Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and 
enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm 
Res 1999, 16, 24-29. 
                                                                                                                                                         
201 
 
86. Gudmundsson, O. S.; Nimkar, K.; Gangwar, S.; Siahaan, T.; Borchardt, R. T. 
Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to 
peptidases and excellent cellular permeation. Pharm Res 1999, 16, 16-23. 
87. Gudmundsson, O. S.; Pauletti, G. M.; Wang, W.; Shan, D.; Zhang, H.; Wang, B.; 
Borchardt, R. T. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic 
stability to peptidases and excellent cellular permeability. Pharm Res 1999, 16, 7-15. 
88. Tang, F.; Borchardt, R. T. Characterization of the efflux transporter(s) responsible for 
restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the 
opioid peptide DADLE. Pharm Res 2002, 19, 787-793. 
89. Ouyang, H.; Tang, F.; Siahaan, T. J.; Borchardt, R. T. A modified coumarinic acid-based 
cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation 
characteristics. Pharm Res 2002, 19, 794-801. 
90. Ouyang, H.; Andersen, T. E.; Chen, W.; Nofsinger, R.; Steffansen, B.; Borchardt, R. T. A 
comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of 
cyclic prodrugs of an opioid peptide (DADLE). J Pharm Sci 2009, 98, 2227-2236. 
91. Ouyang, H.; Chen, W.; Andersen, T. E.; Steffansen, B.; Borchardt, R. T. Factors that 
restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. 
Role of efflux transporters in the intestinal mucosa. J Pharm Sci 2009, 98, 337-348. 
92. Ho, N., Park, J., Morozowich, W., & Higuchi, W., Physical model approach to the design 
with improved intestinal absorption. In Design of biopharmaceutical properties through 
prodrugs and analogues, Roche, E., Ed. APhA/APS: Washington D.C., 1977; pp 136-277. 
93. Pidgeon, C. Solid phase membrane mimetics: immobilized artificial membranes. Enzyme 
Microb Technol 1990, 12, 149-150. 
                                                                                                                                                         
202 
 
94. Malakoutikhah, M.; Teixido, M.; Giralt, E. Toward an optimal blood-brain barrier shuttle 
by synthesis and evaluation of peptide libraries. J Med Chem 2008, 51, 4881-4889. 
95. Malakoutikhah, M.; Prades, R.; Teixido, M.; Giralt, E. N-methyl phenylalanine-rich 
peptides as highly versatile blood-brain barrier shuttles. J Med Chem 2010, 53, 2354-2363. 
96. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: 
parallel artificial membrane permeation assay in the description of passive absorption processes. 
J Med Chem 1998, 41, 1007-1010. 
97. Wilson, T. H.; Wiseman, G. The use of sacs of everted small intestine for the study of the 
transference of substances from the mucosal to the serosal surface. J Physiol 1954, 123, 116-125. 
98. Ussing, H. H.; Zerahn, K. Active transport of sodium as the source of electric current in 
the short-circuited isolated frog skin. Acta Physiol Scand 1951, 23, 110-127. 
99. Artursson, P. Cell cultures as models for drug absorption across the intestinal mucosa. 
Crit Rev Ther Drug Carrier Syst 1991, 8, 305-330. 
100. Artursson, P.; Lindmark, T.; Davis, S. S.; Illum, L. Effect of chitosan on the permeability 
of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994, 11, 1358-1361. 
101. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the human colon 
carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. 
Gastroenterology 1989, 96, 736-749. 
102. Borchardt, R. The application of cell culture systems in drug discovery and development. 
J Drug Target 1995, 3, 179-182. 
103. Matsson, P.; Bergstrom, C. A.; Nagahara, N.; Tavelin, S.; Norinder, U.; Artursson, P. 
Exploring the role of different drug transport routes in permeability screening. J Med Chem 
2005, 48, 604-613. 
                                                                                                                                                         
203 
 
104. Vachon, P. H.; Beaulieu, J. F. Transient mosaic patterns of morphological and functional 
differentiation in the Caco-2 cell line. Gastroenterology 1992, 103, 414-423. 
105. Kumpf, S. L., Ribabeneira, M. D., Sharpe., D, Link, J., Huber, R., Burton, C., Aungst, B 
Isolation and characterization of Caco-2 cells expressing high and low levels of P-glycoprotein. 
AAPS PharmSci 3: 2001; abstract, pp 1383. 
106. Roth, W. J.; Lindley, D. J.; Carl, S. M.; Knipp, G. T. The effects of intralaboratory 
modifications to media composition and cell source on the expression of pharmaceutically 
relevant transporters and metabolizing genes in the Caco-2 cell line. J Pharm Sci 2012, 101, 
3962-3978. 
107. Walter E., K., T. . Heterogeneity in human intestinal cell line Caco-2 leads to differences 
in transepithelial transport. European journal of pharmaceutical sciences 1995, 3, 215-230. 
108. Behrens, I.; Kamm, W.; Dantzig, A. H.; Kissel, T. Variation of peptide transporter 
(PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. J Pharm Sci 2004, 93, 
1743-1754. 
109. Briske-Anderson, M. J.; Finley, J. W.; Newman, S. M. The influence of culture time and 
passage number on the morphological and physiological development of Caco-2 cells. Proc Soc 
Exp Biol Med 1997, 214, 248-257. 
110. Yu, H.; Cook, T. J.; Sinko, P. J. Evidence for diminished functional expression of 
intestinal transporters in Caco-2 cell monolayers at high passages. Pharm Res 1997, 14, 757-762. 
111. Anderle, P.; Niederer, E.; Rubas, W.; Hilgendorf, C.; Spahn-Langguth, H.; Wunderli-
Allenspach, H.; Merkle, H. P.; Langguth, P. P-Glycoprotein (P-gp) mediated efflux in Caco-2 
cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression 
levels. J Pharm Sci 1998, 87, 757-762. 
                                                                                                                                                         
204 
 
112. Behrens, I.; Kissel, T. Do cell culture conditions influence the carrier-mediated transport 
of peptides in Caco-2 cell monolayers? Eur J Pharm Sci 2003, 19, 433-442. 
113. Tucker, S. P.; Melsen, L. R.; Compans, R. W. Migration of polarized epithelial cells 
through permeable membrane substrates of defined pore size. Eur J Cell Biol 1992, 58, 280-290. 
114. Volpe, D. A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. 
J Pharm Sci 2008, 97, 712-725. 
115. Hosoya, K. I.; Kim, K. J.; Lee, V. H. Age-dependent expression of P-glycoprotein gp170 
in Caco-2 cell monolayers. Pharm Res 1996, 13, 885-890. 
116. DeMarco, V. G.; Li, N.; Thomas, J.; West, C. M.; Neu, J. Glutamine and barrier function 
in cultured Caco-2 epithelial cell monolayers. J Nutr 2003, 133, 2176-2179. 
117. D'Souza, V. M., Shertzer, H. G., Menon, A. G., Pauletti, G. M. High glucose 
concentration in isotonic media alters Caco-2 cell permeability. AAPS PharmSci 5 2003, article 
24. 
118. Bestwick, C. S.; Milne, L. Alteration of culture regime modifies antioxidant defenses 
independent of intracellular reactive oxygen levels and resistance to severe oxidative stress 
within confluent Caco-2 "intestinal cells". Dig Dis Sci 2001, 46, 417-423. 
119. Ranaldi, G.; Consalvo, R.; Sambuy, Y.; Scarino, M. L. Permeability characteristics of 
parental and clonal human intestinal Caco-2 cell lines differentiated in serum-supplemented and 
serum-free media. Toxicol In Vitro 2003, 17, 761-767. 
120. Pade, V.; Stavchansky, S. Estimation of the relative contribution of the transcellular and 
paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture 
model. Pharm Res 1997, 14, 1210-1215. 
                                                                                                                                                         
205 
 
121. Rothen-Rutishauser, B.; Braun, A.; Gunthert, M.; Wunderli-Allenspach, H. Formation of 
multilayers in the caco-2 cell culture model: a confocal laser scanning microscopy study. Pharm 
Res 2000, 17, 460-465. 
122. Markowska, M.; Oberle, R.; Juzwin, S.; Hsu, C. P.; Gryszkiewicz, M.; Streeter, A. J. 
Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. 
J Pharmacol Toxicol Methods 2001, 46, 51-55. 
123. Delie, F.; Rubas, W. A human colonic cell line sharing similarities with enterocytes as a 
model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev 
Ther Drug Carrier Syst 1997, 14, 221-286. 
124. Buckley, S. T.; Fischer, S. M.; Fricker, G.; Brandl, M. In vitro models to evaluate the 
permeability of poorly soluble drug entities: challenges and perspectives. Eur J Pharm Sci 2012, 
45, 235-250. 
125. Karlsson, J.; Artursson, P. A new diffusion chamber system for the determination of drug 
permeability coefficients across the human intestinal epithelium that are independent of the 
unstirred water layer. Biochim Biophys Acta 1992, 1111, 204-210. 
126. Hidalgo, I. J.; Hillgren, K. M.; Grass, G. M.; Borchardt, R. T. Characterization of the 
unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus. Pharm Res 
1991, 8, 222-227. 
127. Bourdage, J. S., Burton, P. S., Cole, C. J., Conardi, R. A., Day, J. S., Hilgers, A. R., 
Pfund, W. P. Characterization of Caco-2 permeability model and rat intestinal perfusion model 
for use with the BCS. AAPS PharmSci 1 1999. 
                                                                                                                                                         
206 
 
128. Palmgren, J. J.; Monkkonen, J.; Korjamo, T.; Hassinen, A.; Auriola, S. Drug adsorption 
to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J 
Pharm Biopharm 2006, 64, 369-378. 
129. Ingels, F.; Deferme, S.; Delbar, N.; Oth, M.; Augustijns, P. Implementation of the caco-2 
cell culture model as a predictive tool for the oral absorption of drugs. In-house evaluation 
procedures. J Pharm Belg 2002, 57, 153-158. 
130. Yee, S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small 
intestinal) absorption in man--fact or myth. Pharm Res 1997, 14, 763-766. 
131. Gres, M. C.; Julian, B.; Bourrie, M.; Meunier, V.; Roques, C.; Berger, M.; Boulenc, X.; 
Berger, Y.; Fabre, G. Correlation between oral drug absorption in humans, and apparent drug 
permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental 
Caco-2 cell line. Pharm Res 1998, 15, 726-733. 
132. Turco, L.; Catone, T.; Caloni, F.; Di Consiglio, E.; Testai, E.; Stammati, A. Caco-2/TC7 
cell line characterization for intestinal absorption: how reliable is this in vitro model for the 
prediction of the oral dose fraction absorbed in human? Toxicol In Vitro 2011, 25, 13-20. 
133. Tavelin, S.; Milovic, V.; Ocklind, G.; Olsson, S.; Artursson, P. A conditionally 
immortalized epithelial cell line for studies of intestinal drug transport. J Pharmacol Exp Ther 
1999, 290, 1212-1221. 
134. Tavelin, S.; Taipalensuu, J.; Hallbook, F.; Vellonen, K. S.; Moore, V.; Artursson, P. An 
improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug 
transport: characterization of transport routes. Pharm Res 2003, 20, 373-381. 
                                                                                                                                                         
207 
 
135. Cho, M. J.; Thompson, D. P.; Cramer, C. T.; Vidmar, T. J.; Scieszka, J. F. The Madin 
Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. 
Pharm Res 1989, 6, 71-77. 
136. Irvine, J. D.; Takahashi, L.; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, 
J. R. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J 
Pharm Sci 1999, 88, 28-33. 
137. Braun, A.; Hammerle, S.; Suda, K.; Rothen-Rutishauser, B.; Gunthert, M.; Kramer, S. D.; 
Wunderli-Allenspach, H. Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2000, 11 Suppl 
2, S51-60. 
138. Tang, F.; Horie, K.; Borchardt, R. T. Are MDCK cells transfected with the human MRP2 
gene a good model of the human intestinal mucosa? Pharm Res 2002, 19, 773-779. 
139. Tang, F.; Horie, K.; Borchardt, R. T. Are MDCK cells transfected with the human MDR1 
gene a good model of the human intestinal mucosa? Pharm Res 2002, 19, 765-772. 
140. Wang, M.; Sun, B.; Feng, J.; Zhang, H.; Liu, B.; Li, C.; Chen, Y.; Zhang, Y.; Kong, W. 
Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell 
monolayers. Biol Pharm Bull 2012, 35, 745-752. 
141. Zhang, Q.; He, N.; Zhang, L.; Zhu, F.; Chen, Q.; Qin, Y.; Zhang, Z.; Wang, S.; He, Q. 
The in vitro and in vivo study on self-nanoemulsifying drug delivery system (SNEDDS) based 
on insulin-phospholipid complex. J Biomed Nanotechnol 2012, 8, 90-97. 
142. Amidon, G. E.; Ho, N. F.; French, A. B.; Higuchi, W. I. Predicted absorption rates with 
simultaneous bulk fluid flow in the intestinal tract. J Theor Biol 1981, 89, 195-210. 
                                                                                                                                                         
208 
 
143. Tsuji, A.; Miyamoto, E.; Hashimoto, N.; Yamana, T. GI absorption of beta-lactam 
antibiotics II: deviation from pH--partition hypothesis in penicillin absorption through in situ and 
in vitro lipoidal barriers. J Pharm Sci 1978, 67, 1705-1711. 
144. van Rees, H.; de Wolff, F. A.; Noach, E. L. The influence of diphenylhydantoin on 
intestinal glucose absorption in the rat. Eur J Pharmacol 1974, 28, 310-315. 
145. Doluisio, J. T.; Billups, N. F.; Dittert, L. W.; Sugita, E. T.; Swintosky, J. V. Drug 
absorption. I. An in situ rat gut technique yielding realistic absorption rates. J Pharm Sci 1969, 
58, 1196-1200. 
146. Lennernas, H. Human intestinal permeability. J Pharm Sci 1998, 87, 403-410. 
147. Liu, H.; Sabus, C.; Carter, G. T.; Du, C.; Avdeef, A.; Tischler, M. In vitro permeability of 
poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid 
chromatography/mass spectrometry detection. Pharm Res 2003, 20, 1820-1826. 
148. Ingels, F. M.; Augustijns, P. F. Biological, pharmaceutical, and analytical considerations 
with respect to the transport media used in the absorption screening system, Caco-2. J Pharm Sci 
2003, 92, 1545-1558. 
149. Saha, P.; Kou, J. H. Effect of solubilizing excipients on permeation of poorly water-
soluble compounds across Caco-2 cell monolayers. Eur J Pharm Biopharm 2000, 50, 403-411. 
150. Takahashi, Y.; Kondo, H.; Yasuda, T.; Watanabe, T.; Kobayashi, S.; Yokohama, S. 
Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs. Int J Pharm 
2002, 246, 85-94. 
151. Ginski, M. J., Gadre, N., Vatsaraj, N., Grover, N., and Rhodes, C. Evaluation of 
cosolvents systems to facilitate caco-2 permeability screening of poorly water soluble drug 
candidates. AAPS. PharmSciTech. 2000, 2, 3247-. 
                                                                                                                                                         
209 
 
152. Hanke, U.; May, K.; Rozehnal, V.; Nagel, S.; Siegmund, W.; Weitschies, W. Commonly 
used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-
glycoprotein) and ABCC2 (MRP2). Eur J Pharm Biopharm 2010, 76, 260-268. 
153. Rege, B. D.; Kao, J. P.; Polli, J. E. Effects of nonionic surfactants on membrane 
transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002, 16, 237-246. 
154. Brouwers, J.; Tack, J.; Lammert, F.; Augustijns, P. Intraluminal drug and formulation 
behavior and integration in in vitro permeability estimation: a case study with amprenavir. J 
Pharm Sci 2006, 95, 372-383. 
155. Katneni, K.; Charman, S. A.; Porter, C. J. Permeability assessment of poorly water-
soluble compounds under solubilizing conditions: the reciprocal permeability approach. J Pharm 
Sci 2006, 95, 2170-2185. 
156. Aungst, B. J.; Nguyen, N. H.; Bulgarelli, J. P.; Oates-Lenz, K. The influence of donor 
and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors 
and other lipophilic compounds. Pharm Res 2000, 17, 1175-1180. 
157. Krishna, G.; Chen, K.; Lin, C.; Nomeir, A. A. Permeability of lipophilic compounds in 
drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 2001, 222, 77-89. 
158. Hubatsch, I.; Ragnarsson, E. G.; Artursson, P. Determination of drug permeability and 
prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2007, 2, 2111-2119. 
159. Galia, E.; Nicolaides, E.; Horter, D.; Lobenberg, R.; Reppas, C.; Dressman, J. B. 
Evaluation of various dissolution media for predicting in vivo performance of class I and II 
drugs. Pharm Res 1998, 15, 698-705. 
 
  
                                                                                                                                                         
210 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 - Caco-2 permeability and solubility analysis of opioid macrocyclic 
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6.1 Introduction 
We are interested in metabolically stable peptidic ligands for kappa opioid receptors 
(KOR) as potential treatments for drug abuse and pain. The natural product CJ 15,208 is a 
macrocyclic tetrapeptide (cyclo[Phe-D-Pro-Phe-Trp]) that was reported to exhibit KOR 
antagonism in vitro.
1
 While the L-Trp isomer of CJ 15,208, which appears to be the natural 
product, exhibited mixed agonist activity mediated by KOR and mu opioid receptors (MOR) in 
vivo as well as selective KOR antagonism, the D-Trp isomer exhibited minimal agonist activity 
and dose dependent KOR selective antagonism that lasted less than 18 h in vivo.
2
 Following oral 
administration, the L-Trp isomer displayed both KOR agonism and antagonism and prevented 
stress- and cocaine-induced extinguished cocaine seeking behavior in a dose and time-dependent 
manner.
3
 The D-Trp isomer, which exhibited weak KOR agonism, displayed KOR antagonism 
and prevented stress-induced, but not cocaine-induced extinguished cocaine seeking behavior in 
a dose-dependent manner following oral administration.
4
 These peptides serve as lead 
compounds for further exploration.  
In order to enhance their oral activity we are exploring the physicochemical and 
pharmacokinetic properties of these lead peptides. Because of their hydrophobicity, we have 
examined various solubilizing agents, including organic cosolvents, cyclodextrins and 
surfactants that are compatible with in vivo studies, to solubilize these compounds. To 
investigate the intestinal absorption of the macrocyclic tetrapeptides, we performed bidirectional 
Caco-2 permeability studies.  
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Figure 6.1 Structures of the lead peptides 
6.2 Results and Discussion 
6.2.1 Permeability studies 
The Caco-2 cells were seeded on polycarbonate filters, and monolayers were allowed to 
develop for 21 days. On the 21
st
 day the monolayer integrity was assessed by measuring 
transepithelial electrical resistance (TEER) and lucifer yellow permeability. A TEER value of 
>200 Ω/cm
2 
and a Papp value of ≤1 x 10
-6 
cm/sec for lucifer yellow were the criteria to use the cell 
monolayers for transport studies. All of the cell monolayers used in the present study met the 
required TEER and Papp values. 
 The cyclic tetrapeptides are hydrophobic and require organic cosolvents for 
solubilization. N,N-Dimethylacetamide (DMA, 3%)  or N-methylpyrrolidone (NMP, 2.5%) have 
been used as organic cosolvents to solubilize hydrophobic compounds in the Caco-2 cell 
permeability assay.
5
 The L-Trp and the D-Trp isomers were soluble in 0.25% DMSO + 2.25% 
DMA in Hank’s balanced salt solution (HBSS) (vehicle 1) and 0.25% DMSO + 2.25% NMP in 
HBSS (vehicle 2), respectively, at a concentration of 50 M. These were the working solutions 
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used for the Caco-2 transport studies and the concentrations of these solutions were verified by 
RP-UPLC.  
Due to the high organic content in the vehicles, it was necessary to examine the effect of 
the vehicles on the integrity of the cell monolayers. On the 21
st
 day, the transwells containing 
Caco-2 monolayers were incubated with the vehicles for 2 h, followed by examining transport of 
lucifer yellow in the apical to basolateral direction. Lucifer yellow permeability in monolayers 
exposed to vehicle 1 was 4.2 ± 0.7 x 10-7 cm/sec, while for the monolayers exposed to vehicle 2 
lucifer yellow permeability was 5.4 ± 0.2 x 10-7 cm/sec compared to 1.8 ± 0.4 x 10-7 cm/sec 
displayed by control wells exposed exclusively to HBSS, pH 7.4 (Figure 6.2). Hence, these 
vehicles appeared to be acceptable for Caco-2 permeability studies.  
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Figure 6.2 Effect of the vehicles on Caco-2 monolayer integrity (n=2). The control wells were 
incubated with HBSS, pH 7.4, and vehicle treated wells with the respective vehicles for the 
initial 2 h and lucifer yellow (LY) transport was carried out during the 3
rd
 h.  
The peptide permeability experiments were performed similar to the lucifer yellow 
transport experiment except in both the apical to basolateral (A-B) and basolateral to apical (B-
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A) directions. Liquid chromatography electrospray ionization tandem mass spectroscopy (LC-
ESI-MS/MS) in positive ion mode coupled to reversed phase ultra-high performance liquid 
chromatography (RP-UPLC) was employed for quantifying both the L-Trp and D-Trp isomers. 
Following fragmentation, the fragment ions were quantified by multiple reaction monitoring 
(MRM).  
The L-Trp isomer showed a permeability of 3.2 ± 0.6 x 10-6 cm/sec in the A-B direction 
and 18.9 ± 0.5 x 10-6 cm/sec in the B-A direction (Figure 6.3 and Table 6.1). The value for B-A 
transport was almost 6 times the value for A-B transport which implies that L-Trp isomer is a 
substrate for P-glycoprotein (Pgp) or other efflux transporter, although this needs to be 
confirmed by experiments in the presence of known efflux protein inhibitors. The mass balance 
(± SEM) was 82 ± 3% for the A-B permeability studies and 71 ± 6% for B-A permeability 
studies for the L-Trp isomer (Table 6.1). Because of a lower mass balance value in the B-A 
direction a study investigating possible adsorption of the peptide to the transwells was also 
performed. However, in this study recoveries were >94%, indicating that the peptide may not be 
adsorbing significantly to the transwells.  
The D-Trp isomer showed permeability of 25.5 ± 6.3 x 10-6 cm/sec in the A-B direction 
and 22.7 ± 0.9 x 10-6 cm/sec in the B-A direction (Figure 6.4 and Table 6.1).  Mass balance 
values (± SEM) of 76 ± 3% for the A-B direction and 82 ± 1% for B-A direction were obtained 
for the D-Trp isomer (Table 6.1). Both the L- and D-Trp isomers displayed an initial short lag 
phase (10 min) which is suggestive of carrier mediated transport.
6
  
The difference in the permeabilities of the isomers may be attributed to differences in their 
conformations. The two isomers may exhibit differences in intramolecular hydrogen bonding 
which could affect the permeability of the two peptides. Lokey et al. showed that changes in the 
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intramolecular hydrogen bonding of peptides can affect their permeability.
7
 A detailed 
conformational analysis of the two isomers is currently being performed. 
Subsequent to the peptide transport experiments lucifer yellow transport was performed for 
1 h to monitor the effect of peptide on the integrity of cell monolayers. The lucifer yellow 
transport experiment in the peptide-incubated wells was performed in the A-B direction 
regardless of the direction of the peptide transport. The lucifer yellow permeability values post 
L-Trp isomer transport were 0.8 x 10
-6
 cm/sec and 0.9 x 10
-6
 cm/sec for the wells in which 
peptide transport in the A-B and B-A directions, respectively, was performed compared to 0.9 x 
10
-6
 cm/sec for the wells incubated with vehicle 1 and 1.1 x 10
-6
 cm/sec for control wells (Figure 
6.5). These values indicated that neither vehicle 1 nor the L-Trp isomer compromised the 
integrity of the cell monolayers.  
The lucifer yellow permeability values post D-Trp isomer transport were 5.7 x 10
-6
 cm/sec 
and 13 x 10
-6
 cm/sec for the wells in which peptide transport in the A-B and B-A directions was 
performed, respectively, compared to 8.2 x 10
-6
 cm/sec displayed by wells incubated with 
vehicle 2 and 1.4 x 10
-6
 cm/sec displayed by the control wells (Figure 6.6). These values 
indicated that while vehicle 2 compromised the integrity of the monolayers the D-Trp isomer did 
not appear to have an effect on monolayer integrity. 
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Table 6.1. Results obtained from Caco-2 monolayer permeability experiments for the L- and D-
Trp isomers. 
 
Peptide Peptide transport
a
 Post-peptide LY transport
b
 Mass balance (%)
a
 
 
Papp cm/sec (x 10
-6
) Papp cm/sec (x 10
-6
) 
  
 
A-B  B-A  Peptide (A-B)  Peptide (B-A)  A-B B-A 
   
treated wells 
(cm/sec) 
treated wells 
(cm/sec)   
CJ-15,208 
 (L-Trp isomer) 3.2 ± 0.6   18.9 ± 0.5   0.8c 0.9c 82 ± 3  71 ± 6  
 
D-Trp isomer 25.5 ± 6.3  22.7 ± 0.9  5.7d 13d 76 ± 3  82 ± 1  
a
 Results presented are average ± SEM from duplicate determinations. 
b
 Results presented are from a single determinations. 
c 
Lucifer yellow
 
(LY) transport in the wells incubated with vehicle 1 only was 0.9 x 10
-6
 cm/sec. 
d
 LY transport in the wells incubated with vehicle 2 only was 8.2 x 10
-6
 cm/sec.  
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Figure 6.3 Caco-2 monolayer permeability of the L-Trp isomer (n = 2); error bars are too small 
to be visible. 
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Figure 6.4. Caco-2 monolayer permeability of the D-Trp isomer (n = 2). 
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Figure 6.5. Post L-Trp isomer lucifer yellow (LY) transport through Caco-2 monolayers (n = 1). 
Control wells were incubated with HBSS, vehicle treated wells with vehicle 1 and the peptide 
treated wells with L-Trp isomer solution for the initial 2 h, and LY transport was carried out in 
the wells during the 3
rd
 h. 
                                                                                                                                                         
218 
 
20 40 60 80
-0.02
0.00
0.02
0.04
0.06
Control wells (1.4 x 10
-6
 cm/sec)
vehicle 2 (8.2 x 10
-6
 cm/sec)
(A-B) peptide wells (5.7 x 10
-6
 cm/sec)
(B-A) peptide wells (13 x 10
-6
 cm/sec)
Time (min)
C
u
m
u
la
ti
v
e
 f
ra
c
ti
o
n
 o
f 
L
Y
 t
ra
n
s
p
o
rt
e
d
 
Figure 6.6. Post D-Trp isomer lucifer yellow (LY) transport through Caco-2 monolayers (n = 1).  
Control wells were incubated with HBSS, vehicle treated wells with vehicle 1 and the peptide 
treated wells with D-Trp isomer solution for the initial 2 h, and LY transport was carried out in 
the wells during the 3
rd
 h. 
Transport of caffeine, a high permeability standard was also evaluated through the Caco-
2 monolayers (previously reported Papp values for caffeine in Caco-2 cells are 3.1 x 10
-5
 cm/sec
8
 
and 5.1 x 10
-5
 cm/sec
9
). Caffeine samples were analyzed by HPLC-UV with analysis at 280 nm; 
it displayed a permeability of 4.9 x 10
-5
 cm/sec in the A-B direction (Figure 6.7).  
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Figure 6.7. A-B Caco-2 monolayer permeability of caffeine (n=1). 
Permeability of other molecules, including the macrocyclic peptides cyclosporine,
10
 opioids 
such as morphine and known Pgp substrates including paclitaxel,
11
 have been studied previously 
in Caco-2 monolayers. Cyclosporine displayed permeability values of 1 x 10
-6
 cm/sec in the A-B 
direction and 10 x 10
-6
 cm/sec in the B-A direction when the permeability was studied at a 
concentration of 0.5 M. Thus it showed an efflux ratio of 10, suggesting that it was a substrate 
for an efflux transporter(s). However, at a concentration of 5 M it displayed an efflux ratio of 2, 
suggesting saturation of the efflux transporter. The involvement of Pgp efflux was confirmed by 
the use of known Pgp inhibitors.
10
 Cyclosporine also displayed an initial short lag phase 
indicative of carrier mediated transport.
10
 Studies of the prototypical opioid morphine in Caco-2 
cells showed a permeability of 2 x 10
-6
 cm/sec in the A-B direction and 4 x 10
-6
 cm/sec in B-A 
direction when the transport studies were carried out at concentrations ranging from 10-75 M.
11
 
The anticancer agent paclitaxel showed a permeability of <0.1 x 10
-6
 cm/sec in the A-B direction 
and 18 x 10
-6
 cm/sec in the B-A direction when the transport studies were carried out from 10-75 
M; thus the ratio of transport in the B-A to A-B direction was  over 100.
11
 The efflux ratio for 
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paclitaxel was approximately 1 when the transport study was done in the presence of a known 
Pgp inhibitor. Hence, while morphine appeared to be at best a weak efflux substrate, Pgp caused 
extensive efflux of paclitaxel. Efflux by Pgp could be a likely explanation for the higher B-A 
transport of the L-Trp isomer.   
6.2.2 Solubility studies for in vivo administration  
In addition to the in vitro permeability studies, the macrocyclic tetrapeptides are currently 
being tested in vivo for various potential therapeutic applications including analgesia and drug 
abuse treatment following systemic, including oral administration.
3, 4
 Depending on the route of 
administration, in vivo studies often require higher concentrations of compound be administered 
but can also tolerate a higher concentration of the organic component to solubilize the 
compounds.  Hence, we attempted to enhance the solubility of the L- and D-Trp isomers using 
organic cosolvents such as ethanol and DMSO, the -cyclodextrin derivative Captisol and the 
surfactants Solutol HS 15 and Tween-80 (TW-80). Solutions of the L- and D-Trp isomers (10 
mM) were prepared in 5, 10 and 20% of each of the solubilizing enhancer in normal saline. The 
solutions were filtered and analyzed by RP-HPLC, to determine their peptide concentrations.  At 
either 20% EtOH or 20% TW-80 in normal saline, the L-Trp isomer displayed approximately ~ 
5- and 17-fold lower solubility, respectively, than the D-Trp isomer. At concentrations of either 
20% Captisol or Solutol HS 15 in normal saline, the L-Trp isomer also displayed approximately 
9- to 11-fold lower solubility, respectively, than the D-Trp isomer (Figures 6.8 and 6.9). The L-
Trp absorbance in varying concentrations of DMSO in saline was below the limits of 
quantification by RP-HPLC indicating that the L-Trp peptide CJ-15,208 had very low solubility 
in 5-20% DMSO in normal saline. Initially, a cocktail of 10% EtOH or DMSO + 10% TW-80 in 
normal saline (80%) was used for solubilizing the L- and D-Trp isomers for in vivo studies.
3, 4
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Solutions of both peptides (10 mM) were also prepared in the above cocktail, filtered and the 
peptide concentrations subsequently determined by RP-HPLC (Figures 6.10 a and b). The L-Trp 
isomer displayed 40-fold lower solubility than the D-Trp isomer in 10% EtOH + 10% TW-80 in 
normal saline. The L-Trp solution containing 10% DMSO + 10% TW-80 in normal saline 
formed a gel and could not be filtered and analyzed.    
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Figure 6.8. Solubility analysis of the L-Trp peptide; error bars are too small to be visible. The 
concentrations of peptide with DMSO as a cosolvent were below the limits of quantitation. 
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Figure 6.9. Solubility analysis of the D-Trp peptide; error bars are too small to visualize. 
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Figure 6.10. a) Solubility of the L-Trp isomer in the solvent mixture containing 10% EtOH + 
10% TW-80 in normal saline (sal); error bars are too small to visualize. The solution of the L-
Trp peptide containing 10% DMSO and 10% TW-80 in normal saline formed a gel and could not 
be analyzed. a) Solubility of the D-Trp isomers in solvent mixtures containing 10% EtOH or 
DMSO, 10% TW-80 in normal saline (sal), error bars too small to visualize.  
6.3 Conclusions and future directions  
The Caco-2 monolayer studies of the L- and D-Trp peptides indicate that the D-Trp 
isomer has 7-fold higher permeability compared to CJ-15,208. Based on the ratio of the 
permeabilities in the B-A and A-B directions, the L-Trp isomer appears to be a substrate for one 
or more of the efflux proteins expressed by Caco-2 cells. While in the initial studies neither 
vehicle appeared to significantly affect the integrity of the Caco-2 monolayers, in the post 
peptide lucifer yellow transport studies wells exposed to vehicle 2 exhibited values > 1 x 10
-6
 
cm/sec, suggesting vehicle 2 may affect the monolayer integrity of the cells. A different batch of 
Caco-2 cells from the N2 freezer was used to perform the experiment in Figure 6.2 from those 
performed in Figures 6.5 and 6.6 which could be one reason for the differences in the results.  
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While the permeability studies suggest that the L-Trp isomer CJ-15,208 is a substrate for 
an efflux transporter protein(s), it will be necessary to study the permeability of the L-Trp isomer 
in the presence of known efflux protein inhibitors to identify the specific efflux protein(s) 
involved. In addition, examination of the transport of both peptides, especially the D-Trp isomer, 
at lower concentrations (< 5 M) could potentially identify involvement of efflux transporters 
which might not be apparent at 50 M. Additional future studies could use alternate models such 
as MDCK cells transfected with the appropriate efflux transporter gene to corroborate the results 
obtained from the Caco-2 studies. Transfected MDCK cells are considered a model for the 
blood-brain barrier (BBB), and hence can also be used to study the relative ability of these 
peptides to permeate the BBB.  
The solubility studies indicate that the D-Trp isomer has much higher (5- to 40-fold) 
solubility than the L-Trp isomer irrespective of the type of solubilizing enhancer or combination 
used. 
6.4 Experimental section 
Materials  
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from Gibco (Grand Island, 
NY, USA), and fetal bovine serum (FBS) was obtained from Atlanta Biologics (Lawrenceville, 
GA, USA). Non-essential amino acids, penicillin and streptomycin were purchased from Cellgro 
(Manassas, VA, USA). HBSS pH 7.4, lucifer yellow, and TW-80 were purchased from Sigma-
Aldrich (St. Louis, MO, USA), and polycarbonate transwell filters and polystyrene plates were 
obtained from Costar (Corning, NY, USA). Captisol was a gift from Dr. Valentino Stella, 
University of Kansas, Lawrence and Solutol HS 15 (BASF Lot# 19602536W0) was a gift from 
BASF, NJ, USA. A SpectraMax M3 microplate fluorometer  (Molecular Devices, Sunnyvale, 
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CA) was used for analysis of lucifer yellow transport, while LC-MS/MS analysis for peptide 
transport was performed on an Acquity Ultra Performance Liquid Chromatography system 
coupled to a Quattro mass spectrometer (Waters, Milford, MA, USA). Quantification of caffeine 
and solubility analysis of peptides for in vivo administration was performed on an Agilent 1200 
series liquid chromatograph system equipped with a multiple wavelength UV-Vis detector.   
Cell culture 
Caco-2 cells (American Type Culture Collection, Manassas, VA, USA) (passage 10-16) 
were grown in a humidified incubator at 37 
o
C under 5% CO2 in air in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% heat inactivated FBS, 0.1 mM nonessential amino 
acids, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Caco-2 cells were 
seeded on polycarbonate transwells (0.4 µM pore size, 12 mm diameter, Costar #3401) at a 
density of 3 x 10
5
 cells/cm
2
 and grown for 21 days. Cell culture media was replaced within 12 h 
of seeding, and thereafter every other day for the initial 7 days, and subsequently every day until 
the 21
st
 day. 
Standard curves of the L- and D-Trp peptides for the working solutions for the Caco-2 
transport experiments 
The concentrations of the working solutions of both peptides used for Caco-2 
permeability studies were determined from standard curves (Figures 6.11 and 6.12) obtained by 
RP-UPLC with UV detection at varying concentrations (ranging from 12.5-75 M) in 75% 
MeOH in HBSS. The LC method was from 25-75% of aqueous MeCN with 0.03% formic acid 
over 3min at a flow rate of 0.6 mL/min and at a wavelength of 214 nm. The solutions were 
analyzed on a Acquity UPLC HSS T3 column (1.8 μm, 100 Å, 2.1 x 50 mm). 
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Figure 6.11 Standard curve of the L-Trp peptide CJ-15,208 by RP-UPLC used for determining 
the concentration of working solutions used in the Caco-2 permeability experiments. 
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Figure 6.12 Standard curve of the D-Trp isomer by RP-UPLC used for determining the 
concentration of working solutions used in the Caco-2 permeability experiments. 
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Standard curves of low (Lucifer yellow) and high (caffeine) permeability standards 
The standard curve of Lucifer yellow and caffeine were obtained in HBSS ranging over a 
range of concentrations from 1-100 µM. The solutions of Lucifer yellow (200 L) were analyzed 
using a 96 well fluorescence plate reader with an excitation wavelength of 485 nm and emission 
wavelength of 538 nm and displayed linearity from 1-100 M. (r
2
 = 0.9957, Figure 6.13). 
Solutions of caffeine were analyzed on a Vydac C18 column (5 μm, 300 Å, 4.6 x 50 mm) 
equipped with a Vydac C18 guard cartridge and a gradient of 6-13% aqueous MeCN containing 
0.1% TFA over 7 min with UV detection at 280 nm at a flow rate (1 mL/min) and displayed 
linearity from 1-100 M (r
2
 = 0.9999, Figure 6.14). 
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Figure 6.13 Representative standard curve of lucifer yellow 
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Figure 6.14 Standard curve of caffeine. 
Transport experiments 
The integrity of the cell monolayers was examined by the measurement of TEER values 
and the transport of the low paracellular permeability standard lucifer yellow. The TEER values 
were corrected by subtracting background values for the filters. The monolayers exhibiting 
TEER values, monitored in HBSS pH 7.4 at 37 
o
C, above 200 Ω cm
2 
and apparent permeability 
(Papp) values for lucifer yellow of ≤ 1 x 10
-6
 cm/sec were used for the transport experiments 21–
25 days after seeding. The filters containing cell monolayers were incubated in HBSS pH 7.4 
(apical side volume 0.5 mL and basolateral side volume 1.0 mL) and allowed to equilibrate for 
10 min in a bench top incubator-shaker at 37 
o
C and 100 rpm. For assessment of monolayer 
integrity of the cells, HBSS on the apical side was replaced with lucifer yellow (0.5 mL of 100 
M solution in HBSS). The experiment was performed in triplicate for 120 min with aliquots 
(200 L) taken at 15, 30, 45, 60, 90 and 120 min from the basolateral side. At every time point 
an aliquot was removed it was replaced by an equal amount of HBSS to maintain constant 
volume. Aliquots were taken prior to the start of the experiment to serve as blanks and at the end 
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of the experiments from the apical side for estimating mass balance and recovery. The samples 
were analyzed using a 96 well fluorescence plate reader (see materials). The lucifer yellow 
transport to evaluate cell monolayer integrity was performed simultaneously with the peptide 
transport experiment during the initial 2 h, as opposed to the post-peptide lucifer yellow transport 
experiments which were performed only in the 3
rd
 h.  
Transport experiments for the peptides were performed by the same procedure as 
described for lucifer yellow, except that for transport in the B-A direction the donor solution of 
the peptide was placed on the basolateral side and the aliquots were taken from the apical side 
with an additional 5 min time point. The additional time point was taken to monitor an initial lag 
in the transport of the two peptides. The working concentrations used for both the L- and D-Trp 
isomers were 50 µM in vehicle 1 and vehicle 2, respectively. Aliquots of the donor compartment 
were taken at the beginning and the end of the experiments to monitor mass balance and were 
diluted 10 times with the respective vehicle immediately after the experiment.  The peptide 
concentrations were determined by LC-MS/MS (see below). Transport experiments involving 
the high permeability standard caffeine were analyzed by RP-HPLC with a gradient of 6-13% 
aqueous MeCN containing 0.1% TFA over 7 min with UV detection at 280 nm and at flow rate 
of 1 mL/min. 
LC-ESI-MS/MS analysis  
Sample preparation for the L- and D-Trp macrocyclic peptides 
The samples from the transport studies of the L- and D-Trp macrocyclic peptides were 
stored at -20 
o
C immediately after the experiments. Following thawing of the Caco-2 samples, 
the internal standard cyclo[L-Phe-NMe-D-Ala-L-Phe-Trp] (20 L of a 12.5 M solution in 
MeCN) was added to 80 L of the  sample from the transport studies. The samples were 
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vortexed and injected into the LC-ESI-MS/MS for quantification. As the peptides are 
hydrophobic they can adsorb to plastic, and hence all of the samples were prepared and stored in 
glass vials. 
LC-MS/MS method for the L- and D-Trp isomers 
The LC method used a Hypersil BDS C8 column (3 m, 2.1 x 50 mm) with a flow rate of 
200 L/min and a gradient of solvent A (99% H2O, 1% MeCN, 0.08% formic acid) and solvent 
B (99% MeCN, 1% H2O, 0.08% formic acid). The initial conditions were 20% B for the first 2 
min, followed by a rapid increase to 50% over one minute and then increasing from 50 to 80% 
over 3 min. The same LC method was used for both macrocyclic tetrapeptides. The retention 
times for the L- and D-Trp isomers were 4.4 min and 5.7 min, respectively. The retention time of 
the IS was 5.0 min. Ions between m/z 70 to 600 were captured after electrospray ionization.  
 
Figure 6.15 Mass spectral fragmentation of the cyclic tetrapeptides 
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The following mass spectrometer settings were used during sample quantification: 
capillary voltage 3.8 kV, cone voltage 80 V, source temperature 100 
o
C, desolvation temperature 
150 
o
C. The collision energy (CE) varied with the transitions; the ion transitions used were 600.1 
> 572.2 (CE 35 eV), 578 > 245.2 (CE 35 eV), 578 > 217.2 (CE 35 eV), 578 > 159 (CE 35 eV), 
578 > 120.1 (60 eV), and 578 > 70.2 (CE 60 eV) for the L-Trp and D-Trp isomers, and 588 > 
559.8 (CE 35 eV) and 566.2 > 232.9 (CE 22 eV) for the IS. The standard curve for the L-Trp 
isomer was obtained from 25 nM to 25 M and displayed linearity (r
2
 = 0.9976, Figure 6.16). 
The standard curve for the D-Trp isomer was obtained from 100 nM to 10 M and also displayed 
linearity (r
2
 = 0.9867, Figure 6.17). The Caco-2 samples were analyzed using the same 
conditions as the standards.  
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Figure 6.16 Representative standard curve of the L-Trp isomer by LC-MS/MS used for 
determining Caco-2 monolayer permeability. 
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Figure 6.17 Representative standard curve of the D-Trp isomer by LC-MS/MS used for 
determining Caco-2 monolayer permeability. 
Papp calculations 
The cumulative fraction of the drug transported for each time point was calculated by 
dividing the concentration in the receiver at each time point following correction for aliquot 
removal (by addition of an equal volume of HBSS) by the donor concentration (concentration of 
the drug at time = 0). The cumulative fraction transported was plotted vs. time to obtain the slope 
of the line (flux). The Papp value was then calculated from the following formula: 
Papp = slope x volume of receiver chamber (cm
3
)/Area of the filter (cm
2
) x 60 (sec) 
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Solubility analysis for in vivo applications 
Solutions of the L-Trp and D-Trp peptides (10 mM) were prepared by initially adding 
EtOH, DMSO or TW-80 to the preweighed drug powder followed by vortexing (30 sec) and 
sonication (2 min). Subsequently, normal saline was added to the drug solutions. The drug 
solutions involving Captisol and Solutol HS 15 were prepared by adding solutions containing 5, 
10 and 20% Captisol or Solutol HS 15 in normal saline to the drug powder. The peptide solutions 
containing Captisol and Solutol HS 15 were also vortexed (30 sec) and sonicated (2 min). All the 
peptide solutions were incubated in a water bath at 25 
o
C for 24 h with simultaneous shaking at 
25 rpm. The solutions were centrifuged at 13,000 rpm for 30 min followed by filtration using 
nylon syringe filters. The solutions were diluted to a concentration range of 50-500 M with the 
corresponding vehicles containing mixtures of solubilizing enhancers in normal saline and then 
analyzed by RP-HPLC-UV analysis using a gradient of 20-80% aqueous MeCN with 0.1% TFA 
over 10 min at 280 nm and at a flow rate (1 mL/min). 
Standard curves for the L-Trp and D-Trp peptides for solubility studies were analyzed by 
RP-HPLC-UV analysis at 280 nm. The standard curve samples were prepared over a 
concentration range of 50-500 µM in 2% DMSO in MeOH and analyzed using the same HPLC 
conditions as above (Figures 6.18 and 6.19). 
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Figure 6.18 Standard curve of the L-Trp isomer for solubility studies 
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Figure 6.19 Standard curve of the D-Trp isomer for solubility studies 
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7.1 Introduction 
 One of the objectives of this dissertation was to study structure-activity relationships 
(SAR) of dynorphin (Dyn) analogs. The SAR of two Dyn analogs, Dyn B amide and the 
selective kappa opioid receptor (KOR) antagonist [N
α
-benzylTyr
1
,cyclo(D-Asp
5
,Dap
8
)]Dyn A(1–
11)NH2 (now called zyklophin),
1
 were studied. The information obtained from the SAR studies 
of Dyn B amide is useful to explore the contributions of different residues of Dyn B amide to its 
opioid activity. The SAR of zyklophin provided information about the role of different 
modifications to zyklophin’s KOR activity and hence will aid in designing novel zyklophin 
analogs with improved affinity, selectivity and antagonist potency at KOR. 
 Another objective of this dissertation was to explore the pharmacokinetic and 
physicochemical properties of the opioid macrocyclic natural product CJ 15,208 (cyclo[L-Phe-D-
Pro-L-Phe-L-Trp]) and its D-Trp isomer. We studied their bidirectional permeability in the 
Caco-2 cell monolayer model for intestinal absorption and solubility of these peptides in various 
solubilizing enhancers. The results from the Caco-2 permeability studies may reflect the 
intestinal permeability of these peptides, while those from the solubility studies provided us with 
information about possible vehicles that can be used for in vivo studies. 
7.2 Conclusions and future work for research projects 
Project 1: Structure-activity relationships of Dynorphin B amide (Chapter 3). 
Dyn A and Dyn B have identical N-terminal sequences but their C-terminal sequences 
differ. Although Dyn B exhibits lower affinity, potency and selectivity for KOR (see chapter 3, 
section 3.2), it has been reported to be devoid of the cytotoxic non-opioid effects exhibited by 
Dyn A.
2
 Hence, the differences in the C-terminal sequence results in the differences in their 
pharmacological actions. 
                                                                                                                                                         
239 
 
Tyr
1
-Gly-Gly-Phe
4
-Leu
5
-Arg
6
-Arg
7
-Ile
8
-Arg
9
-Pro
10
-Lys
11
-Leu-Lys   
Dyn A(1-13) 
Tyr
1
-Gly-Gly-Phe
4
-Leu
5
-Arg
6
-Arg
7
-Gln
8
-Phe
9
-Lys
10
-Val
11
-Val-Thr-NH2   
Dyn B amide 
Figure 7.1 Dyn A(1-13) and Dyn B amide 
 In this project, alanine substituted analogs of Dyn B amide were synthesized. All of the 
non-glycine residues up to residue 11 were substituted with Ala in order to explore the 
importance of these residues to the activity of Dyn B. The alanine scan of Dyn B amide revealed 
that Tyr
1
 and Phe
4
 in the N-terminal region of the peptide are critical for opioid receptor binding 
affinity. These residues also contribute to the KOR vs. mu opioid receptor (MOR) selectivity of 
Dyn B amide. While the basic residue Arg
7
 appears to be important, Arg
6
 and Lys
10
 also 
contribute to the KOR binding affinity of Dyn B amide. While the basic residues Arg
6
 and Arg
7
 
contribute to KOR selectivity by both increasing KOR affinity and decreasing MOR affinity, the 
Lys
10
 residue contributes to the KOR selectivity primarily by increasing the KOR affinity of Dyn 
B amide. In the case of Dyn A(1-13), along with Arg
6
 and Arg
7
,
 
basic residues Arg
9
 and Lys
11
 
also make minor contributions to the opioid receptor binding affinity.
3
 Hence it appears that the 
basic residues in the C-terminus of both peptides contribute to opioid receptor binding; however, 
the differences in their relative positions in positions 8-11 might be one of the reasons 
contributing to their different pharmacological profiles.  
The pharmacological information obtained from the Ala substituted analogs could be 
used to design newer analogs of Dyn B amide that could provide additional information about 
the SAR of Dyn B amide and aid in the development of peptidic opioid ligands as 
pharmacological tools.  
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Project 2:  Structure-activity relationships of the KOR selective antagonist zyklophin 
(Chapter 4).  
The cyclic Dyn A derivative zyklophin is a selective KOR antagonist in vitro
1
 and is 
active in vivo after systemic administration.
4
 However, there is minimal SAR information 
available for zyklophin. The objectives of this project were to study the SAR of zyklophin, 
identify structural features of zyklophin responsible for its high selectivity and antagonist 
activity, and to enhance its antagonist potency.  
 
Figure 7.2 Zyklophin 
The synthesis of the zyklophin analogs involved dissolution of the N-terminal N-alkyl 
amino acid in DMF at elevated temperature because of its low solubility, followed by cooling 
and coupling with the (2-11) peptide fragment on resin.
1
 This could potentially lead to 
racemization of the N-terminal residue of zyklophin or its analogs.  While we did not observe 
racemization with N-benzyl-Tyr-OH in the synthesis of zyklophin, N-benzyl-Phe-OH appeared 
to undergo racemization. Also the N-CPM-Tyr-OH had minimal solubility in DMF and did not 
couple with the peptide fragment on resin. Therefore, we devised a modified synthetic strategy to 
prepare N-alkyl amino acids that would be readily soluble in DMF at room temperature (RT) and 
hence would not require use of an elevated temperature for solubilization. This involved 
preparing Alloc derivatives of the N-alkyl amino acids which were readily soluble at RT in the 
solvents used for the coupling reaction, thereby minimizing potential for racemization of the N-
terminal residue of the zyklophin analogs. 
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To study the SAR of zyklophin, both linear analogs containing modifications in positions 
5 and 8 and cyclic analogs including N-terminal N-alkyl analogs, ring variants and alanine 
substituted analogs were synthesized. The results from the radioligand binding assays for the 
linear analogs suggested that the residue at position 5 has a greater influence on the affinity of 
zyklophin as compared to residue 8. The L-configuration and/or the hydrophobic side chain of 
Leu in position 5 of [N-benzylTyr
1
,Dap(Ac)
8
]Dyn A(1-11)NH2 could be responsible for its high 
KOR affinity. However, the KOR binding affinity for the ring variant analog with L-Asp at 
position 5 suggested that changing the configuration of residue 5 does not have a significant 
influence on the affinity of cyclic zyklophin analogs. While all of the N-terminal modifications 
and ring variations were well tolerated in zyklophin, to date the analog with the N-CPM 
modification on the N-terminal residue displayed the highest KOR affinity. It was also shown 
that the basic secondary amine and the phenol of the N-terminal Tyr were not necessary for 
maintaining the KOR affinity of zyklophin. The pharmacological results for the alanine 
substituted analogs suggested that residues at positions 4 and 6, but not Tyr
1
, are important for 
zyklophin’s KOR affinity, while the basic residues 7 and 9 did not appear to be important for the 
maintaining the KOR affinity of zyklophin. Surprisingly, the Ala substitution at position 7 
displayed a 3-fold increase in KOR affinity, suggesting that the Ala residue might result in 
favorable interactions or eliminate unfavorable interactions with the receptor that are responsible 
for its increased affinity.  
The results from the GTPS assay indicated that none of the structural changes to the 
cyclic zyklophin analogs altered the low efficacy of zyklophin. Preliminary results from Schild 
analysis suggested that among the analogs evaluated the N-CPM modification at the N-terminal 
resulted in the most potent analog. The results for the Phe
1
 analog of zyklophin suggested that 
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the Tyr phenol is not required for KOR antagonist potency of zyklophin. Thus, the N-CPM-Tyr
1
 
and N-benzyl-Phe
1
 analogs of zyklophin appear to promising analogs for in vivo studies towards 
the development of potent Dyn A based KOR antagonists.  
Future studies include performing molecular modeling studies of zyklophin with the aid 
of the reported crystal structure of KOR.
5
 The crystal structure provides a starting framework for 
analysis of potential interactions of zyklophin with the receptor. The docking studies with 
zyklophin analogs could provide insight into which analogs would have better affinity and 
activity at KOR. However, due to the variety of conformations exhibited by zyklophin it is 
challenging to perform molecular docking studies using the reported crystal structure. The 
crystal structure of JDTic with KOR is a single snap shot and does not take into account the 
dynamic nature of the receptor and the conformational flexibility of JDTic. It is also reported that 
the peptides and non-peptides may interact differently with the receptor,
6, 7
 hence interactions of 
zyklophin with the receptor may be significantly different compared to JDTic. The SAR of 
zyklophin suggests that neither the phenol of Tyr
1
 nor a basic N-terminus is required for 
maintaining the KOR activity of zyklophin. However, in the case of JDTic the basic amines of 
piperidine and tetrahydrisoquinoline (Tic) groups make key salt-bridge interactions with Asp 138 
in KOR. Further, the removal of the hydroxyl groups on the piperidine and Tic causes a 100-fold 
loss in KOR affinity.
5
 Other KOR antagonists like norbinaltorphimine (norBNI) and 5-
guanidinonaltrindole (5’-GNTI) have been docked with the KOR crystal structure, and those 
studies suggest that while the amino group of N-cyclopropylmethyl (CPM) moiety interacts with 
Asp 138, the second amine moiety (the second amino group in norBNI and the guanidine group 
in GNTI) in these antagonists interacts with Glu 297 residue which is thought to be responsible 
for their KOR selectivity. The N-CPM group in norBNI and GNTI appears to be in the same 
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position in the crystal structure as that of the isopropyl group of JDTic. The discovery of norBNI 
and GNTI was based on the “message-address” concept (see chapter 2, section 2.7) for opioid 
ligands, and can be related to the endogenous ligands dynorphins.
8
 Thus, incorporating an 
isopropyl group or other hydrophobic alkyl group instead of a benzyl group in zyklophin may 
produce an analog(s) with potent KOR antagonism. Hence, although the discovery of the KOR 
crystal structure is ground breaking, the information obtained from this structure should be 
applied with caution while designing second-generation zyklophin analogs. In addition, while 
docking to the crystal structure can be used to suggest modifications to incorporate into 
zyklophin, experimental evidence will be needed to evaluate the proposed docking structures. 
Project 3: Caco-2 permeability and solubility analysis of opioid macrocyclic tetrapeptides 
(chapter 6) 
The natural product CJ 15,208, a macrocyclic tetrapeptide (cyclo[L-Phe-D-Pro-L-Phe-L-
Trp]), was reported to exhibit KOR antagonism in vitro.
9
 The L- and D-Trp isomers of this 
peptide exhibit different pharmacological profiles in vivo after intracerebroventricular 
administration to mice,
10
 and both exhibit opioid activity following oral administration.
11, 12
 
Because of the promise of these lead compounds we wanted to explore their pharmacokinetic 
properties such as bidirectional Caco-2 permeability and physicochemical properties such as 
solubility.  
The aim of this project was to study the bidirectional permeability of the peptides in the 
Caco-2 monolayer model for intestinal permeability and examine the solubility of these peptides 
in various solubilizing agents, including organic cosolvents such as ethanol and N,N-
dimethylsulfoxide (DMSO), the cyclodextrin Captisol and the surfactants Solutol HS 15 and 
Tween-80. 
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Figure 7.3 CJ-15,208 and its D-Trp isomer. 
The Caco-2 permeability studies indicated that the D-Trp isomer (25.5 ± 6.3 x 10-6 
cm/sec) has 7-fold higher permeability in the A-B direction compared to the L-Trp isomer (3.2 ± 
0.6 x 10
-6
 cm/sec). CJ-15,208 displayed a Papp ratio (Papp (B-A)/Papp (A-B)) ratio of 6, suggesting 
it is a substrate for one or more of the efflux proteins expressed by Caco-2 cells. The ratio of D-
Trp isomer was close to 1, suggesting that it was not an efflux substrate.  
The solubility studies showed that the D-Trp isomer has much higher (5- to 40-fold) 
solubility than the L-Trp isomer irrespective of the type of solubilizing enhancer or combination 
used. 
In order to identify the protein involved in the efflux of CJ-15,208 we need to study the 
Caco-2 permeability of this peptide in the presence of known efflux inhibitors. In addition, the 
examination of the transport of both peptides, especially the D-Trp isomer, at lower 
concentrations (< 5 M) could potentially detect involvement of efflux transporters that might 
not be apparent at 50 M. Additional future studies could also use alternate models such as 
Madin-Darby canine kidney (MDCK) cells transfected with the appropriate efflux transporter 
gene to corroborate the results obtained from the Caco-2 studies. The MDCK permeability could 
also give an estimation of the blood-brain barrier (BBB) permeability of these peptides. 
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